0001564590-20-021960.txt : 20200506 0001564590-20-021960.hdr.sgml : 20200506 20200506162204 ACCESSION NUMBER: 0001564590-20-021960 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 52 CONFORMED PERIOD OF REPORT: 20200331 FILED AS OF DATE: 20200506 DATE AS OF CHANGE: 20200506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Atara Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001604464 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 460920988 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36548 FILM NUMBER: 20852926 BUSINESS ADDRESS: STREET 1: 611 GATEWAY BLVD STREET 2: SUITE 900 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-278-8930 MAIL ADDRESS: STREET 1: 611 GATEWAY BLVD STREET 2: SUITE 900 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 10-Q 1 atra-10q_20200331.htm 10-Q atra-10q_20200331.htm
false Q1 0001604464 --12-31 Large Accelerated Filer 2012-08-01 P6Y6M 0001604464 2020-01-01 2020-03-31 xbrli:shares 0001604464 2020-04-30 iso4217:USD 0001604464 2020-03-31 0001604464 2019-12-31 iso4217:USD xbrli:shares 0001604464 2019-01-01 2019-03-31 0001604464 us-gaap:CommonStockMember 2019-12-31 0001604464 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001604464 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001604464 us-gaap:RetainedEarningsMember 2019-12-31 0001604464 atra:AtTheMarketOfferingMember us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001604464 atra:AtTheMarketOfferingMember us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001604464 atra:AtTheMarketOfferingMember 2020-01-01 2020-03-31 0001604464 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001604464 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001604464 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001604464 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001604464 us-gaap:CommonStockMember 2020-03-31 0001604464 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001604464 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001604464 us-gaap:RetainedEarningsMember 2020-03-31 0001604464 us-gaap:CommonStockMember 2018-12-31 0001604464 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001604464 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001604464 us-gaap:RetainedEarningsMember 2018-12-31 0001604464 2018-12-31 0001604464 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001604464 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001604464 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001604464 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001604464 us-gaap:CommonStockMember 2019-03-31 0001604464 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001604464 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001604464 us-gaap:RetainedEarningsMember 2019-03-31 0001604464 2019-03-31 0001604464 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-03-31 0001604464 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-03-31 0001604464 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001604464 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-03-31 0001604464 atra:EmployeeStockPurchasePlanMember 2020-01-01 2020-03-31 0001604464 atra:EmployeeStockPurchasePlanMember 2019-01-01 2019-03-31 0001604464 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001604464 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001604464 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001604464 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001604464 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001604464 us-gaap:FairValueInputsLevel2Member us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001604464 us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001604464 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001604464 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001604464 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001604464 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001604464 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001604464 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001604464 us-gaap:FairValueInputsLevel2Member us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001604464 us-gaap:FairValueInputsLevel2Member us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001604464 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001604464 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001604464 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001604464 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001604464 2019-01-01 2019-12-31 0001604464 us-gaap:LeaseholdImprovementsMember 2020-03-31 0001604464 us-gaap:LeaseholdImprovementsMember 2019-12-31 0001604464 us-gaap:EquipmentMember 2020-03-31 0001604464 us-gaap:EquipmentMember 2019-12-31 0001604464 us-gaap:MachineryAndEquipmentMember 2020-03-31 0001604464 us-gaap:MachineryAndEquipmentMember 2019-12-31 0001604464 atra:ComputerEquipmentAndSoftwareMember 2020-03-31 0001604464 atra:ComputerEquipmentAndSoftwareMember 2019-12-31 0001604464 us-gaap:FurnitureAndFixturesMember 2020-03-31 0001604464 us-gaap:FurnitureAndFixturesMember 2019-12-31 0001604464 us-gaap:ConstructionInProgressMember 2020-03-31 0001604464 us-gaap:ConstructionInProgressMember 2019-12-31 0001604464 atra:MemorialSloanKetteringCancerCenterAgreementMember 2020-03-31 0001604464 atra:MemorialSloanKetteringCancerCenterAgreementMember 2019-01-01 2019-03-31 0001604464 atra:UnderwrittenPublicOfferingMember us-gaap:WarrantMember 2019-07-18 0001604464 atra:UnderwrittenPublicOfferingMember us-gaap:WarrantMember 2019-07-18 2019-07-18 xbrli:pure 0001604464 atra:UnderwrittenPublicOfferingMember us-gaap:WarrantMember srt:MaximumMember 2019-07-18 2019-07-18 0001604464 atra:UnderwrittenPublicOfferingMember us-gaap:WarrantMember srt:MinimumMember 2019-07-18 2019-07-18 0001604464 atra:UnderwrittenPublicOfferingMember 2020-03-31 0001604464 atra:AtTheMarketOfferingMember atra:CowenAndCompanyLimitedLiabilityCompanyMember srt:MaximumMember 2019-02-25 0001604464 atra:AtTheMarketOfferingMember atra:CowenAndCompanyLimitedLiabilityCompanyMember srt:MaximumMember 2020-02-28 0001604464 atra:AtTheMarketOfferingMember atra:CowenAndCompanyLimitedLiabilityCompanyMember srt:MaximumMember 2019-02-25 2019-02-25 0001604464 atra:AtTheMarketOfferingMember atra:CowenAndCompanyLimitedLiabilityCompanyMember srt:MaximumMember 2020-02-28 2020-02-28 0001604464 atra:CowenAndCompanyLimitedLiabilityCompanyMember atra:AtTheMarketOfferingMember 2020-01-01 2020-03-31 0001604464 atra:CowenAndCompanyLimitedLiabilityCompanyMember atra:AtTheMarketOfferingMember 2020-01-03 2020-01-03 0001604464 atra:CowenAndCompanyLimitedLiabilityCompanyMember atra:TwoThousandNineteenAtTheMarketOfferingMember 2020-03-31 0001604464 atra:CowenAndCompanyLimitedLiabilityCompanyMember atra:TwoThousandTwentyAtTheMarketOfferingMember 2020-03-31 0001604464 us-gaap:RestrictedStockUnitsRSUMember atra:FromDateOfGrantMember 2020-01-01 2020-03-31 0001604464 srt:MinimumMember 2020-01-01 2020-03-31 0001604464 srt:MinimumMember atra:TenPercentShareHolderMember 2020-01-01 2020-03-31 0001604464 atra:EmployeesAndNonEmployeesMember 2020-01-01 2020-03-31 0001604464 srt:MinimumMember atra:EmployeesAndNonEmployeesMember 2020-01-01 2020-03-31 0001604464 atra:EmployeesAndNonEmployeesMember srt:MaximumMember 2020-01-01 2020-03-31 0001604464 atra:TwoThousandAndFourteenEquityIncentivePlanMember 2020-03-31 0001604464 atra:InducementPlanMember 2020-03-31 0001604464 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0001604464 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-03-31 0001604464 us-gaap:RestrictedStockUnitsRSUMember 2020-03-31 0001604464 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0001604464 atra:TwoThousandFourteenEquityIncentivePlanAndInducementPlanMember 2019-12-31 0001604464 atra:TwoThousandFourteenEquityIncentivePlanAndInducementPlanMember 2020-01-01 2020-03-31 0001604464 atra:TwoThousandFourteenEquityIncentivePlanAndInducementPlanMember 2020-03-31 0001604464 us-gaap:EmployeeStockOptionMember 2020-03-31 0001604464 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001604464 atra:TwoThousandEighteenInducementPlanMember 2020-03-31 0001604464 atra:TwoThousandFourteenEmployeeStockPurchasePlanMember 2020-03-31 0001604464 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001604464 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-03-31 0001604464 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-03-31 0001604464 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-03-31

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2020

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from              to             

Commission file number 001-36548

 

ATARA BIOTHERAPEUTICS, INC.

(Exact name of Registrant as specified in its Charter)

 

 

Delaware

 

46-0920988

(State or other jurisdiction of incorporation or organization)

 

(I.R.S. Employer Identification No.)

 

 

 

611 Gateway Blvd., Suite 900

South San Francisco, CA

 

94080

(Address of principal executive offices)

 

(Zip Code)

Registrant’s telephone number, including area code: (650) 278-8930

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

 

Trading Symbol(s)

 

Name of Each Exchange on Which Registered

Common Stock, par value $0.0001 per share

 

ATRA

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).    Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

  

Accelerated filer

 

Non-accelerated filer

 

  

Smaller reporting company

Emerging growth company

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  

The number of outstanding shares of the Registrant’s Common Stock as of April 30, 2020 was 58,952,045 shares.

 

 

 

 


 

ATARA BIOTHERAPEUTICS, INC.

INDEX

 

 

  

 

  

Page

PART I.

  

FINANCIAL INFORMATION

  

 

 

 

 

Item 1.

  

Financial Statements (Unaudited)

  

 

 

 

 

 

  

Condensed Consolidated Balance Sheets

  

3

 

 

 

 

  

Condensed Consolidated Statements of Operations and Comprehensive Loss

  

4

 

 

 

 

  

Condensed Consolidated Statements of Changes in Stockholders’ Equity

  

5

 

 

 

 

  

Condensed Consolidated Statements of Cash Flows

  

6

 

 

 

 

  

Notes to Condensed Consolidated Financial Statements

  

7

 

 

 

Item 2.

  

Management’s Discussion and Analysis of Financial Condition and Results of Operations

  

16

 

 

 

Item 3.

  

Quantitative and Qualitative Disclosures about Market Risk

  

24

 

 

 

Item 4.

  

Controls and Procedures

  

24

 

 

 

PART II.

  

OTHER INFORMATION

  

 

 

 

 

Item 1.

  

Legal Proceedings

  

25

 

 

 

Item 1A.

  

Risk Factors

  

25

 

 

 

Item 2.

  

Unregistered Sales of Equity Securities and Use of Proceeds

  

58

 

Item 3.

  

Defaults Upon Senior Securities

  

58

 

Item 4.

  

Mine Safety Disclosures

  

58

 

Item 5.

  

Other Information

  

58

 

Item 6.

  

Exhibits

  

59

 

 

 

  

Signatures

  

60

 

 

 

 

 

 

2


 

Atara Biotherapeutics, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

(In thousands, except per share amounts)

 

 

 

March 31,

 

 

December 31,

 

 

 

2020

 

 

2019

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

70,203

 

 

$

74,317

 

Short-term investments

 

 

144,428

 

 

 

184,792

 

Restricted cash - short-term

 

 

194

 

 

 

194

 

Prepaid expenses and other current assets

 

 

14,392

 

 

 

13,689

 

Total current assets

 

 

229,217

 

 

 

272,992

 

Property and equipment, net

 

 

54,442

 

 

 

54,176

 

Operating lease assets

 

 

13,691

 

 

 

14,007

 

Restricted cash - long-term

 

 

1,200

 

 

 

1,200

 

Other assets

 

 

997

 

 

 

567

 

Total assets

 

$

299,547

 

 

$

342,942

 

 

 

 

 

 

 

 

 

 

Liabilities and stockholders’ equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

8,079

 

 

$

7,963

 

Accrued compensation

 

 

9,676

 

 

 

14,706

 

Accrued research and development expenses

 

 

7,827

 

 

 

8,341

 

Other current liabilities

 

 

5,938

 

 

 

5,733

 

Total current liabilities

 

 

31,520

 

 

 

36,743

 

Operating lease liabilities - long-term

 

 

13,809

 

 

 

14,136

 

Other long-term liabilities

 

 

1,396

 

 

 

1,282

 

Total liabilities

 

 

46,725

 

 

 

52,161

 

 

 

 

 

 

 

 

 

 

Commitments and contingencies (Note 7)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

Common stock—$0.0001 par value, 500,000 shares authorized as of March 31,

   2020 and December 31, 2019; 58,940 and 56,806 shares issued and

   outstanding as of March 31, 2020 and December 31, 2019, respectively

 

 

6

 

 

 

6

 

Additional paid-in capital

 

 

1,144,082

 

 

 

1,108,516

 

Accumulated other comprehensive income

 

 

204

 

 

 

220

 

Accumulated deficit

 

 

(891,470

)

 

 

(817,961

)

Total stockholders’ equity

 

 

252,822

 

 

 

290,781

 

Total liabilities and stockholders’ equity

 

$

299,547

 

 

$

342,942

 

 

 

See accompanying notes.

3


 

Atara Biotherapeutics, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

(In thousands, except per share amounts)

 

 

 

Three Months Ended March 31,

 

 

 

2020

 

 

2019

 

Operating expenses:

 

 

 

 

 

 

 

 

Research and development

 

$

57,659

 

 

$

48,668

 

General and administrative

 

 

17,038

 

 

 

19,223

 

Total operating expenses

 

 

74,697

 

 

 

67,891

 

Loss from operations

 

 

(74,697

)

 

 

(67,891

)

Interest and other income, net

 

 

1,188

 

 

 

1,634

 

Net loss

 

$

(73,509

)

 

$

(66,257

)

Other comprehensive (loss) gain:

 

 

 

 

 

 

 

 

Unrealized (loss) gain on available-for-sale securities

 

 

(16

)

 

 

378

 

Comprehensive loss

 

$

(73,525

)

 

$

(65,879

)

Net loss per common share:

 

 

 

 

 

 

 

 

Basic and diluted net loss per common share

 

$

(1.20

)

 

$

(1.44

)

 

 

 

 

 

 

 

 

 

Weighted-average shares outstanding used to calculate basic

   and diluted net loss per common share

 

 

61,208

 

 

 

46,124

 

 

See accompanying notes.

4


 

Atara Biotherapeutics, Inc.

Condensed Consolidated Statements of Changes in Stockholders’ Equity

(Unaudited)

(In thousands)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

Common

 

 

Additional

 

 

Other

 

 

 

 

 

 

Total

 

 

 

Stock

 

 

Paid-in

 

 

Comprehensive

 

 

Accumulated

 

 

Stockholders’

 

For the Three Months Ended March 31, 2020

 

Shares

 

 

Amount

 

 

Capital

 

 

Income

 

 

Deficit

 

 

Equity

 

Balance as of December 31, 2019

 

 

56,806

 

 

$

6

 

 

$

1,108,516

 

 

$

220

 

 

$

(817,961

)

 

$

290,781

 

Issuance of common stock through ATM facilities, net of commissions

   and offering costs of $704

 

 

1,528

 

 

 

 

 

 

22,987

 

 

 

 

 

 

 

 

 

22,987

 

Exercise of pre-funded warrants

 

 

57

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

RSU settlements, net of shares withheld

 

 

455

 

 

 

 

 

 

(1,395

)

 

 

 

 

 

 

 

 

(1,395

)

Issuance of common stock pursuant to employee stock awards

 

 

94

 

 

 

 

 

 

1,330

 

 

 

 

 

 

 

 

 

1,330

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

12,644

 

 

 

 

 

 

 

 

 

12,644

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(73,509

)

 

 

(73,509

)

Unrealized loss on available-for-sale securities

 

 

 

 

 

 

 

 

 

 

 

(16

)

 

 

 

 

 

(16

)

Balance as of March 31, 2020

 

 

58,940

 

 

$

6

 

 

$

1,144,082

 

 

$

204

 

 

$

(891,470

)

 

$

252,822

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

Common

 

 

Additional

 

 

Other

 

 

 

 

 

 

Total

 

 

 

Stock

 

 

Paid-in

 

 

Comprehensive

 

 

Accumulated

 

 

Stockholders’

 

For the Three Months Ended March 31, 2019

 

Shares

 

 

Amount

 

 

Capital

 

 

(Loss) Income

 

 

Deficit

 

 

Equity

 

Balance as of December 31, 2018

 

 

45,951

 

 

$

5

 

 

$

866,541

 

 

$

(340

)

 

$

(527,349

)

 

$

338,857

 

Effect of the adoption of ASC topic 842 (Leases)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

364

 

 

 

364

 

Balance as of January 1, 2019

 

 

45,951

 

 

$

5

 

 

$

866,541

 

 

$

(340

)

 

$

(526,985

)

 

$

339,221

 

RSU settlements, net of shares withheld

 

 

197

 

 

 

 

 

 

(4,575

)

 

 

 

 

 

 

 

 

(4,575

)

Issuance of common stock pursuant to employee stock awards

 

 

159

 

 

 

 

 

 

2,898

 

 

 

 

 

 

 

 

 

2,898

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

12,269

 

 

 

 

 

 

 

 

 

12,269

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(66,257

)

 

 

(66,257

)

Unrealized gain on available-for-sale securities

 

 

 

 

 

 

 

 

 

 

 

378

 

 

 

 

 

 

378

 

Balance as of March 31, 2019

 

 

46,307

 

 

$

5

 

 

$

877,133

 

 

$

38

 

 

$

(593,242

)

 

$

283,934

 

 

See accompanying notes.

5


 

Atara Biotherapeutics, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(In thousands)

 

 

 

Three Months Ended March 31,

 

 

 

2020

 

 

2019

 

Operating activities

 

 

 

 

 

 

 

 

Net loss

 

$

(73,509

)

 

$

(66,257

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Stock-based compensation expense

 

 

12,644

 

 

 

12,269

 

Depreciation and amortization expense

 

 

1,949

 

 

 

1,648

 

Amortization (accretion) of investment premiums (discounts)

 

 

42

 

 

 

(458

)

Non-cash operating lease expense

 

 

364

 

 

 

331

 

Asset retirement obligation accretion expense

 

 

19

 

 

 

17

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Prepaid expenses and other current assets

 

 

(1,888

)

 

 

(1,434

)

Other assets

 

 

(209

)

 

 

38

 

Accounts payable

 

 

(590

)

 

 

2,672

 

Accrued compensation

 

 

(5,030

)

 

 

(3,177

)

Accrued research and development expenses

 

 

(514

)

 

 

(13,016

)

Other current liabilities

 

 

(169

)

 

 

(2,572

)

Operating lease liabilities

 

 

(153

)

 

 

(261

)

Net cash used in operating activities

 

 

(67,044

)

 

 

(70,200

)

Investing activities

 

 

 

 

 

 

 

 

Purchases of short-term investments

 

 

(56,851

)

 

 

(7,427

)

Proceeds from maturities and sales of short-term investments

 

 

97,157

 

 

 

75,819

 

Purchases of property and equipment

 

 

(1,333

)

 

 

(796

)

Net cash provided by investing activities

 

 

38,973

 

 

 

67,596

 

Financing activities

 

 

 

 

 

 

 

 

Proceeds from issuance of common stock through ATM facilities, net

 

 

24,277

 

 

 

 

Proceeds from employee stock awards

 

 

1,330

 

 

 

2,747

 

Taxes paid related to net share settlement of restricted stock units

 

 

(1,395

)

 

 

(4,575

)

Principal payments on finance lease obligations

 

 

(90

)

 

 

(98

)

Other financing activities, net

 

 

(165

)

 

 

 

Net cash provided by (used in) financing activities

 

 

23,957

 

 

 

(1,926

)

Decrease in cash, cash equivalents and restricted cash

 

 

(4,114

)

 

 

(4,530

)

Cash, cash equivalents and restricted cash at beginning of period

 

 

75,711

 

 

 

62,092

 

Cash, cash equivalents and restricted cash at end of period

 

$

71,597

 

 

$

57,562

 

Non-cash investing and financing activities

 

 

 

 

 

 

 

 

Property and equipment purchases included in accounts payable and other accrued liabilities

 

$

1,098

 

 

$

666

 

Finance lease assets obtained in exchange for lease obligations

 

$

281

 

 

$

 

Accrued costs related to ATM facilities

 

$

112

 

 

$

 

Receivable for options exercised

 

$

 

 

$

151

 

Supplemental cash flow disclosure

 

 

 

 

 

 

 

 

Cash paid for interest

 

$

17

 

 

$

 

Cash paid for income taxes

 

$

 

 

$

 

 

See accompanying notes.

6


 

Atara Biotherapeutics, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

1.

Description of Business

Atara Biotherapeutics, Inc. (“Atara”, “we”, “our” or “the Company”) was incorporated in August 2012 in Delaware. Atara is a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases, including solid tumors, hematologic cancers and autoimmune disease.

We have several T-cell immunotherapies in clinical development and are progressing multiple next-generation allogeneic chimeric antigen receptor T-cell (“CAR T”) programs.

We have licensed rights to T-cell product candidates from Memorial Sloan Kettering Cancer Center (“MSK”), rights related to our next-generation CAR T programs from MSK and from Moffitt Cancer Center, and rights to know-how and technology from the Council of the Queensland Institute of Medical Research (“QIMR Berghofer”). See Note 6 for further information.

 

2.

Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements include the accounts of Atara and its wholly-owned subsidiaries and have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These condensed consolidated financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, except for the adoption of accounting pronouncements relating to credit losses on financial instruments, implementation of cloud computing arrangements, and simplification of income tax accounting, effective January 1, 2020, as discussed below. In the opinion of management, the condensed consolidated financial statements reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair presentation of the Company’s consolidated financial statements. The results of operations for any interim period are not necessarily indicative of the results to be expected for the full year or any other future period. The condensed consolidated balance sheet as of December 31, 2019 has been derived from audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete consolidated financial statements.

Liquidity and Going Concern

In accordance with Accounting Standards Codification (“ASC”) 205-40, Going Concern, we have evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern for one year from the date the accompanying financial statements are issued. We have incurred significant operating losses since inception and have relied on public and private equity financings to fund our operations. As of March 31, 2020, we had an accumulated deficit of $891.5 million.

As we continue to incur losses, our transition to profitability will depend on the successful development, approval and commercialization of product candidates and on the achievement of sufficient revenues to support our cost structure. We may never achieve profitability, and unless and until we do, we will need to continue to raise additional capital. We expect that our cash, cash equivalents and short-term investments as of March 31, 2020 will be sufficient to fund our planned operations into the second quarter of 2021. However, the uncertainties inherent in the Company’s future operations and in our ability to obtain additional funding raise substantial doubt about our ability to continue as a going concern beyond one year from the date these financial statements are issued. The interim condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. We currently plan to raise additional funding as required, based on the status of our development programs and our projected cash flows. We may also need to pursue the sale or sublicense of rights to the Company’s programs and assets on terms potentially unfavorable to us. If we are unable to obtain additional funding, we will be forced to delay, limit, reduce or terminate preclinical studies, clinical studies or other development activities for one or more of our product candidates.

7


 

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions, and judgments that affect the amounts reported in the financial statements and accompanying notes. Significant estimates relied upon in preparing these financial statements include estimates related to clinical trial and other accruals, stock-based compensation expense and income taxes. Actual results could differ materially from those estimates.

Recent Accounting Pronouncements

The Company considers the applicability and impact of any Accounting Standards Update (“ASU”) issued by the Financial Accounting Standards Board (“FASB”). Other than the ASUs we adopted effective January 1, 2020 and listed below, all other ASUs were assessed and determined to be either not applicable or are expected to have minimal impact on our consolidated financial statements.

Adoption of New Accounting Pronouncements

We adopted ASU No. 2016-13 (as amended by ASUs 2018-19, 2019-04, 2019-05 and 2019-11), Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, prospectively on January 1, 2020. Under this new guidance, a company is required to estimate credit losses on certain types of financial instruments using an expected-loss model, replacing the current incurred-loss model, and record the estimate through an allowance for credit losses. We do not hold material amounts of the types of financial instruments impacted by this guidance on our balance sheet. The guidance also establishes a new impairment model for available-for-sale debt securities. The adoption did not have a material impact on our condensed consolidated balance sheet or our condensed consolidated statements of operations and comprehensive loss, changes in stockholders’ equity, and cash flows for the three months ended March 31, 2020 and 2019.

We adopted ASU No. 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, effective January 1, 2020, electing a prospective adoption method. The new standard requires that certain implementation costs for cloud computing arrangements are capitalized and amortized over the term of associated hosted cloud computing arrangement service. Capitalized implementation costs are classified in the same line on the balance sheet as amounts prepaid for hosted cloud computing arrangement service, or prepaid expenses and other assets. The amortization of the capitalized asset is presented in the same line on the statement of operations and comprehensive loss as the fees for the associated hosted cloud computing arrangement service and not included with depreciation or amortization expense related to property and equipment or intangible assets. Cash flows related to capitalized implementation costs are presented consistent with the presentation of cash flows for fees related to the hosted cloud computing arrangement service, or cash flows used in operating activities. The adoption did not have a material impact on our condensed consolidated balance sheet or our condensed consolidated statements of operations and comprehensive loss, changes in stockholders’ equity, and cash flows for the three months ended March 31, 2020 and 2019.

We adopted ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, as of January 1, 2020, which eliminates certain exceptions related to the general principles in ASC 740 and makes amendments to other areas with the intention of simplifying various aspects related to accounting for income taxes. The provisions of the ASU that are applicable to Atara are applied on a prospective basis. The adoption did not have a material impact on our condensed consolidated balance sheet or our condensed consolidated statements of operations and comprehensive loss, changes in stockholders’ equity, and cash flows for the three months ended March 31, 2020 and 2019.

 

3.

Net Loss per Common Share

Basic net loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock and pre-funded warrants outstanding during the period, without consideration of common share equivalents. Diluted net loss per common share is computed by dividing net loss by the weighted-average number of shares of common stock, pre-funded warrants and common share equivalents outstanding for the period. The pre-funded warrants are included in the computation of basic and diluted net loss per common share as the exercise price is negligible and the pre-funded warrants are fully vested and exercisable. Common share equivalents are only included in the calculation of diluted net loss per common share when their effect is dilutive.

Potential dilutive securities, which include unvested restricted stock units (“RSUs”), unvested performance-based RSUs for which established performance criteria have been achieved as of the end of the respective periods, vested and unvested options to purchase common stock and shares to be issued under our employee stock purchase plan (“ESPP”), have been excluded from the computation of diluted net loss per share as the effect is antidilutive. Therefore, the denominator used to calculate both basic and diluted net loss per common share is the same in all periods presented.

8


 

The following table represents the potential common shares issuable pursuant to outstanding securities as of the related period end dates that were excluded from the computation of diluted net loss per common share, as their inclusion would have an antidilutive effect:

 

 

As of March 31,

 

 

2020

 

 

2019

 

Unvested RSUs

 

3,630,713

 

 

 

1,860,374

 

Vested and unvested options

 

8,096,471

 

 

 

6,842,443

 

ESPP share purchase rights

 

178,397

 

 

 

37,538

 

Total

 

11,905,581

 

 

 

8,740,355

 

 

 

4.

Financial Instruments

Our financial assets are measured at fair value on a recurring basis using the following hierarchy to prioritize valuation inputs, in accordance with applicable U.S. GAAP:

 

Level 1:

Quoted prices in active markets for identical assets or liabilities that we have the ability to access

 

Level 2:

Observable market-based inputs or unobservable inputs that are corroborated by market data such as quoted prices, interest rates and yield curves

 

Level 3:

Inputs that are unobservable data points that are not corroborated by market data

We review the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels of certain securities within the fair value hierarchy. We recognize transfers into and out of levels within the fair value hierarchy in the period in which the actual event or change in circumstances that caused the transfer occurs. There have been no transfers between Level 1, Level 2 and Level 3 in any periods presented.

Financial assets and liabilities are considered Level 2 when their fair values are determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis. U.S. Treasury, government agency and corporate debt obligations, commercial paper and asset-backed securities are valued primarily using market prices of comparable securities, bid/ask quotes, interest rate yields and prepayment spreads and are included in Level 2.

Financial assets and liabilities are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies, or similar techniques, and at least one significant model assumption or input is unobservable. We have no Level 3 financial assets or liabilities.

9


 

The following tables summarize the estimated fair value and related valuation input hierarchy of our available-for-sale securities as of each period end:

 

 

 

 

 

Total

 

 

Total

 

 

Total

 

 

Total

 

 

 

 

 

Amortized

 

 

Unrealized

 

 

Unrealized

 

 

Estimated

 

As of March 31, 2020:

 

Input Level

 

Cost

 

 

Gain

 

 

Loss

 

 

Fair Value

 

 

 

 

 

(in thousands)

 

Money market funds

 

Level 1

 

$

42,382

 

 

$

 

 

$

 

 

$

42,382

 

U.S. Treasury obligations

 

Level 2

 

 

58,993

 

 

 

318

 

 

 

 

 

 

59,311

 

Government agency obligations

 

Level 2

 

 

6,686

 

 

 

9

 

 

 

(2

)

 

 

6,693

 

Corporate debt obligations

 

Level 2

 

 

85,121

 

 

 

92

 

 

 

(210

)

 

 

85,003

 

Commercial paper

 

Level 2

 

 

14,471

 

 

 

 

 

 

 

 

 

14,471

 

Asset-backed securities

 

Level 2

 

 

5,269

 

 

 

2

 

 

 

(4

)

 

 

5,267

 

Total available-for-sale securities

 

 

 

 

212,922

 

 

 

421

 

 

 

(216

)

 

 

213,127

 

Less: amounts classified as cash equivalents

 

 

 

 

(68,689

)

 

 

(10

)

 

 

 

 

 

(68,699

)

Amounts classified as short-term investments

 

 

 

$

144,233

 

 

$

411

 

 

$

(216

)

 

$

144,428

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total

 

 

Total

 

 

Total

 

 

Total

 

 

 

 

 

Amortized

 

 

Unrealized

 

 

Unrealized

 

 

Estimated

 

As of December 31, 2019:

 

Input Level

 

Cost

 

 

Gain

 

 

Loss

 

 

Fair Value

 

 

 

 

 

(in thousands)

 

Money market funds

 

Level 1

 

$

63,554

 

 

$

 

 

$

 

 

$

63,554

 

U.S. Treasury obligations

 

Level 2

 

 

52,805

 

 

 

46

 

 

 

(1

)

 

 

52,850

 

Government agency obligations

 

Level 2

 

 

6,151

 

 

 

1

 

 

 

(1

)

 

 

6,151

 

Corporate debt obligations

 

Level 2

 

 

100,512

 

 

 

180

 

 

 

(10

)

 

 

100,682

 

Commercial paper

 

Level 2

 

 

26,290

 

 

 

 

 

 

 

 

 

26,290

 

Asset-backed securities

 

Level 2

 

 

7,266

 

 

 

6

 

 

 

 

 

 

 

7,272

 

Certificates of deposit

 

Level 2

 

 

500

 

 

 

 

 

 

 

 

 

500

 

Total available-for-sale securities

 

 

 

 

257,078

 

 

 

233

 

 

 

(12

)

 

 

257,299

 

Less: amounts classified as cash equivalents

 

 

 

 

(72,507

)

 

 

 

 

 

 

 

 

(72,507

)

Amounts classified as short-term investments

 

 

 

$

184,571

 

 

$

233

 

 

$

(12

)

 

$

184,792

 

 

The amortized cost and fair value of our available-for-sale securities by contractual maturity were as follows:

 

 

As of March 31, 2020

 

 

As of December 31, 2019

 

 

Amortized

 

 

Estimated

 

 

Amortized

 

 

Estimated

 

 

Cost

 

 

Fair Value

 

 

Cost

 

 

Fair Value

 

 

(in thousands)

 

 

(in thousands)

 

Maturing within one year

$

174,851

 

 

$

174,853

 

 

$

214,085

 

 

$

214,199

 

Maturing in one to five years

 

38,071

 

 

 

38,274

 

 

 

42,993

 

 

 

43,100

 

Total available-for-sale securities

$

212,922

 

 

$

213,127

 

 

$

257,078

 

 

$

257,299

 

 

As of March 31, 2020, no significant facts or circumstances were present to indicate a deterioration in the creditworthiness of the issuers of the available-for-sale securities we hold, and the Company has no requirement or intention to sell these securities before maturity or recovery of their amortized cost basis. We considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic and determined that our investments were not significantly impacted. For all securities with a fair value less than its amortized cost basis, we determined the decline in fair value below amortized cost basis to be immaterial and non-credit related, and therefore no allowance for losses has been recorded. During the three months ended March 31, 2020 and 2019, we did not recognize any impairment losses on our investments.

We have elected the practical expedient to exclude the applicable accrued interest from both the fair value and the amortized cost basis of our available-for-sale securities for purposes of identifying and measuring an impairment. We present accrued interest receivable related to our available-for-sale securities in prepaid expenses and other current assets, separate from short-term investments on our condensed consolidated balance sheet. As of March 31, 2020 and December 31, 2019, accrued interest receivable was $0.8 million and $0.9 million, respectively. Our accounting policy is to not measure an allowance for credit losses for accrued interest receivables and to write-off any uncollectible accrued interest receivable as a reversal of interest income in a timely manner, which we consider to be in the period in which we determine the accrued interest will not be collected by us. We have not written off any accrued interest receivables for the three months ended March 31, 2020 and 2019.

10


 

In addition, restricted cash collateralized by money market funds is a financial asset measured at fair value and is a Level 1 financial instrument under the fair value hierarchy. As of March 31, 2020 and December 31, 2019, restricted cash was $1.4 million. 

The following table provides a reconciliation of cash, cash equivalents and restricted cash within the condensed consolidated balance sheets that sum to the total of the same such amounts in the condensed consolidated statement of cash flows:

 

 

 

March 31,

 

 

December 31,

 

 

 

2020

 

 

2019

 

 

 

(in thousands)

 

Cash and cash equivalents

 

$

70,203

 

 

$

74,317

 

Restricted cash - short term

 

 

194

 

 

 

194

 

Restricted cash - long term

 

 

1,200

 

 

 

1,200

 

Total cash, cash equivalents and restricted cash

 

$

71,597

 

 

$

75,711

 

 

 

5.

Property and Equipment

Property and equipment consisted of the following as of each period end:

 

 

 

March 31,

 

 

December 31,

 

 

 

2020

 

 

2019

 

 

 

(in thousands)

 

Leasehold improvements

 

$

49,703

 

 

$

49,028

 

Lab equipment

 

 

7,060

 

 

 

6,815

 

Machinery and equipment

 

 

4,074

 

 

 

3,832

 

Computer equipment and software

 

 

3,797

 

 

 

3,299

 

Furniture and fixtures

 

 

2,019

 

 

 

1,764

 

Construction in progress

 

 

1,356

 

 

 

1,116

 

Property and equipment, gross

 

 

68,009

 

 

 

65,854

 

Less: accumulated depreciation and amortization

 

 

(13,567

)

 

 

(11,678

)

Property and equipment, net

 

$

54,442

 

 

$

54,176

 

 

Depreciation and amortization expense was $1.9 million and $1.6 million for the three months ended March 31, 2020 and 2019.

 

6.

License and Collaboration Agreements

MSK Agreements – In June 2015, we entered into an exclusive license agreement with MSK for three clinical stage T-cell therapies. We are required to make additional payments of up to $33.0 million to MSK based on achievement of specified regulatory and sales-related milestones, as well as mid-single-digit percentage tiered royalty payments based on future sales of products resulting from the development of the licensed product candidates, if any. In addition, under certain circumstances, we are required to make certain minimum annual royalty payments to MSK, which are creditable against earned royalties owed for the same annual period. We are also required to pay a low double-digit percentage of any consideration we receive for sublicensing the licensed rights. The license agreement expires on a product-by-product and country-by-country basis on the later of: (i) expiration of the last licensed patent rights related to each licensed product, (ii) expiration of any market exclusivity period granted by law with respect to each licensed product, and (iii) a specified number of years after the first commercial sale of the licensed product in each country. Upon expiration of the license agreement, Atara will retain non-exclusive rights to the licensed products.

In May 2018 and December 2018, we licensed additional technology from MSK. In connection with the effectiveness of the December 2018 license agreement, we made upfront cash payments of $12.5 million in the first quarter of 2019, which were recorded as research and development expense in our consolidated statement of operations and comprehensive loss in the fourth quarter of 2018. We are obligated to make additional milestone payments based on achievement of specified development, regulatory and sales-related milestones, as well as mid-single-digit percentage tiered royalty payments based on future sales of products resulting from the development of the licensed product candidates, if any.

11


 

QIMR Berghofer Agreements – In October 2015, we entered into an exclusive license agreement and a research and development collaboration agreement with QIMR Berghofer. Under the terms of the license agreement, we obtained an exclusive, worldwide license to develop and commercialize allogeneic T-cell therapy programs utilizing technology and know-how developed by QIMR Berghofer. In September 2016, the exclusive license agreement and research and development collaboration agreement were amended and restated. Under the amended and restated agreements, we obtained an exclusive, worldwide license to develop and commercialize additional T-cell programs, as well as the option to license additional technology. We exercised this option in June 2018. We further amended and restated our license agreement and research and development collaboration agreements with QIMR Berghofer in August 2019 to eliminate our license to certain rights related to cytomegalovirus. Our current license agreement also provides for various milestone and royalty payments to QIMR Berghofer based on future product sales, if any. Under the terms of our current research and development collaboration agreement, we are also required to reimburse the cost of agreed-upon development activities related to programs developed under the collaboration. These payments are expensed on a straight-line basis over the related development periods. The agreement also provides for various milestone payments to QIMR Berghofer based on achievement of certain developmental and regulatory milestones.

From time to time, we have entered into other license and collaboration agreements with other parties. For example, we licensed additional rights related to our MSK-partnered next-generation CAR T programs from MSK in May 2018 and we licensed rights related to our next-generation CAR T programs from Moffitt Cancer Center in August 2018, and we agreed to collaborate through sponsored research in connection with each of these licenses. We also licensed rights related to our MSK-partnered next generation CAR T programs from the National Institutes of Health in December 2018.

Milestones and royalties under each of the above agreements are contingent upon future events and will be recorded as expense when it is probable that the milestones will be achieved or royalties are due. As of March 31, 2020 and December 31, 2019, there were no outstanding obligations for milestones and royalties under our license and collaboration agreements.

Cognate Agreement - In December 2019, we entered into a Commercial Manufacturing Services Agreement (the “Manufacturing Agreement”) with Cognate BioServices, Inc. (“Cognate”) to supersede the Development and Manufacturing Agreement that was entered into with Cognate in August 2015 and amended in December 2017, May 2018, November 2018, June 2019 and November 2019. Pursuant to the Manufacturing Agreement, Cognate provides manufacturing services for certain of our product candidates. The initial term of the Manufacturing Agreement is from January 1, 2020 until December 31, 2021 and is renewable with Cognate’s approval for an additional one-year period. We may terminate the Manufacturing Agreement for convenience on six months’ written notice to Cognate, or immediately if Cognate is unable to perform the services under the Manufacturing Agreement or fails to obtain or maintain certain necessary approvals. The Manufacturing Agreement includes standard mutual termination rights for uncured breach or insolvency, or a force majeure event preventing the performance of services for at least ninety days.

7.

Commitments and Contingencies

License and Collaboration Agreements

Potential payments related to our license and collaboration agreements, including milestone and royalty payments, are detailed in Note 6.

Other Research and Development Agreements

We may enter into contracts in the normal course of business with clinical research organizations for clinical trials, with contract manufacturing organizations for clinical supplies, and with other vendors for pre-clinical studies, supplies and other services for our operating purposes. These contracts generally provide for termination on notice. As of March 31, 2020 and December 31, 2019, there were immaterial and no amounts accrued related to contract termination charges or minimum purchase volumes not being met, respectively.

 

Indemnification Agreements

In the normal course of business, we enter into contracts and agreements that contain a variety of representations and warranties and provide for indemnification for certain liabilities. The exposure under these agreements is unknown because it involves claims that may be made against us in the future but have not yet been made. To date, we have not paid any claims or been required to defend any action related to our indemnification obligations. However, we may record charges in the future as a result of these indemnification obligations. We also have indemnification obligations to our directors and executive officers for specified events or occurrences, subject to some limits, while they are serving at our request in such capacities. There have been no claims to date and we believe the fair value of these indemnification agreements is minimal. Accordingly, we did not record liabilities for these agreements as of March 31, 2020 and December 31, 2019.

12


 

Contingencies

From time to time, we may be involved in legal proceedings, as well as demands, claims and threatened litigation, which arise in the normal course of our business or otherwise. The ultimate outcome of any litigation is uncertain and unfavorable outcomes could have a negative impact on our results of operations and financial condition. Regardless of outcome, litigation can have an adverse impact on us because of the defense costs, diversion of management resources and other factors. We are not currently involved in any material legal proceedings.

 

8.

Stockholders’ Equity

Our authorized capital stock consists of 520,000,000 shares, all with a par value of $0.0001 per share, of which 500,000,000 shares are designated as common stock and 20,000,000 shares are designated as preferred stock. There were no shares of preferred stock outstanding as of March 31, 2020 and December 31, 2019.

 

As part of our July 2019 underwritten public offering, we issued and sold pre-funded warrants to purchase shares of common stock. Each pre-funded warrant entitles the holder to purchase one share of common stock at an exercise price of $0.0001 per share and expires seven years from the date of issuance. These warrants were recorded as a component of stockholders’ equity within additional paid-in capital. Per the terms of the warrant agreement, a holder of the outstanding warrants is not entitled to exercise any portion of any pre-funded warrant if, upon exercise of the warrant, the holder’s ownership (together with its affiliates) of our common stock or combined voting power of our securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% after giving effect to the exercise (“Maximum Ownership Percentage”). Upon at least 61 days’ prior notice to us by the holder, any holder may increase or decrease the Maximum Ownership Percentage to any other percentage not to exceed 19.99%. As of March 31, 2020, 2,888,526 pre-funded warrants were outstanding.

 

ATM Facilities

 

In February 2019, we entered into a sales agreement (the “2019 ATM Facility”) with Cowen and Company, LLC (“Cowen”), which provides for the sale, in our sole discretion, of shares of our common stock, in the aggregate offering price of up to $100.0 million through Cowen, as our sales agent. The issuance and sale of these shares by us pursuant to the 2019 ATM Facility are deemed “at the market” offerings as defined in Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”), and are registered under the Securities Act. We pay a commission of up to 3.0% of gross sales proceeds of any common stock sold under the 2019 ATM Facility.

 

In February 2020, we entered into a new sales agreement (the “2020 ATM Facility”) with Cowen, which provides for the sale, in our sole discretion, of shares of our common stock having an aggregate offering price of up to $100.0 million through Cowen, as our sales agent. The 2020 ATM Facility is separate from and does not replace the 2019 ATM Facility in any way. The issuance and sale of these shares by us pursuant to the 2020 ATM Facility are deemed “at the market” offerings and are registered under the Securities Act of 1933, as amended. We will pay a commission of up to 3.0% of gross sales proceeds of any common stock sold under the 2020 ATM Facility.

 

During the three months ended March 31, 2020, we sold an aggregate of 1,528,216 shares of common stock under the 2019 ATM Facility, at an average price of $15.50 per share, for gross proceeds of $23.7 million and net proceeds of $23.1 million, after deducting commissions and other offering expenses payable by us. Additionally, on January 3, 2020, we received net proceeds of approximately $1.2 million from sales of shares of common stock under the 2019 ATM Facility that occurred during 2019. As of March 31, 2020, $25.9 million and $100.0 million of common stock remained available to be sold under the 2019 ATM Facility and 2020 ATM Facility, respectively, subject to certain conditions as specified in the agreement.

 

Equity Incentive Plans

Under the terms of the 2014 Equity Incentive Plan, as amended (“2014 EIP”), we may grant stock options, restricted stock awards (“RSAs”) and RSUs to employees, directors, consultants and other service providers. RSUs generally vest over four years. In the first quarter of 2020, we granted performance-based RSUs to certain of our employees that provide for the issuance of common stock if specified Company performance criteria related to our clinical programs are achieved. The number of performance-based RSUs that ultimately vests depends upon if, when and which performance criteria are achieved, as well as the employee’s continuous service, as defined in the 2014 EIP, through the date of vesting. The fair value of performance-based RSUs is determined as the closing stock price on the date of grant.

13


 

Stock options are granted at prices no less than 100% of the estimated fair value of the shares on the date of grant as determined by the board of directors, provided, however, that the exercise price of an option granted to a 10% shareholder cannot be less than 110% of the estimated fair value of the shares on the date of grant. Options granted generally vest over four years and expire in seven to ten years. As of March 31, 2020, a total of 14,316,451 shares of common stock were reserved for issuance under the 2014 EIP, of which 2,483,425 shares were available for future grant and 11,833,026 shares were subject to outstanding options and RSUs, including performance-based RSUs.

In February 2018, we adopted the 2018 Inducement Plan (“Inducement Plan”), under which we may grant options, stock appreciation rights, RSAs and RSUs to new employees. As of March 31, 2020, 1,196,086 shares of common stock were reserved for issuance under the Inducement Plan, of which 272,336 shares were available for future grant and 923,750 shares were subject to outstanding options and RSUs.

Restricted Stock Units

The following is a summary of RSU activity under our 2014 EIP and Inducement Plan:

 

 

 

RSUs

 

 

 

Shares

 

 

Weighted

Average

Grant Date Fair Value

 

Unvested as of December 31, 2019

 

 

1,910,764

 

 

$

26.93

 

Granted

 

 

3,387,890

 

 

$

12.15

 

Forfeited

 

 

(85,851

)

 

$

18.66

 

Vested

 

 

(552,498

)

 

$

25.04

 

Unvested as of March 31, 2020

 

 

4,660,305

 

 

$

16.56

 

 

As of March 31, 2020, there was $63.9 million of unrecognized stock-based compensation expense related to RSUs that is expected to be recognized over a weighted average period of 2.9 years. This excludes unrecognized stock-based compensation expense for performance-based RSUs that were deemed not probable of vesting in accordance with U.S GAAP.

 

Stock Options

The following is a summary of stock option activity under our 2014 EIP and Inducement Plan. The table below also includes the activity relating to options for 275,000 shares of our common stock which were issued in 2017 outside of these plans:

 

 

 

Shares

 

 

Weighted Average

Exercise Price

 

 

Weighted Average

Remaining

Contractual Term

(Years)

 

 

Aggregate Intrinsic

Value

(in thousands)

 

Outstanding as of December 31, 2019

 

 

6,934,262

 

 

$

28.25

 

 

 

 

 

 

 

 

 

Granted

 

 

1,489,925

 

 

 

12.91

 

 

 

 

 

 

 

 

 

Exercised

 

 

(93,719

)

 

 

14.19

 

 

 

 

 

 

 

 

 

Forfeited or expired

 

 

(233,997

)

 

 

32.28

 

 

 

 

 

 

 

 

 

Outstanding as of March 31, 2020

 

 

8,096,471

 

 

$

25.47

 

 

 

6.5

 

 

$

-

 

 

Aggregate intrinsic value represents the difference between the closing stock price of our common stock on March 31, 2020 and the exercise price of outstanding, in-the-money options. As of March 31, 2020, there was $71.1 million of unrecognized stock-based compensation expense related to stock options that is expected to be recognized over a weighted average period of 3.0 years.

14


 

Reserved Shares

The following shares of common stock were reserved for future issuance under our equity incentive plans as of March 31, 2020:

 

 

Total Shares

Reserved

 

2014 Equity Incentive Plan

 

14,316,451

 

2018 Inducement Plan

 

1,196,086

 

2014 Employee Stock Purchase Plan

 

1,233,317

 

Total reserved shares of common stock

 

16,745,854

 

 

Stock-based Compensation Expense

Total stock-based compensation expense related to all employee and non-employee stock awards was as follows:

 

 

Three Months Ended March 31,

 

 

2020

 

 

2019

 

 

(in thousands)

 

Research and development

$

7,650

 

 

$

6,065

 

General and administrative

 

4,994

 

 

 

6,204

 

Total stock-based compensation expense

$

12,644

 

 

$

12,269

 

 

15


 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with our condensed consolidated financial statements and related notes included elsewhere in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020. This discussion and other parts of this Quarterly Report contain forward-looking statements that involve risk and uncertainties, such as statements of our plans, objectives, expectations and intentions. As a result of many factors, including those factors set forth in the “Risk Factors” section of this Quarterly Report, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Overview

Atara Biotherapeutics is a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases, including solid tumors, hematologic cancers and autoimmune disease. With our lead program in Phase 3 clinical development, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases or other severe diseases through incorporation of engineered chimeric antigen receptors, or CARs, or T-cell receptors, or TCRs. Atara is applying this one platform to create a robust pipeline. Our strategic priorities are:

 

Tab-cel®: Atara’s most advanced T-cell immunotherapy, tab-cel® (tabelecleucel), currently in Phase 3 development for patients with Epstein-Barr virus, or EBV, associated post-transplant lymphoproliferative disease, or EBV+ PTLD, who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-associated hematologic malignancies and solid tumors;

 

ATA188: T-cell immunotherapy targeting EBV antigens believed to be important for the potential treatment of multiple sclerosis;

 

ATA2271/ATA3271: CAR T immunotherapy targeting mesothelin, with autologous (ATA2271) to allogeneic (ATA3271) development planned; and

 

ATA3219: Allogeneic CAR T targeting CD19 as proof-of-concept for our next generation technologies and EBV T-cell CAR T platform.

Our T-cell immunotherapy platform includes the capability to progress both allogeneic and autologous programs and is potentially applicable to a broad array of targets and diseases. Our off-the-shelf, allogeneic T-cell platform allows for rapid delivery of a T-cell immunotherapy product manufactured in advance of patient need and stored in inventory, with each manufactured lot of cells providing therapy for numerous potential patients. This differs from autologous treatments, in which each patient’s own cells must be extracted, genetically modified outside the body and then delivered back to the patient, and requires a complex logistics network. For our allogeneic programs, we select the appropriate set of cells for use based on a patient’s unique immune profile. In addition, our manufacturing facility is capable of producing multiple types of therapies and Atara MatchMe™, our proprietary T-cell order management platform, is being developed to select and deliver the most appropriate treatments to the healthcare teams caring for patients.

We have entered into research collaborations with leading academic institutions such as Memorial Sloan Kettering Cancer Center, or MSK, the Council of the Queensland Institute of Medical Research, or QIMR Berghofer, and H. Lee Moffitt Cancer Center and Research Institute, or Moffitt, to acquire rights to novel and proprietary technologies and programs.

We recognize that our clinical studies may not be available to all patients and we have established expanded access and compassionate use programs in instances where there is a significant patient need.

Pipeline

Tab-cel®

Atara’s most advanced T-cell immunotherapy, tab-cel®, is in Phase 3 development for the treatment of patients with EBV+ PTLD who have failed rituximab or rituximab plus chemotherapy. Based on our market research, we estimate there were several hundred EBV+ PTLD patients who failed rituximab or rituximab plus chemotherapy in the U.S. in 2018. Tab-cel® is also under development for other EBV-associated hematologic malignancies and solid tumors through a multi-cohort study, and for nasopharyngeal carcinoma, or NPC, in a separate clinical study.

16


 

While clinical study operations and the opening of additional Phase 3 study sites in the United States, Canada and Europe have been impacted by the spread of COVID-19, at this time most sites remain open for patient enrollment, and we believe we remain on track to initiate a biologics license application, or BLA, submission for patients with EBV+ PTLD in the second half of 2020. We plan to discuss the totality of tab-cel® data with the U.S. Food and Drug Administration, or FDA, in a pre-BLA meeting prior to initiating the BLA submission. We remain in discussions with the European Medicines Agency, or EMA, and have submitted a Pediatric Investigation Plan, or PIP, to EMA. Following an agreement with EMA on the PIP, we plan to submit a tab-cel® EU marketing authorization application for patients with EBV+ PTLD in 2021.

In 2019, after discussion and alignment with regulators, we combined MATCH and ALLELE into a single study (which we now refer to as the ALLELE study) that now consists of a hematopoietic cell transplants, or HCT, cohort for EBV+ PTLD patients who have failed rituximab and a single solid organ transplant, or SOT, cohort for EBV+ PTLD patients who have failed rituximab with both chemotherapy and non-chemotherapy prior treatment experience. Additionally, we expect to expand the ALLELE study geographically to include clinical sites outside the U.S. We have submitted clinical trial applications, or CTAs, to several European countries to enable opening European clinical sites in 2020, and our CTAs in United Kingdom, Spain, France and Austria have been approved.

We expect to pursue development of tab-cel® in earlier lines of therapy, including in our planned Phase 2 multi-cohort study. Based on clinical data from treating a variety of ultra-rare EBV+ diseases, we expect to initiate enrollment in this study, including up to six additional ultra-rare EBV+ patient populations, in the second half of 2020.

Our Phase 1/2 study of tab-cel® in combination with Merck’s anti-PD-1 (programmed death receptor-1) therapy, KEYTRUDA® (pembrolizumab), in patients with platinum-resistant or recurrent EBV-associated NPC enrolled the final planned patient in the Phase 1b part of the study in February 2020. Based on our market research, we estimate the incidence during 2018 of NPC in the U.S., United Kingdom, France, Germany, Italy and Spain was collectively approximately 3,800 patients and approximately 71,000 patients in East Asia. Our study is designed to address a sub-population of the total incidence of this disease.

ATA188

Atara is also developing ATA188, a T-cell immunotherapy targeting EBV antigens believed to be important for the potential treatment of multiple sclerosis, or MS. In the fourth quarter of 2017, we initiated an open label, single arm, multi-center, multi-national Phase 1 study with allogeneic ATA188 for patients with progressive MS, or PMS. The primary objective of this Phase 1 study is to assess the safety of ATA188 in patients followed for at least one year after the first dose. Key secondary endpoints in the study include measures of clinical improvement, using recognized scales for MS symptoms, function and disability including Expanded Disability Status Scale, or EDSS, Fatigue Severity Score, MS Impact Scale-29 (physical), Timed 25-Foot Walk (T25FW), 9-Hole Peg Test, 12-Item MS Walking Scale (MSWS-12) and Visual Acuity. Enrollment for the fourth and final Phase 1 dose escalation cohort was completed in the third quarter of 2019 and we presented initial efficacy and updated safety results from this study in September 2019 at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). These results were based on data as of July 29, 2019, and showed that across four planned dose cohorts, ATA188 was well tolerated in PMS patients, with no evidence of cytokine release syndrome, graft versus host disease or dose-limiting toxicities.

Following a six-month assessment of patients in cohort 3 of this study, we selected this cohort 3 dose to initiate the randomized, placebo-controlled Phase 1b part of this study. Although we have temporarily paused the screening and enrollment of patients in this study to ensure sites can focus on meeting the needs of patients with COVID-19 and to protect the safety of study participants, investigators and staff, we still expect to initiate enrollment in the second or third quarter of 2020. We expect to present ATA188 Phase 1a six-month clinical results for the dose-escalating cohorts 1-4 and 12-month results for cohorts 1-3 in an appropriate forum in the second quarter of 2020. Additionally, we expect to present 12-month cohort 4 data in the second half of 2020.

ATA2271/ATA3271

Atara’s pipeline includes next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 targeting mesothelin, which are partnered with MSK.

We have prioritized our mesothelin-targeted next-generation CAR T program, which consists of ATA2271 and ATA3271. Results from an academic program run by our collaborators at MSK have demonstrated that regionally-delivered mesothelin-targeted, 1st generation autologous CAR T cells were well tolerated and showed encouraging anti-tumor activity in combination with pembrolizumab, a PD-1 checkpoint inhibitor. These collaborator results support our planned development of ATA2271, a next-generation, mesothelin-targeted autologous CAR T immunotherapy using MSK’s novel 1XX CAR signaling domain and PD-1 dominant negative receptor, or DNR, checkpoint inhibition technologies for patients with mesothelin-associated solid tumors. We expect our collaborators at MSK to submit an investigational new drug, or IND, application to the FDA for ATA2271 for patients with advanced mesothelioma in the second or third quarter of 2020. Data from IND-enabling studies for ATA2271 are expected to be presented at an appropriate forum in the second quarter of 2020. Additional clinical data for the first-generation academic program from MSK are expected to be presented in an upcoming forum in the second half of 2020. In parallel, we have initiated IND-enabling studies for an allogeneic version of this mesothelin CAR T program, ATA3271.

17


 

ATA3219

We are also developing ATA3219, an off-the-shelf allogeneic CAR T immunotherapy targeting CD19 for patients with B-cell lymphomas, to serve as a potential proof-of-concept for our next generation technologies and allogeneic EBV CAR T platform, and we have initiated IND-enabling studies for this program.

In February 2020, an academic off-the-shelf, allogeneic CD19 CAR T clinical study using an EBV T-cell construct for patients with relapsed/refractory B-cell malignancies was presented at the 2020 Transplantation and Cellular Therapy (TCT) Meetings. Findings from this study provide initial clinical proof-of-principle that an EBV T-cell platform has the potential to generate off-the-shelf, allogeneic CAR T immunotherapies with high and durable responses, low risk of toxicity and that can be rapidly delivered to patients.

Additional Programs and Platform Expansion Activities

In addition to the prioritized programs described above, we have a number of preclinical programs. For example, in August 2018, we entered into a strategic collaboration with Moffitt. As part of this relationship, we agreed to collaborate with Moffitt to develop multi-targeted CAR T immunotherapies designed to address cancers with diverse cell types that often become resistant to treatment, such as acute myeloid leukemia, or AML, (ATA2321) and B-cell malignancies (ATA2431), and to make certain milestone and royalty payments associated with the collaboration targets. In addition, the collaboration includes the use of novel CAR T intracellular co-stimulatory domains that may improve CAR T proliferation when responding to an appropriate antigen and enhance CAR T persistence by reducing T-cell exhaustion.

We believe our platform will have utility beyond the current set of targets to which it has been directed. We continue to evaluate additional product candidates, including those derived from collaborations with our partners. We expect to further research and develop additional cellular therapies, which may include T-cell programs targeted against other antigens as well as engineered T-cell immunotherapies such as CAR T-cell programs. We believe that viral antigens are well suited to adoptive immunotherapy given that people with normal immune systems are able to mount robust responses to these viral targets, but immunocompromised patients and some cancer patients are not. We also continue to evaluate opportunities to license or acquire additional product candidates or technologies to enhance our existing platform.

Manufacturing

Our manufacturing facility in Thousand Oaks, California has the flexibility to manufacture multiple T-cell and CAR T immunotherapies while integrating research and process science functions to enable increased collaboration for rapid product development. Our research and development and process and analytical development labs are currently supporting preclinical development activities. Our facility is designed to global regulatory standards, and the required facility commissioning and qualification activities to support clinical manufacturing are complete. Commercial production qualification activities for our facility are progressing well and, together with our contracted manufacturing partner, are aligned with our planned commercial product supply strategy.

In addition to our manufacturing facility, we also work with Cognate BioServices, Inc., or Cognate, pursuant to a Commercial Manufacturing Services Agreement, or the Manufacturing Agreement, that we entered into in December 2019. Pursuant to the Manufacturing Agreement, Cognate provides manufacturing services for certain of our product candidates. The initial term of the Manufacturing Agreement runs until December 31, 2021 and is renewable with Cognate’s approval for an additional one-year period. We may terminate the Manufacturing Agreement for convenience on six months’ written notice to Cognate, or immediately if Cognate is unable to perform the services under the Manufacturing Agreement or fails to obtain or maintain certain necessary approvals. The Manufacturing Agreement includes standard mutual termination rights for uncured breach or insolvency, or a force majeure event preventing the performance of services for at least ninety days.

 

Financial Overview

We have a limited operating history. Since our inception in 2012, we have devoted substantially all of our resources to identify, acquire and develop our product candidates, including conducting preclinical and clinical studies, acquiring or manufacturing materials for clinical studies, constructing our manufacturing facility and providing general and administrative support for these operations.

18


 

Our net losses were $73.5 million and $66.3 million for the three months ended March 31, 2020 and 2019, respectively. As of March 31, 2020, we had an accumulated deficit of $891.5 million. Substantially all of our net losses have resulted from costs incurred in connection with our research and development programs and from general and administrative expenses associated with our operations. As of March 31, 2020, our cash, cash equivalents and short-term investments totaled $214.6 million, which we intend to use to fund our operations. We are actively seeking additional funds through additional public or private equity offerings or debt financings, through potential collaborations, partnering or other strategic arrangements, or a combination of the foregoing.

Revenues

We have never generated revenues and have incurred losses since inception. We do not expect to receive any revenues from any product candidates that we develop until we obtain regulatory approval and commercialize our products or enter into collaborative agreements with third parties.

Research and Development Expenses

The largest component of our total operating expenses since inception has been our investment in research and development activities, including the preclinical and clinical development of our product candidates. Research and development expenses consist primarily of compensation and benefits for research and development employees, including stock-based compensation; expenses incurred under agreements with contract research organizations and investigative sites that conduct preclinical and clinical studies; the costs of acquiring and manufacturing clinical study materials and other supplies; payments under licensing and research and development agreements; other outside services and consulting costs; and facilities, information technology and overhead expenses. Research and development costs are expensed as incurred.

We plan to continue investment in the development of our product candidates. Our current planned research and development activities include the following:

 

continuing to initiate sites and enroll patients in our Phase 3 clinical study of tab-cel® for the treatment of patients with EBV+ PTLD after HCT and SOT who have failed rituximab;

 

process development, testing and manufacturing of drug supply to support clinical studies and IND-enabling studies;

 

continuing to develop product candidates based on our next-generation CAR T programs;

 

continuing development of ATA188 in progressive MS;

 

continuing to develop our product candidates in additional indications, including tab-cel® for NPC and EBV+ cancers;

 

continuing to develop other pre-clinical product candidates; and

 

leveraging our relationships and experience to in-license or acquire additional product candidates or technologies.

In addition, we believe it is important to invest in the development of new product candidates to continue to build the value of our product candidate pipeline and our business. We plan to continue to advance our most promising early product candidates into preclinical development with the objective to advance these early-stage programs to human clinical studies over the next several years.

Our expenditures on current and future preclinical and clinical development programs are subject to numerous uncertainties in timing and cost to completion. The duration, costs, and timing of clinical studies and development of our product candidates will depend on a variety of factors, including:

 

the availability of qualified drug supply for use in our ongoing Phase 3 or other clinical studies;

 

the scope, rate of progress, and expenses of our ongoing clinical studies, potential additional clinical studies and other research and development activities;

 

the potential review or reanalysis of our clinical study results;

 

future clinical study results;

 

uncertainties in clinical study enrollment rates or discontinuation rates of patients, including any potential impact of the COVID-19 pandemic;

19


 

 

potential additional safety monitoring or other studies requested by regulatory agencies;

 

changing medical practice patterns related to the indications we are investigating;

 

significant and changing government regulation;

 

disruptions caused by manmade or natural disasters or public health pandemics or epidemics, including, for example, the recent outbreak of COVID-19; and

 

the timing and receipt of any regulatory approvals, as well as potential post-market requirements.

The process of conducting the necessary clinical research to obtain approval from the FDA and other regulators is costly and time consuming and the successful development of our product candidates is highly uncertain. The risks and uncertainties associated with our research and development projects are discussed more fully in the section of this report titled “1A. Risk Factors.” As a result of these risks and uncertainties, we are unable to determine with any degree of certainty the duration and completion costs of our research and development projects, or if, when, or to what extent we will generate revenues from the commercialization and sale of any of our product candidates that obtain regulatory approval. We may never succeed in achieving regulatory approval for any of our product candidates.

General and Administrative Expenses

General and administrative expenses consist primarily of compensation and benefits for legal, human resources, finance, commercial and other general and administrative employees, including stock-based compensation; outside professional service costs, including legal, patent, human resources, audit and accounting services; other outside services and consulting costs, including those related to pre-commercial activities; and information technology and facilities costs.

Interest and Other Income, net

Interest and other income, net consists primarily of interest earned on our cash, cash equivalents and short-term investments.

Critical Accounting Policies and Significant Judgments and Estimates

Except for the adoption of ASU No. 2016-13, as amended, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, and ASU No. 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, and ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, none of which had a material impact to us as disclosed in Note 2 to our condensed consolidated financial statements, there have been no significant changes to our critical accounting policies and significant judgments and estimates during the three months ended March 31, 2020 from those disclosed in our management’s discussion and analysis of financial condition and results of operations included in our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on February 27, 2020.

Results of Operations

Comparison of the Three Months Ended March 31, 2020 and 2019

Research and development expenses

Research and development expenses consisted of the following costs, by program, in the periods presented:

 

 

 

Three Months Ended

 

 

 

 

 

 

 

March 31,

 

 

Increase

 

 

 

2020

 

 

2019

 

 

(Decrease)

 

 

 

(in thousands)

 

 

 

 

 

Tab-cel® expenses

 

$

14,798

 

 

$

11,639

 

 

$

3,159

 

ATA188, CAR T and other program expenses

 

 

4,115

 

 

 

6,106

 

 

 

(1,991

)

Employee and overhead expenses

 

 

38,746

 

 

 

30,923

 

 

 

7,823

 

Total research and development expenses

 

$

57,659

 

 

$

48,668

 

 

$

8,991

 

 

Tab-cel® expenses were $14.8 million in the three months ended March 31, 2020, as compared to $11.6 million in the comparative 2019 period. The increase was primarily due to increased production activity, as well as process performance qualification activities at our manufacturing facility.

20


 

ATA188, CAR T and other program expenses were $4.1 million in the three months ended March 31, 2020, as compared to $6.1 million in the comparative 2019 period. The decrease in 2020 was primarily related to lower clinical study, manufacturing and other outside services costs for programs that are no longer in active development.

Employee and overhead expenses were $38.7 million in the three months ended March 31, 2020, as compared to $30.9 million in the comparative 2019 period. The increase was primarily due to higher compensation-related costs from increased headcount and higher facility-related costs in support of our continuing expansion of research and development activities. For the three months ended March 31, 2020, payroll and related costs increased by $6.2 million, facility-related costs increased by $1.3 million and professional services costs increased by $0.3 million.

General and administrative expenses

 

 

 

Three Months Ended

 

 

 

 

 

 

 

March 31,

 

 

Increase

 

 

 

2020

 

 

2019

 

 

(Decrease)

 

 

 

(in thousands)

 

General and administrative expenses

 

$

17,038

 

 

$

19,223

 

 

$

(2,185

)

 

General and administrative expenses decreased to $17.0 million in the three months ended March 31, 2020, as compared to $19.2 million in the comparative 2019 period. The decrease in 2020 was primarily due to a decrease in professional services costs.

Liquidity and Capital Resources

Sources of Liquidity

Since our inception in 2012, we have funded our operations primarily through the issuance of common and preferred stock.

In February 2019, we entered into a sales agreement, or the 2019 ATM Facility, with Cowen and Company, LLC, or Cowen, which provides for the sale, in our sole discretion, of shares of our common stock having an aggregate offering price of up to $100.0 million through Cowen, as our sales agent. The issuance and sale of these shares by us pursuant to the 2019 ATM Facility are deemed “at the market” offerings defined in Rule 415 under the Securities Act of 1933, as amended, or the Securities Act, and are registered under the Securities Act. We pay a commission of up to 3.0% of gross sales proceeds of any common stock sold under the 2019 ATM Facility.

In February 2020, we entered into a new sales agreement (the “2020 ATM Facility”) with Cowen, which provides for the sale, in our sole discretion, of shares of our common stock having an aggregate offering price of up to $100.0 million through Cowen, as our sales agent. The 2020 ATM Facility is separate from and does not replace the 2019 ATM Facility in any way. The issuance and sale of these shares by us pursuant to the 2020 ATM Facility are deemed “at the market” offerings and are registered under the Securities Act of 1933, as amended. We will pay a commission of up to 3.0% of gross sales proceeds of any common stock sold under the 2020 ATM Facility.

During the three months ended March 31, 2020, we sold an aggregate of 1,528,216 shares of common stock under the 2019 ATM Facility, at an average price of $15.50 per share for net proceeds of $23.1 million, after deducting commissions and other offering expenses payable by us. Additionally, on January 3, 2020, we received net proceeds of approximately $1.2 million from sales of shares of our common stock under the 2019 ATM Facility that occurred during 2019.

We have incurred losses and negative cash flows from operations in each year since inception. As of March 31, 2020, we had an accumulated deficit of $891.5 million. We do not expect to receive any revenues from any product candidates that we develop until we obtain regulatory approval and commercialize our products. As such, we anticipate that we will continue to incur losses in the foreseeable future. Additionally, as a result of the COVID-19 outbreak, we have experienced, and may experience in the future, disruptions that could severely impact our business, preclinical studies and clinical trials. We expect that our operating expenses will continue to increase. As a result, we will need additional capital to fund our operations, which we may raise through a combination of equity offerings, debt financings, other third-party funding, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements. We may borrow funds on terms that may include restrictive covenants, including covenants that restrict the operation of our business, liens on assets, high effective interest rates and repayment provisions that reduce cash resources and limit future access to capital markets. In addition, we are actively seeking additional funds through additional public or private equity offerings or debt financings including by utilizing our ATM facilities, through potential collaborations, partnering or other strategic arrangements, or a combination of the foregoing. However, the trading prices for our common stock and other biopharmaceutical companies have been highly volatile as a result of the COVID-19 pandemic. As a consequence, we may face

21


 

difficulties raising capital through sales of our common stock or such sales may be on unfavorable terms. We may face similar difficulties in obtaining funding through debt financing or other arrangements. To the extent that we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. To the extent that we raise additional funds through collaboration or partnering arrangements, we may be required to relinquish some of our rights to our technologies or rights to market and sell our products in certain geographies, grant licenses on terms that are not favorable to us, or issue equity that may be substantially dilutive to our stockholders.

Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. Currently, our cash, cash equivalents and short-term investments are held in bank and custodial accounts and consist of money market funds, U.S. Treasury, government agency and corporate debt obligations, commercial paper and asset-backed securities. We expect that existing cash, cash equivalents and short-term investments as of March 31, 2020 will be sufficient to fund our planned operations into the second quarter of 2021. Refer to the going concern evaluation under Note 2 to our unaudited interim condensed consolidated financial statements included in this report.

Our cash, cash equivalents and short-term investments balances as of the dates indicated were as follows:

 

 

 

March 31,

 

 

December 31,

 

 

 

2020

 

 

2019

 

 

 

(in thousands)

 

Cash and cash equivalents

 

$

70,203

 

 

$

74,317

 

Short-term investments

 

 

144,428

 

 

 

184,792

 

Total cash, cash equivalents and short-term investments

 

$

214,631

 

 

$

259,109

 

 

Cash Flows

Comparison of the Three Months Ended March 31, 2020 and 2019

The following table details the primary sources and uses of cash for each of the periods set forth below:

 

 

 

Three Months Ended March 31,

 

 

 

2020

 

 

2019

 

 

 

(in thousands)

 

Net cash (used in) provided by:

 

 

 

 

 

 

 

 

Operating activities

 

$

(67,044

)

 

$

(70,200

)

Investing activities

 

 

38,973

 

 

 

67,596

 

Financing activities

 

 

23,957

 

 

 

(1,926

)

Net decrease in cash, cash equivalents and restricted cash

 

$

(4,114

)

 

$

(4,530

)

 

Operating activities

Net cash used in operating activities was $67.0 million in the 2020 period as compared to $70.2 million in the 2019 period. The decrease of $3.2 million was primarily due to decreased working capital usage, partially offset by a $7.3 million increase in net loss.

Investing activities

Net cash provided by investing activities in the 2020 period consisted primarily of $97.2 million received from maturities and sales of available-for-sale securities, partially offset by $56.9 million used to purchase available-for-sale securities and $1.3 million in purchases of property and equipment. Net cash provided by investing activities in the 2019 period consisted primarily of $75.8 million received from maturities and sales of available-for-sale securities, partially offset by $7.4 million used to purchase available-for-sale securities.

Financing activities

Net cash provided by financing activities in the 2020 period consisted primarily of $24.3 million of net proceeds received from the 2019 ATM Facility and $1.3 million of net proceeds from employee stock award transactions, partially offset by $1.4 million of taxes paid related to the net share settlement of RSUs. Net cash used in financing activities in the 2019 period consisted primarily of $4.6 million of taxes paid related to the net share settlement of restricted stock, partially offset by $2.7 million of net proceeds from employee stock transactions.

22


 

Operating Capital Requirements and Plan of Operations

To date, we have not generated any revenue from product sales. We do not know when, or if, we will generate any revenue from product sales. We do not expect to generate significant revenue from product sales unless and until we obtain regulatory approval of and commercialize one of our current or future product candidates. We anticipate that we will continue to generate losses for the foreseeable future, and we expect the accumulated losses to increase as we continue the development of and seek regulatory approvals for our product candidates and begin to commercialize any approved products. We are subject to all of the risks inherent in the development of new products, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. We anticipate that we will need to raise substantial additional funding in connection with our continuing and expected expansion of our operations.

We expect that our existing cash, cash equivalents and short-term investments will be sufficient to fund our planned operations into the second quarter of 2021. In order to complete the process of obtaining regulatory approval for any of our product candidates and to build the sales, marketing and distribution infrastructure that we believe will be necessary to commercialize our product candidates, if approved, we will require substantial additional funding. Currently, we are actively seeking additional funds through additional public or private equity offerings or debt financings, through potential collaborations, partnering or other strategic arrangements, or a combination of the foregoing.

We have based our projections of operating capital requirements on assumptions that may prove to be incorrect and we may use all of our available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:

 

the timing and costs of our ongoing and planned clinical and preclinical studies for our product candidates, including any potential impact of the COVID-19 pandemic;

 

our success in establishing and scaling commercial manufacturing capabilities;

 

the number and characteristics of product candidates that we pursue;

 

the outcome, timing and costs of seeking regulatory approvals;

 

subject to receipt of regulatory approval, costs associated with the commercialization of our product candidates and the amount of revenues received from commercial sales of our product candidates;

 

the terms and timing of any future collaborations, licensing, consulting or other arrangements that we may establish;

 

the amount and timing of any payments we may be required to make in connection with the licensing, filing, prosecution, maintenance, defense and enforcement of any patents or patent applications or other intellectual property rights;

 

the extent to which we in-license or acquire other products and technologies; and

 

the timing of capital expenditures, including the qualification of our manufacturing facility.

Until we are able to generate a sufficient amount of product revenue and generate positive net cash flows from operations, which we may never do, meeting our long-term capital requirements is in large part reliant on access to public and private equity and debt capital markets, augmented by cash generated from operations and interest income earned on the investment of our cash balances. We are actively seeking and expect to continue to seek access to the equity and debt capital markets to support our development efforts and operations. To the extent that we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. To the extent that we raise additional funds through collaboration or partnering arrangements, we may be required to relinquish some of our rights to our technologies or rights to market and sell our products in certain geographies, grant licenses on terms that are not favorable to us, or issue equity that may be substantially dilutive to our stockholders.

As a result of economic conditions, general global economic uncertainty, political change and other factors, including the ongoing COVID-19 pandemic, we do not know whether additional capital will be available when needed, or that, if available, we will be able to obtain additional capital on reasonable terms. If we are unable to raise additional capital due to the volatile global financial markets, general economic uncertainty or other factors, we will be forced to delay, limit, reduce or terminate preclinical studies, clinical studies or other development activities for one or more of our product candidates.

Contractual Obligations and Commitments

We lease our corporate headquarters in South San Francisco, California under a non-cancellable lease agreement for approximately 13,670 square feet of office space. The lease expires in April 2021.

23


 

In February 2017, we entered into a lease agreement for approximately 90,580 square feet of office, lab and cellular therapy manufacturing space in Thousand Oaks, California. The initial 15-year term of this lease commenced in February 2018, and the contractual obligations during the initial term are $16.4 million in aggregate. We have the option to extend this lease for two additional periods of ten and nine years, respectively, after the initial term. In connection with this lease, we were required to issue a letter of credit in the amount of $1.2 million to the landlord, which is recorded as long-term restricted cash in our condensed consolidated balance sheet.

In November 2018, we entered into a lease agreement for approximately 51,160 square feet of office space in Thousand Oaks, California. The initial term of this lease expires in February 2026. The contractual obligations during the initial term are $8.5 million in aggregate. We have the option to extend the lease for an additional period of five years after the initial term.

In May 2019, we entered into a new lease agreement for our approximately 8,800 square feet of office and lab space in Aurora, Colorado. The term of this lease expires in April 2024. The contractual obligations during the lease term are $1.1 million in aggregate.

Our contractual obligations primarily consist of our obligations under non-cancellable operating and finance leases and contracts we enter into in the normal course of business with clinical research organizations for clinical studies, with contract manufacturing organizations for clinical supplies, and with other vendors for preclinical studies and supplies and other services and products for operating purposes. These contracts generally provide for termination on notice, with the exception of one of our contract manufacturing agreements which we may terminate for convenience upon six months’ written notice. There have been no material changes to our contractual obligations disclosed in our Annual Report on Form 10-K for the year ended December 31, 2019.

Off-Balance Sheet Arrangements

We did not have, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC, during the periods presented.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

During the three months ended March 31, 2020, there were no material changes to our interest rate risk disclosures, market risk disclosures and foreign currency exchange rate risk disclosures reported in our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on February 27, 2020.

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

Under the supervision of our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act as of March 31, 2020. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of March 31, 2020 to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely discussion regarding required disclosures. In designing and evaluating our disclosure controls and procedures, management recognizes that any disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the three months ended March 31, 2020 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. We have not experienced any material impact to our internal controls over financial reporting despite the fact that most of our employees are working remotely due to the COVID-19 pandemic. We are continually monitoring and assessing the COVID-19 situation to minimize the impact to the design and operating effectiveness of our internal controls.

24


 

PART II. OTHER INFORMATION

 

None.

 

Item 1A. Risk Factors

Investing in our common stock involves a high degree of risk. Investors should carefully consider all of the risk factors and uncertainties described below, in addition to the other information contained in this Quarterly Report on Form 10-Q, including the section of this report titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our consolidated and combined financial statements and related notes, before investing in our common stock.

The risks described below may not be the only ones relating to our company and additional risks that we currently believe are immaterial may also affect us. If any of these risks, including those described below, materialize, our business, competitive position, reputation, financial condition, results of operations, cash flows and future prospects could be seriously harmed. In these circumstances, the market price of our common stock could decline, and investors may lose all or a part of their investment.

Risks Related to Our Financial Results and Capital Needs

We have incurred substantial losses since our inception and anticipate that we will continue to incur substantial and increasing losses for the foreseeable future.

We are a clinical-stage biopharmaceutical company. Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that a product candidate will fail to prove effective, gain regulatory approval or become commercially viable. We do not have any products approved by regulatory authorities and have not generated any revenues from product sales or otherwise to date, and have incurred significant research, development and other expenses related to our ongoing operations and expect to continue to incur such expenses. As a result, we have not been profitable and have incurred significant operating losses in every reporting period since our inception. For the three months ended March 31, 2020, we reported a net loss of $73.5 million and we had an accumulated deficit of $891.5 million as of March 31, 2020.

We do not expect to generate revenues for the foreseeable future, if at all. We expect to continue to incur significant expenses and operating losses for the foreseeable future. We anticipate these losses to increase as we continue to research, develop and seek regulatory approvals for our product candidates and any additional product candidates we may acquire, in-license or develop, and potentially begin to commercialize product candidates that may achieve regulatory approval. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenues. If any of our product candidates fails in clinical studies or does not gain regulatory approval, or if approved, fails to achieve market acceptance, we may never become profitable. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. We anticipate that our expenses will increase in the future as we continue to invest in research and development of our existing product candidates, investigate and potentially acquire new product candidates and expand our manufacturing and commercialization activities.

We have a limited operating history, which may make it difficult to evaluate the success of our business to date and to assess our future viability.

Our company was formed in August 2012. Our operations to date have been limited to organizing and staffing our company, acquiring product and technology rights and conducting product development activities for our product candidates. We have not yet demonstrated our ability to successfully complete any Phase 2 or Phase 3 clinical studies, obtain regulatory approval, consistently manufacture a commercial scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization for any of our product candidates. In addition, the adoptive immunotherapy technology underlying our T-cell product candidates, including our next-generation CAR T programs, is new and largely unproven. Any predictions about our future success, performance or viability, particularly in view of the rapidly evolving immunotherapy field, may not be as accurate as they could be if we had a longer operating history or approved products on the market.

In addition, as a young business, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We will need to transition at some point from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a transition. We expect our financial condition and operating results to continue to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, any of our quarterly or annual periods’ results are not indicative of future operating performance.

25


 

We currently have no source of revenues. We may never generate revenues or achieve profitability.

To date, we have not generated any revenues from product sales or otherwise. Even if we are able to successfully achieve regulatory approval for our product candidates, we do not know when we will generate revenues or become profitable, if at all. Our ability to generate revenues from product sales and achieve profitability will depend on our ability to successfully commercialize products, including any of our current product candidates, and other product candidates that we may develop, in-license or acquire in the future. Our ability to generate revenues and achieve profitability also depends on a number of additional factors, including our ability to:

 

successfully complete development activities, including the necessary clinical studies;

 

complete and submit regulatory submissions to the FDA, EMA or other agencies and obtain regulatory approval for indications for which there is a commercial market;

 

obtain coverage and adequate reimbursement from third parties, including government and private payors;

 

set commercially viable prices for our products, if any;

 

develop manufacturing and distribution processes for our novel T-cell immunotherapy product candidates;

 

develop commercial quantities of our products at acceptable cost levels;

 

establish and maintain adequate supply of our products, including cell lines with sufficient breadth to treat patients;

 

establish and maintain manufacturing relationships with reliable third parties or qualify our manufacturing facility such that we can maintain the supply of our products by ensuring adequate, manufacturing of bulk drug substances and drug products in a manner that is compliant with global legal requirements;

 

achieve market acceptance of our products, if any;

 

attract, hire and retain qualified personnel;

 

protect our rights in our intellectual property portfolio;

 

develop a commercial organization capable of sales, marketing and distribution for any products we intend to sell ourselves in the markets in which we choose to commercialize on our own; and

 

find suitable distribution partners to help us market, sell and distribute our approved products in other markets.

Our revenues for any product candidate for which regulatory approval is obtained will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted price for the product, the ability to get reimbursement at any price, and whether we own the commercial rights for that territory. If the number of our addressable disease patients is not as significant as we estimate, the indication approved by regulatory authorities is narrower than we expect, or the reasonably accepted population for treatment is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenues from sales of our products, even if approved. In addition, we anticipate incurring significant costs associated with commercializing any approved product candidate. As a result, even if we generate revenues, we may not become profitable and may need to obtain additional funding to continue operations. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and may be forced to reduce our operations.

We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts.

We expect to expend substantial resources for the foreseeable future to continue the clinical development and manufacturing of our T-cell immunotherapy product candidates, and the advancement and expansion of our preclinical research pipeline. We also expect to continue to expend resources for the development and manufacturing of product candidates and the technology we have licensed or have an exclusive right to license from our partners. These expenditures will include costs associated with research and development, potentially acquiring or licensing new product candidates or technologies, conducting preclinical and clinical studies and potentially obtaining regulatory approvals and manufacturing products, as well as marketing and selling products approved for sale, if any. Under the terms of our license agreements with each of our partners, we are obligated to make payments upon the achievement of certain development, regulatory and commercial milestones. We will also need to make significant expenditures to develop a commercial organization capable of sales, marketing and distribution for any products, if any, that we intend to sell ourselves in the markets in which we choose to commercialize on our own. In addition, other unanticipated costs may arise. Because the design and outcome of our ongoing, planned and anticipated clinical studies is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates.

26


 

Our future capital requirements depend on many factors, including:

 

the scope, progress, results and costs of researching and developing our product candidates, and conducting preclinical and clinical studies;

 

the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates, if clinical studies are successful, including any costs from post-market requirements;

 

the cost of commercialization activities for our product candidates, if any of these product candidates is approved for sale, including marketing, sales and distribution costs;

 

the cost of manufacturing our product candidates for clinical studies in preparation for regulatory approval and in preparation for commercialization;

 

our ability to establish and maintain strategic licensing or other arrangements and the financial terms of such agreements;

 

the costs to develop, acquire or in-license future product candidates or technologies;

 

the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation costs and the outcome of such litigation;

 

the timing, receipt and amount of sales of, or royalties on, our future products, if any; and

 

the emergence of competing technologies or other adverse market developments.

We believe that our existing cash, cash equivalents and short-term investments will be sufficient to fund our planned operations into the second quarter of 2021. As of March 31, 2020, we had total cash, cash equivalents and short-term investments of $214.6 million. However, our operating plan may change as a result of many factors currently unknown to us, and we may need additional funds sooner than planned.

We do not have any committed external source of funds. While we are actively seeking additional funds through additional public or private equity offerings or debt financings, through potential collaborations, partnering or other strategic arrangements, or a combination of the foregoing, additional funds may not be available when we need them on terms that are acceptable to us, or at all. Our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide, including the trading price of common stock, resulting from the ongoing COVID-19 pandemic. If adequate funds are not available to us on a timely basis, we may be required to delay, limit, reduce or terminate preclinical studies, clinical studies or other development activities for one or more of our product candidates or delay, limit, reduce or terminate our establishment of sales, marketing and distribution capabilities or other activities that may be necessary to commercialize our product candidates.

We have identified conditions and events that raise substantial doubt about our ability to continue as a going concern.

We may be forced to amend, delay, limit, reduce or terminate the scope of our development programs and/or limit or cease our operations if we are unable to obtain additional funding. As of March 31, 2020 we had cash, cash equivalents and short-term investments of $214.6 million. Based on our current operating plans, we do not have sufficient cash and cash equivalents to fund our operating expenses and capital expenditures for at least the next 12 months from the filing date of this Quarterly Report on Form 10-Q. We will require additional capital to sustain our operations. We are actively seeking additional funds through equity or debt financings or through collaborations, licensing transactions or other sources. However, there can be no assurance that we will be able to complete any such transaction on acceptable terms or otherwise. The failure to obtain sufficient funds on commercially acceptable terms when needed would have a material adverse effect on our business, results of operations and financial condition. We may implement cost reduction strategies, which may include amending, delaying, limiting, reducing, or terminating one or more of our ongoing or planned clinical trials of our product candidates. These factors raise substantial doubt about our ability to continue as a going concern.

Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our product candidates on terms that are unfavorable to us.

We may seek required additional capital through a variety of means, including through private and public equity offerings and debt financings. To the extent that we raise additional capital through the sale of equity or convertible debt securities, or if existing holders of warrants exercise their rights to purchase common stock, the ownership interest of existing stockholders will be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of stockholders. To the extent equity valuations, including the trading price of our common stock, are depressed as a result of economic disruptions and uncertainty concerning the COVID-19 pandemic or other factors, the potential magnitude of this dilution will increase. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take certain actions, including incurring additional debt, making

27


 

capital expenditures, entering into licensing arrangements, or declaring dividends. If we raise additional funds from third parties, we may have to relinquish valuable rights to our technologies or product candidates or grant licenses on terms that are not favorable to us. If we are unable to raise additional funds through equity or debt financing when needed, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts for our product candidates, grant to others the rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves or take other actions that are adverse to our business.

Risks Related to the Development of Our Product Candidates

We are early in our development efforts and have only a small number of product candidates in clinical development. All of our other product candidates are still in preclinical development. If we or our collaborators are unable to successfully develop and commercialize product candidates or experience significant delays in doing so, our business may be materially harmed.

We are early in our development efforts, and only a small number of our product candidates are in clinical development. The majority of our product candidates are currently in preclinical development. We have invested substantial resources in identifying and developing potential product candidates, conducting preclinical and clinical studies, manufacturing activities and preparing for the potential commercial launch of our product candidates. Our ability to generate revenues, which we do not expect will occur for several years, if ever, will depend heavily on the successful development and eventual commercialization of our product candidates. The success of our product candidates will depend on many factors, including the following:

 

completion of preclinical and clinical studies with positive results;

 

receipt of regulatory approvals from applicable authorities;

 

protecting our rights in our intellectual property portfolio, including by obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates;

 

establishing or making arrangements with third-party manufacturers or completing our own manufacturing facility for clinical and commercial manufacturing purposes;

 

developing manufacturing and distribution processes for our novel T-cell product candidates and next-generation CAR T programs;

 

manufacturing our product candidates at an acceptable cost;

 

launching commercial sales of our products, if approved by applicable regulatory authorities, whether alone or in collaboration with others;

 

acceptance of our products, if approved by applicable regulatory authorities, by patients and the medical community;

 

obtaining and maintaining coverage and adequate reimbursement by third-party payors, including government payors, for our products, if approved by applicable regulatory authorities;

 

effectively competing with other therapies;

 

maintaining a continued acceptable benefit/risk profile of the products following approval; and

 

maintaining and growing an organization of scientists and functional experts who can develop and commercialize our products and technology.

If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully develop and commercialize our product candidates, which could materially harm our business.

Our business could be adversely affected by the effects of health epidemics, including the evolving effects of the COVID-19 pandemic, in regions where we or third parties on which we rely have significant manufacturing facilities, clinical trial sites or other business operations.

Our business could be adversely affected by health epidemics and pandemics, including the recent outbreak of COVID-19, which has presented a substantial public health and economic challenge around the world, and is affecting our employees, patients, communities and business operations, as well as the U.S. economy and financial markets. The pandemic has resulted in travel and other restrictions to reduce the spread of the disease, including a California executive order and many other foreign, state and local orders (including in locations where we operate facilities), which, among other things, direct individuals to shelter at their places of residence, direct businesses and governmental agencies to cease non-essential operations at physical locations, prohibit certain non-essential gatherings, and order cessation of non-essential travel. As a result of these recent developments, we have implemented work-from-home policies for most of our employees. In connection with these measures, we may be subject to claims based upon, arising

28


 

out of, or related to COVID-19 and our actions and responses thereto, including any determinations that we may make to continue to operate or to re-open our facilities where permitted by applicable law. The effects of current and potential future state executive orders, local shelter-in-place orders, government-imposed quarantines and our work-from-home policies and other similar, and perhaps more severe, actions may negatively impact productivity, disrupt our business and delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course.

Quarantines, shelter-in-place and similar government orders, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, related to COVID-19 or other infectious diseases, could impact our manufacturing capabilities and third-party manufacturing facilities in the United States and other countries, or the availability or cost of materials, which would disrupt our supply chain. In particular, standard transportation channels have been impacted and we and other manufacturing, testing, product disposition, contract manufacturing organizations and external testing laboratories are subject to enhanced risk assessment and mitigation measures. In addition, there have been and may continue to be interruptions in the supply of leukapheresis collections, which supply raw materials used in our products.

Our clinical trials may be affected by health epidemics, including the COVID-19 pandemic. Clinical site initiation and patient enrollment may be delayed as a result of the pandemic, including due to the prioritization of hospital resources toward COVID-19 and away from clinical trials or as a result of changing practice patterns that impact the diseases our trials address. Some patients may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services or if patients contract COVID-19 or are forced to quarantine. For example, while most clinical trial sites for our Phase 3 clinical trial of tab-cel® in patients with EBV+ PTLD remain open to enrollment for patients, governmental orders related to COVID-19, or fear of infection, may limit patients’ abilities to access clinical sites. COVID-19-related travel restrictions may also interrupt key clinical trial activities, such as clinical trial site data monitoring and efficacy, safety and translational data collection, processing and analyses. In April 2020, we announced that we were pausing the screening and enrollment of patients in our Phase 1b study of ATA188 in patients with progressive MS. Similarly, our ability to recruit and retain principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19, may be adversely impacted.

In addition, while the potential economic impact brought by, and the duration of, the COVID-19 pandemic and the various actions taken in response to it may be difficult to assess or predict, the pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.

While we expect the COVID-19 pandemic to continue to adversely affect our business operations, the extent of the impact on our clinical development and regulatory efforts and the value of and market for our common stock will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the U.S. and in other countries, and the effectiveness of actions taken globally to contain and treat COVID-19. In addition, to the extent the evolving effects of the ongoing COVID-19 pandemic adversely affect our business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties described elsewhere in this “Risk Factors” section.

Our future success is dependent on the regulatory approval of our product candidates.

We do not have any products that have gained regulatory approval. Currently, our prioritized clinical-stage product candidates include tab‑cel® and ATA188. Our business is substantially dependent on our ability to obtain regulatory approval for, and, if approved, to successfully commercialize our product candidates in a timely manner.

We cannot commercialize product candidates in the U.S. without first obtaining regulatory approval for the product from the FDA; similarly, we cannot commercialize product candidates outside of the U.S. without obtaining regulatory approval from comparable foreign regulatory authorities. Before obtaining regulatory approvals for the commercial sale of any product candidate for a target indication, we must demonstrate with substantial evidence gathered in preclinical and clinical studies, that the product candidate is safe and effective for use for that target indication and that the manufacturing facilities, processes and controls are adequate with respect to such product candidate to assure safety, purity and potency.

The time required to obtain approval by the FDA and comparable foreign regulatory authorities is unpredictable but typically takes many years following the commencement of preclinical and clinical studies and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate’s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate and it is possible that none of our existing product candidates or any future product candidates will ever obtain regulatory approval.

29


 

Our product candidates could fail to receive regulatory approval from the FDA or a comparable foreign regulatory authority for many reasons, including:

 

disagreement with the design or conduct of our clinical studies;

 

failure to demonstrate positive benefit/risk profile of the product candidate for its proposed indication;

 

failure of clinical studies to meet the level of statistical significance required for approval;

 

disagreement with our interpretation of data from preclinical studies or clinical studies;

 

the insufficiency of data collected from clinical studies of our product candidates to support the submission and filing of a BLA or other submission or to obtain regulatory approval;

 

failure to obtain approval of our manufacturing processes or facilities of third-party manufacturers with whom we contract for clinical and commercial supplies or our own manufacturing facility; or

 

changes in the approval policies or regulations that render our preclinical and clinical data insufficient for approval.

The FDA or a comparable foreign regulatory authority may require more information, including additional preclinical or clinical data to support approval, which may delay or prevent approval and our commercialization plans, or we may decide to abandon the development program. If we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request (including failing to approve the most commercially promising indications), may grant approval contingent on the performance of costly post-marketing clinical studies, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate.

In addition, the clinical study requirements of the FDA, EMA and other regulatory agencies and the criteria these regulators use to determine the safety and efficacy of a product candidate are determined according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel product candidates, such as our novel T-cell product candidates and next-generation CAR T programs, can be more complex and consequently more expensive and take longer than for other, better known or extensively studied pharmaceutical or other product candidates. Approvals by the EMA and FDA for existing autologous CAR T therapies, such as Novartis’s Kymriah® and Gilead’s Yescarta®, may not be indicative of what these regulators may require for approval of our therapies. Moreover, our product candidates may not perform successfully in clinical studies or may be associated with adverse events that distinguish them from that which have previously been approved, such as existing autologous CAR T therapies. For instance, allogeneic product candidates may result in adverse events not experienced with autologous products.

In January 2019, the U.S. federal government entered a prolonged shutdown suspending services deemed non-essential, including certain activities of the FDA, and U.S. politicians have expressed interest in future similar shutdowns as a negotiating tactic. Our development and commercialization activities could be harmed or delayed by a similar shutdown of the U.S. federal government in the future, which may significantly delay the FDA’s ability to timely review and process any submissions we have filed or may file or cause other regulatory delays.

Even if a product candidate were to successfully obtain approval from the FDA and comparable foreign regulatory authorities, any approval might contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, or may be subject to burdensome post-approval study or risk management requirements. If we are unable to obtain regulatory approval for one of our product candidates in one or more jurisdictions, or any approval contains significant limitations, we may not be able to obtain sufficient funding to continue the development of that product or generate revenues attributable to that product candidate. Also, any regulatory approval of our current or future product candidates, once obtained, may be withdrawn.

Our T-cell immunotherapy product candidates and our next-generation CAR T programs represent new therapeutic approaches that could result in heightened regulatory scrutiny, delays in clinical development or delays in or our inability to achieve regulatory approval, commercialization or payor coverage of our product candidates.

Our future success is dependent on the successful development of T-cell immunotherapies and our next-generation CAR T programs in general and our development product candidates in particular. Because these programs, particularly our pipeline of allogeneic T-cell product candidates that are bioengineered from donors, represent a new approach to immunotherapy for the treatment of cancer and other diseases, developing and commercializing our product candidates subject us to a number of challenges, including:

 

obtaining regulatory approval from the FDA and other regulatory authorities, which have limited experience with regulating the development and commercialization of T-cell immunotherapies;

30


 

 

developing and deploying consistent and reliable processes for procuring blood from consenting third-party donors, isolating T cells from the blood of such donors, activating the isolated T cells against a specific antigen, characterizing and storing the resulting activated T cells for future therapeutic use, selecting and delivering a sufficient supply and breadth of appropriate partially HLA-matched cell line from among the available T cell lines, and finally infusing these activated T cells into patients;

 

utilizing these product candidates in combination with other therapies (e.g. immunomodulatory approaches such as checkpoint inhibitors), which may increase the risk of adverse side effects;

 

educating medical personnel regarding the potential side effect profile of each of our product candidates, particularly those that may be unique to our allogeneic T-cell product candidates and to our next-generation CAR T programs;

 

understanding and addressing variability in the quality of a donor’s T cells, which could ultimately affect our ability to manufacture product in a reliable and consistent manner;

 

developing processes for the safe administration of these products, including long-term follow-up and registries, for all patients who receive these product candidates;

 

manufacturing our product candidates to our specifications and in a timely manner to support our clinical studies and, if approved, commercialization;

 

sourcing clinical and, if approved by applicable regulatory authorities, commercial supplies for the materials used to manufacture and process these product candidates that are free from viruses and other pathogens that may increase the risk of adverse side effects;

 

developing a manufacturing process and distribution network that can provide a stable supply with a cost of goods that allows for an attractive return on investment;

 

establishing sales and marketing capabilities ahead of and after obtaining any regulatory approval to gain market acceptance, and obtaining adequate coverage, reimbursement and pricing by third-party payors and government authorities; and

 

developing therapies for types of diseases beyond those initially addressed by our current product candidates.

We cannot be sure that the manufacturing processes used in connection with our T-cell immunotherapy product candidates will yield a sufficient supply of satisfactory products that are safe, pure and potent, comparable to those T cells produced by our partners historically, scalable or profitable.

Moreover, actual or perceived safety issues, including adoption of new therapeutics or novel approaches to treatment, may adversely influence the willingness of subjects to participate in clinical studies, or if approved by applicable regulatory authorities, of physicians to subscribe to the novel treatment mechanics. The FDA or other applicable regulatory authorities may ask for specific post-market requirements, and additional information informing benefits or risks of our products may emerge at any time prior to or after regulatory approval.

Physicians, hospitals and third-party payors often are slow to adopt new products, technologies and treatment practices that require additional upfront costs and training. Physicians may not be willing to undergo training to adopt this novel therapy, may decide the therapy is too complex to adopt without appropriate training or not cost-efficient, and may choose not to administer the therapy. Based on these and other factors, hospitals and payors may decide that the benefits of this new therapy do not or will not outweigh its costs.

The results of preclinical studies or earlier clinical studies are not necessarily predictive of future results. Our existing product candidates in clinical studies, and any other product candidate we advance into clinical studies, may not have favorable results in later clinical studies or receive regulatory approval.

Success in preclinical studies and early clinical studies does not ensure that later clinical studies will generate adequate data to demonstrate the efficacy and safety of an investigational drug. Likewise, a number of companies in the pharmaceutical and biotechnology industries, including those with greater resources and experience than us, have suffered significant setbacks in clinical studies, even after seeing promising results in earlier preclinical studies or clinical studies. Despite the results reported in earlier preclinical studies or clinical studies for our product candidates, we do not know whether the clinical studies we may conduct will demonstrate adequate efficacy and safety to result in regulatory approval to market tab-cel®, ATA188, any product candidates resulting from our next-generation CAR T programs or any of our other product candidates in any particular jurisdiction.

31


 

Tab-cel® has been predominantly evaluated in single-center studies under investigator-sponsored INDs held by MSK and in our EAP, utilizing different response criteria and endpoints from those we may utilize in later clinical studies. The findings may not be reproducible in late phase studies we conduct. For instance, the current protocol for our ALLELE study is designed to rule out a 20% ORR as the null hypothesis. This means that if the lower bound of the 95% confidence interval on ORR among patients receiving at least one dose of tab-cel® exceeds 20% at the end of the study, then the study would be expected to meet the primary endpoint for the treatment of PTLD. For example, assuming enrollment of 33 patients in a cohort of ALLELE, an observed ORR above approximately 37% would be expected to meet the primary endpoint for that cohort. In addition, our amended ALLELE study protocol includes an interim analysis as well as a final study analysis. Depending on discussions with regulators, we may, for example, submit a filing on the basis of interim data from a subset of the required patients or submit a filing on the basis of the final data. A filing based on interim data would impact the required ORR. If conditional marketing authorization is granted from the European Commission, we may be subject to ongoing obligations, including the need to provide additional clinical data at a later stage to confirm a positive benefit/risk balance.

For regulatory approvals of tab-cel®, we plan on using independent radiologist and/or oncologist assessment of responses which may not correlate with the investigator-reported assessments. In addition, the Phase 2 clinical studies with tab-cel® enrolled a heterogeneous group of patients with a variety of EBV-associated malignancies, including EBV+ PTLD after HCT and EBV+ PTLD after SOT. These Phase 2 studies were not prospectively designed to evaluate the efficacy of tab-cel® in the treatment of a single disease state for which we may later seek approval.

Moreover, final study results may not be consistent with interim study results. Efficacy data from prospectively designed studies may differ significantly from those obtained from retrospective subgroup analyses. In addition, clinical data obtained from a clinical study with an allogeneic product candidate may not yield the same or better results as compared to an autologous product candidate. If later-stage clinical studies do not produce favorable results, our ability to achieve regulatory approval for any of our product candidates may be adversely impacted. Even if we believe that we have adequate data to support an application for regulatory approval to market any of our product candidates, the FDA or other regulatory authorities may not agree and may require that we conduct additional clinical studies.

Interim “top line” and preliminary data from our clinical studies that we may announce or share with regulatory authorities from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.

From time to time, we may announce or share with regulatory authorities interim “top line” or preliminary data from our clinical studies. Interim data from clinical studies that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or “top line” data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously announced. As a result, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could impact the regulatory approval of, and significantly harm the prospects of any product candidate that is impacted by the applicable data.

Clinical drug development involves a lengthy and expensive process with an uncertain outcome.

Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical study process. Product candidates in later stages of clinical studies may fail to show the desired safety and efficacy traits despite having progressed through preclinical and clinical studies.

We may experience delays in our ongoing or future clinical studies and we do not know whether clinical studies will begin or enroll subjects on time, will need to be redesigned or will be completed on schedule, if at all. There can be no assurance that the FDA or comparable foreign regulatory authorities will not put clinical studies of any of our product candidates on clinical hold in the future. Clinical studies may be delayed, suspended or prematurely terminated for a variety of reasons, such as:

 

delays in enrollment due to travel, shelter-in-place or quarantine policies, or other factors, related to the COVID-19 pandemic;

 

delay or failure in reaching agreement with the FDA or a comparable foreign regulatory authority on a study design that we are able to execute;

 

delay or failure in obtaining authorization to commence a study or inability to comply with conditions imposed by a regulatory authority regarding the scope or design of a study;

32


 

 

delay or failure in reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical study sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and study sites;

 

delay or failure in obtaining institutional review board, or IRB, approval or the approval of other reviewing entities, including comparable foreign regulatory authorities, to conduct a clinical study at each site;

 

withdrawal of clinical study sites from our clinical studies or the ineligibility of a site to participate in our clinical studies;

 

delay or failure in recruiting and enrolling suitable subjects to participate in a study;

 

delay or failure in subjects completing a study or returning for post-treatment follow-up;

 

clinical sites and investigators deviating from study protocol, failing to conduct the study in accordance with regulatory requirements, or dropping out of a study;

 

inability to identify and maintain a sufficient number of study sites, including because potential study sites may already be engaged in competing clinical study programs for the same indication that we are treating;

 

failure of our third-party clinical study managers to satisfy their contractual duties, meet expected deadlines or return trustworthy data;

 

delay or failure in adding new study sites;

 

interim results or data that are ambiguous or negative or are inconsistent with earlier results or data;

 

feedback from the FDA, the IRB, data safety monitoring boards or comparable foreign authorities, or results from earlier stage or concurrent preclinical and clinical studies, that might require modification to the protocol for a study;

 

a decision by the FDA, the IRB, comparable foreign authorities, or us, or a recommendation by a data safety monitoring board or comparable foreign authority, to suspend or terminate clinical studies at any time for safety issues or for any other reason;

 

unacceptable benefit/risk profile, unforeseen safety issues or adverse side effects;

 

failure to demonstrate a benefit from using a product candidate;

 

difficulties in manufacturing or obtaining from third parties sufficient quantities and breadth of appropriate partially HLA matched cell lines from among the available T-cell lines to start or to use in clinical studies;

 

lack of adequate funding to continue a study, including the incurrence of unforeseen costs due to enrollment delays, requirements to conduct additional studies or increased expenses associated with the services of our CROs and other third parties; or

 

changes in governmental regulations or administrative actions or lack of adequate funding to continue a clinical study.

Patient enrollment, a significant factor in the timing of clinical studies, is affected by many factors including:

 

the size and nature of the patient population;

 

the possibility that the rare diseases that many of our product candidates address are under-diagnosed;

 

changing medical practice patterns or guidelines related to the indications we are investigating;

 

the severity of the disease under investigation, our ability to open clinical study sites;

 

the proximity of subjects to clinical sites;

 

the patient referral practices of physicians;

 

the design and eligibility criteria of the clinical study;

 

ability to obtain and maintain patient consents;

 

risk that enrolled subjects will drop out or die before completion;

 

competition for patients from other clinical studies;

 

our ability to manufacture the requisite materials for a study;

 

risk that we do not have appropriately matched HLA cell lines;

33


 

 

clinicians’ and patients’ perceptions as to the potential advantages and risks of the drug being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating; and

 

disruptions caused by man-made or natural disasters or public health pandemics or epidemics, including, for example, the recent COVID-19 pandemic.

As an example, we activated additional clinical sites over the course of 2018 and increased HLA coverage during this period. As a result, enrollment in our studies was limited in the early part of 2018 and increased through the course of the year as we increased clinical sites and HLA coverage. However, in May 2019, we announced that enrollment in our Phase 3 studies of tab-cel® for patients with EBV+ PTLD was proceeding slower than anticipated. Many of our product candidates are designed to treat rare diseases, and as a result the pool of potential patients with respect to a given disease is small. We may not be able to initiate or continue to support clinical studies of tab-cel®, ATA188 or any other product candidates if we are unable to locate and enroll a sufficient number of eligible participants in these studies as required by the FDA or other regulatory authorities. Even if we are able to enroll a sufficient number of patients in our clinical studies, if the pace of enrollment is slower than we expect, the development costs for our product candidates may increase and the completion of our studies may be delayed or our studies could become too expensive to complete.

We rely on CROs, other vendors and clinical study sites to ensure the proper and timely conduct of our clinical studies, and while we have agreements governing their committed activities, we have limited influence over their actual performance.

If we experience delays or quality issues in the conduct, completion or termination of any clinical study of our product candidates, the approval and commercial prospects of such product candidate will be harmed, and our ability to generate product revenues from such product candidate will be delayed. In addition, any delays in completing our clinical studies will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Any delays in completing our clinical studies for our product candidates may also decrease the period of commercial exclusivity. In addition, many of the factors that could cause a delay in the commencement or completion of clinical studies may also ultimately lead to the denial of regulatory approval of our product candidates.

Our product candidates, the methods used to deliver them or their dosage levels may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label or result in significant negative consequences following any regulatory approval.

Undesirable side effects caused by our product candidates, their delivery methods or dosage levels could cause us or regulatory authorities to interrupt, delay or halt clinical studies and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign regulatory authority. As a result of safety or toxicity issues that we may experience in our clinical studies, we may not receive approval to market any product candidates, which could prevent us from ever generating revenues or achieving profitability. Results of our studies could reveal an unacceptably high severity and incidence of side effects, or side effects outweighing the benefits of our product candidates. In such an event, our studies could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled subjects to complete the study or result in potential product liability claims.

Additionally, if any of our product candidates receives regulatory approval, and we or others later identify undesirable side effects caused by such product, a number of potentially significant negative consequences could result, including that:

 

we may be forced to suspend marketing of that product;

 

regulatory authorities may withdraw or change their approvals of that product;

 

regulatory authorities may require additional warnings on the label or limit access of that product to selective specialized centers with additional safety reporting and with requirements that patients be geographically close to these centers for all or part of their treatment;

 

we may be required to conduct post-marketing studies;

 

we may be required to change the way the product is administered;

 

we could be sued and held liable for harm caused to subjects or patients; and

 

our reputation may suffer.

Any of these events could diminish the usage or otherwise limit the commercial success of our product candidates and prevent us from achieving or maintaining market acceptance of the affected product candidate, if approved by applicable regulatory authorities.

34


 

The market opportunities for our product candidates may be limited to those patients who are ineligible for or have failed prior treatments and may be small.

The FDA often approves new therapies initially only for use in patients with relapsed or refractory metastatic disease. We expect to initially seek approval of tab-cel® and our other product candidates in this setting. Subsequently, for those products that prove to be sufficiently beneficial, if any, we would expect to seek approval in earlier lines of treatment and potentially as a first line therapy, but there is no guarantee that our product candidates, even if approved, would be approved for earlier lines of therapy, and, prior to any such approvals, we will have to conduct additional clinical trials.

Our projections of both the number of people who have the diseases we are targeting, as well as the subset of people with these diseases in a position to receive second or later lines of therapy, and who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations, or our own market research, and may prove to be incorrect, including if the COVID-19 pandemic and associated responses impact treatment practices that relate to the indications our product candidates address. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates. For instance, we expect our lead product candidate, tab-cel®, to initially target a small patient population that suffers from aggressive EBV+PTLD who have failed rituximab or rituximab plus chemotherapy. As a result of the COVID-19 pandemic, we have observed a temporary slow-down in stem cell and solid organ transplant volumes. If these reductions are not transient, but instead are long-lasting, this reduction could result in lower PTLD incidence and thus reduced demand for tab-cel®. Even if we obtain significant market share for our product candidates, because the potential target populations are small, we may never achieve profitability without obtaining regulatory approval for additional indications.

We may not be able to obtain or maintain orphan drug exclusivity for our product candidates.

Regulatory authorities in some jurisdictions, including the U.S. and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the U.S. Both the FDA and the EMA have granted us orphan designation for tab-cel® for EBV+ PTLD after HCT or SOT.

Generally, if a product with an orphan drug designation subsequently receives the first regulatory approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the EMA or the FDA from approving another marketing application for the same drug for that time period. The applicable period is seven years in the U.S. and ten years in Europe. The European exclusivity period can be reduced to six years if a drug no longer meets the criteria for orphan drug designation or if the drug is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition.

Even if we obtain orphan drug exclusivity for a product, that exclusivity may not be maintained or effectively protect the product from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve a new drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care.

Breakthrough Therapy Designation by the FDA may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.

Although we have obtained Breakthrough Therapy Designation, or BTD, for tab-cel® for EBV+ PTLD, this may not lead to faster development or regulatory review and does not increase our likelihood of success. A breakthrough therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug, or biologic in our case, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the study can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Biologics designated as breakthrough therapies by the FDA may also be eligible for priority review.

35


 

Designation as a breakthrough therapy is within the discretion of the FDA. Receipt of a BTD for a product candidate may not result in a faster development process, review or approval compared to drugs considered for approval under non-expedited the FDA review procedures and does not assure ultimate approval by the FDA. In addition, the FDA may later decide that the product no longer meets the conditions for qualification and rescind BTD or decide that the time period for FDA review or approval will not be shortened.

Failure to obtain regulatory approval in international jurisdictions would prevent our product candidates from being marketed abroad.

In addition to regulations in the U.S., to market and sell our products in the European Union, many Asian countries and other jurisdictions, we must obtain separate regulatory approvals and comply with numerous and varying regulatory requirements, both from a clinical and manufacturing perspective. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the U.S. generally includes all of the risks associated with obtaining FDA approval. Clinical studies accepted in one country may not be accepted by regulatory authorities in other countries. In addition, many countries outside the U.S. require that a product be approved for reimbursement before it can be approved for sale in that country. A product candidate that has been approved for sale in a particular country may not receive reimbursement approval in that country. We may not be able to obtain approvals from regulatory authorities or payor authorities outside the U.S. on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory or payor authorities in other countries or jurisdictions, and approval by one regulatory or payor authority outside the U.S. does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may not be able to file for regulatory approvals and may not receive necessary approvals to commercialize our products in any market. If we are unable to obtain approval of any of our product candidates by regulatory or payor authorities in the European Union, Asia or elsewhere, the commercial prospects of that product candidate may be significantly diminished.

Even if our product candidates receive regulatory approval, they may still face future development and regulatory difficulties.

Even if we obtain regulatory approval for a product candidate, it would be subject to ongoing requirements by the FDA and comparable foreign regulatory authorities governing the manufacture, quality control, further development, labeling, packaging, storage, distribution, adverse event reporting, safety surveillance, import, export, advertising, promotion, recordkeeping and reporting of safety and other post-marketing information. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance by us and/or our contract manufacturing organizations, or CMOs, and CROs for any post-approval clinical studies that we conduct. The safety profile of any product will continue to be closely monitored by the FDA and comparable foreign regulatory authorities after approval. If the FDA or comparable foreign regulatory authorities become aware of new safety information after approval of any of our product candidates, they may require labeling changes or establishment of a risk evaluation and mitigation strategy, impose significant restrictions on a product’s indicated uses or marketing or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance.

In addition, manufacturers of drug products and their facilities are subject to initial and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with current good manufacturing practices, or cGMP, current Good Clinical Practices, or GCP, current good tissue practices, or cGTP, and other regulations. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. If we, our product candidates or the manufacturing facilities for our product candidates fail to comply with applicable regulatory requirements, a regulatory agency may:

 

issue warning letters or untitled letters;

 

mandate modifications to promotional materials or require us to provide corrective information to healthcare practitioners;

 

require us to enter into a consent decree, which can include imposition of various fines, reimbursements for inspection costs, required due dates for specific actions and penalties for noncompliance;

 

seek an injunction or impose civil or criminal penalties or monetary fines;

 

suspend, withdraw or modify regulatory approval;

 

suspend or modify any ongoing clinical studies;

 

refuse to approve pending applications or supplements to applications filed by us;

36


 

 

suspend or impose restrictions on operations, including costly new manufacturing requirements; or

 

seize or detain products, refuse to permit the import or export of products, or require us to initiate a product recall.

The occurrence of any event or penalty described above may inhibit our ability to successfully commercialize our products.

Advertising and promotion of any product candidate that obtains approval in the U.S. will be heavily scrutinized by the FDA, the Department of Justice, or the DOJ, the Office of Inspector General of the HHS, state attorneys general, members of the U.S. Congress and the public. Additionally, advertising and promotion of any product candidate that obtains approval outside of the U.S. will be heavily scrutinized by comparable foreign entities and stakeholders. For example, a company may not promote “off-label” uses for its drug products. An off-label use is the use of a product for an indication that is not described in the product’s FDA-approved label in the U.S. or for uses in other jurisdictions that differ from those approved by the applicable regulatory agencies. Physicians, on the other hand, may prescribe products for off-label uses. Although the FDA and other regulatory agencies do not regulate a physician’s choice of drug treatment made in the physician’s independent medical judgment, they do restrict promotional communications from companies or their sales force with respect to off-label uses of products for which marketing clearance has not been issued. However, companies may share truthful and not misleading information that is otherwise consistent with a product’s FDA approved labeling. Violations, including actual or alleged promotion of our products for unapproved or off-label uses, are subject to enforcement letters, inquiries and investigations, and civil and criminal sanctions by the FDA or comparable foreign bodies. Any actual or alleged failure to comply with labeling and promotion requirements may result in fines, warning letters, mandates to corrective information to healthcare practitioners, injunctions, or civil or criminal penalties.

Regulations, guidelines and recommendations published by various government agencies and organizations may affect the use of our product candidates.

Changes to regulations, recommendations or other guidelines advocating alternative therapies for the indications we treat could result in decreased use of our products. For example, although treatment with EBV-specific T cells is recognized as a recommended treatment for persistent or progressive EBV+ PTLD as set forth in the 2017 National Comprehensive Cancer Network Guidelines, future guidelines from governmental agencies, professional societies, practice management groups, private health/science foundations and other organizations could lead to decreased ability of developing our product candidates, or decreased use of our products once approved by applicable regulatory authorities.

We may not successfully identify, acquire, develop or commercialize new potential product candidates.

Part of our business strategy is to expand our product candidate pipeline by identifying and validating new product candidates, which we may develop ourselves, in-license or otherwise acquire from others. In addition, in the event that our existing product candidates do not receive regulatory approval or are not successfully commercialized, then the success of our business will depend on our ability to expand our product pipeline through in-licensing or other acquisitions. We may be unable to identify relevant product candidates. If we do identify such product candidates, we may be unable to reach acceptable terms with any third party from which we desire to in-license or acquire them.

We may not realize the benefits of strategic alliances that we may form in the future or of potential future product acquisitions or licenses.

We may desire to form strategic alliances, create joint ventures or collaborations, enter into licensing arrangements with third parties or acquire products or business, in each case that we believe will complement or augment our existing business. These relationships or transactions, or those like them, may require us to incur nonrecurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing stockholders, reduce the potential profitability of the products that are the subject of the relationship or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic alliances and transactions and the negotiation process is time-consuming and complex and there can be no assurance that we can enter into any of these transactions even if we desire to do so. Moreover, we may not be successful in our efforts to establish a strategic alliance or other alternative arrangements for any future product candidates and programs because our research and development pipeline may be insufficient, our product candidates and programs may be deemed to be at too early a stage of development for collaborative effort and third parties may not view our product candidates and programs as having the requisite potential to demonstrate a positive benefit/risk profile. Any delays in entering into new strategic alliances agreements related to our product candidates could also delay the development and commercialization of our product candidates and reduce their competitiveness even if they reach the market.

37


 

If we license products or acquire businesses, we may not be able to realize the benefit of these transactions if we are unable to successfully integrate them with our existing operations and company culture. We cannot be certain that, following an acquisition or license, we will achieve the financial or strategic results that would justify the transaction.

Risks Related to Manufacturing

We are subject to a multitude of manufacturing risks, any of which could substantially increase our costs and limit supply of our product candidates.

Concurrently with the license of our existing product candidates, we acquired manufacturing process know-how and, in some cases, inventory of process intermediates and clinical materials from our partners. Transferring manufacturing processes, testing and associated know-how is complex and involves review and incorporation of both documented and undocumented processes that may have evolved over time. In addition, transferring production to different facilities may require utilization of new or different processes to meet the specific requirements of a given facility. Each stage is retroactively and concurrently verified to be compliant with appropriate regulations. As a result, there is a risk that all relevant know-how was not adequately transferred to us from our partners or that previous execution was not compliant with applicable regulations.

In addition, we need to conduct significant development and scale-up work to transfer these processes and manufacture each of our product candidates for various studies, clinical studies and commercial launch readiness. To the extent we elect to transfer manufacturing within our network, we are required to demonstrate that the product manufactured in the new or “receiving” facility is comparable to the product manufactured in the original or “sending” facility. The inability to demonstrate to each of the applicable regulatory authorities that comparable drug product was manufactured could delay the development of our product candidates.

The processes by which our product candidates are manufactured were initially developed by our partners for clinical purposes. We intend to evolve the existing processes with our partners to support advanced clinical studies and commercialization requirements. Developing commercially viable manufacturing processes is a difficult and uncertain task, and there are risks associated with scaling to the level required for advanced clinical studies or commercialization, including cost overruns, potential problems with process scale-up, process reproducibility, stability issues, consistency and timely availability of reagents or raw materials. The manufacturing facilities in which our product candidates will be made could be adversely affected by the ongoing COVID-19 pandemic, earthquakes and other natural or man-made disasters, equipment failures, labor shortages, power failures, and numerous other factors.

The process of manufacturing cellular therapies is susceptible to product loss due to contamination, equipment failure or improper installation or operation of equipment, or vendor or operator error. Even minor deviations from normal manufacturing and distribution processes for any of our product candidates could result in reduced production yields, impact to key product quality attributes, and other supply disruptions. Product defects can also occur unexpectedly. If microbial, viral or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, these manufacturing facilities may need to be closed for an extended period of time to allow us to investigate and remedy the contamination. Because our T-cell immunotherapy product candidates are manufactured from the blood of third-party donors, the process of manufacturing is susceptible to the availability of the third-party donor material. The process of developing products that can be commercialized may be particularly challenging, even if they otherwise prove to be safe and effective. The manufacture of these product candidates involves complex processes. Some of these processes require specialized equipment and highly skilled and trained personnel. The process of manufacturing these product candidates will be susceptible to additional risks, given the need to maintain aseptic conditions throughout the manufacturing process. Contamination with viruses or other pathogens in either the donor material or materials utilized in the manufacturing process or ingress of microbiological material at any point in the process may result in contaminated or unusable product. This type of contaminations could result in delays in the manufacture of products which could result in delays in the development of our product candidates. These contaminations could also increase the risk of adverse side effects. Furthermore, our allogeneic products ultimately consist of many individual cell lines, each with a different HLA profile. As a result, the selection and distribution of the appropriate cell line for therapeutic use in a patient requires close coordination between clinical operations, supply chain and quality assurance personnel.

Any adverse developments affecting manufacturing operations for our product candidates may result in lot failures, inventory shortages, shipment delays, product withdrawals or recalls or other interruptions in the supply of our drug product which could delay the development of our product candidates. We may also have to write off inventory, incur other charges and expenses for supply of drug product that fails to meet specifications, undertake costly remediation efforts, or seek more costly manufacturing alternatives. Inability to meet the demand for our product candidates could damage our reputation and the reputation of our products among physicians, healthcare payors, patients or the medical community that supports our product development efforts, including hospitals and outpatient clinics.

38


 

We intend to manufacture a majority of our product candidates ourselves. Delays in receiving regulatory approvals for product candidates produced in our manufacturing facility could delay our development plans and thereby limit our ability to generate revenues.

The research and development and process and analytical development labs within our manufacturing facility in Thousand Oaks, California are currently supporting preclinical development activities. The facility commissioning and qualification activities required to support production at our facility were completed in 2018. Product-specific qualification to support clinical development is complete and commercial production qualification activities are ongoing. If the appropriate regulatory approvals for manufacturing product candidates in our facility are delayed, we may not be able to manufacture sufficient quantities of our product candidates, which would limit our development activities and our opportunities for growth.

In addition to the similar manufacturing risks described in “Risks Related to Our Dependence on Third Parties,” our manufacturing facility will be subject to ongoing, periodic inspection by the FDA, EMA or other comparable regulatory agencies to ensure compliance with cGMP and GTP. Our failure to follow and document our adherence to these regulations or other regulatory requirements may lead to significant delays in the availability of products for clinical or, in the future, commercial use, may result in the termination of or a hold on a clinical study, or may delay or prevent filing or approval of commercial marketing applications for our product candidates. We also may encounter problems with the following:

 

achieving adequate or clinical-grade materials that meet regulatory agency standards or specifications with consistent and acceptable production yield and costs; 

 

shortages of qualified personnel, raw materials or key contractors; and

 

ongoing compliance with cGMP regulations and other requirements of the FDA, EMA or other comparable regulatory agencies.

Failure to comply with applicable regulations could also result in sanctions being imposed on us, including fines, injunctions, civil penalties, a requirement to suspend or put on hold one or more of our clinical studies, failure of regulatory authorities to grant marketing approval of our product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates, operating restrictions and criminal prosecutions, any of which could harm our business.

Developing advanced manufacturing techniques and process controls is required to fully utilize our facility. Without further investment, advances in manufacturing techniques may render our facility and equipment inadequate or obsolete.

A number of the product candidates in our portfolio, if approved by applicable regulatory authorities, may require significant commercial supply to meet market demand. In these cases, we may need to increase, or “scale up,” the production process by a significant factor over the initial level of production. If we are unable to do so, are delayed, or if the cost of this scale up is not economically feasible for us or we cannot find a third-party supplier, we may not be able to produce our product candidates in a sufficient quantity to meet future demand.

If our sole clinical or commercial manufacturing facility or our CMO is damaged or destroyed or production at these facilities is otherwise interrupted, our business would be negatively affected.

If any manufacturing facility in our manufacturing network, or the equipment in these facilities, is either damaged or destroyed, we may not be able to quickly or inexpensively replace our manufacturing capacity or replace it at all. In the event of a temporary or protracted loss of a facility or its equipment, we may not be able to transfer manufacturing to a third party in the time required to maintain supply. Even if we could transfer manufacturing to a third party, the shift would likely be expensive and time-consuming, particularly since the new facility would need to comply with the necessary regulatory requirements or may require regulatory approval before selling any products manufactured at that facility. Such an event could delay our clinical studies or reduce our commercial product sales.

Currently, we maintain insurance coverage against damage to our property and to cover business interruption and research and development restoration expenses. However, our insurance coverage may not reimburse us, or may not be sufficient to reimburse us, for any expenses or losses we may suffer. We may be unable to meet our requirements for our product candidates if there were a catastrophic event or failure of our current manufacturing facility or processes.

39


 

Risks Related to Our Dependence on Third Parties

Maintaining clinical and commercial timelines is dependent on our end-to-end supply chain network to support manufacturing; if we experience problems with our third party suppliers we may delay development and/or commercialization of our product candidates.

We rely in part on our CMOs or our partners for the current production of our product candidates and the acquisition of materials incorporated in or used in the manufacturing or testing of our product candidates. Our CMOs or partners are not our employees, and except for remedies available to us under our agreements with our CMOs or partners, we cannot directly control whether or not they devote sufficient time and resources, including experienced staff, to the manufacturing of supply for our ongoing clinical, nonclinical and preclinical programs.

To meet our projected supply needs for clinical and commercial materials to support our activities through regulatory approval and commercial manufacturing of tab-cel®, ATA188, any product candidates resulting from our next-generation CAR T programs or any other product candidates, we will need to transition the manufacturing of these materials to a CMO or our own facility. Regardless of where production occurs, we will need to develop relationships with suppliers of critical starting materials or reagents, increase the scale of production and demonstrate comparability of the material produced at these facilities to the material that was previously produced. Transferring manufacturing processes and know-how is complex and involves review and incorporation of both documented and undocumented processes that may have evolved over time.

In addition, transferring production to different facilities may require utilization of new or different processes to meet the specific requirements of a given facility. We would expect additional comparability work will also need to be conducted to support the transfer of certain manufacturing processes and process improvements. We cannot be certain that all relevant know-how and data has been adequately incorporated into the manufacturing process until the completion of studies (and the related evaluations) intended to demonstrate the comparability of material previously produced with that generated by our CMO.

If we are not able to successfully transfer and produce comparable product candidates, our ability to further develop and manufacture our product candidates may be negatively impacted.

While our manufacturing facility in Thousand Oaks, California provides us with flexibility within our manufacturing network, we still may need to identify additional CMOs for continued production of supply for some of our product candidates. Given the nature of our manufacturing processes, the number of CMOs who possess the requisite skill and capability to manufacture our T-cell immunotherapy product candidates is limited. We have not yet identified alternate suppliers in the event the current CMOs that we utilize are unable to scale production, or if we otherwise experience any problems with them.

Manufacturing cellular therapies is complicated and tightly regulated by the FDA and comparable regulatory authorities around the world, and although alternative third-party suppliers with the necessary manufacturing and regulatory expertise and facilities exist, it could be expensive and take a significant amount of time to arrange for alternative suppliers, transfer manufacturing procedures to these alternative suppliers, and demonstrate comparability of material produced by such new suppliers. New manufacturers of any product candidate or intermediate would be required to qualify under applicable regulatory requirements. These manufacturers may not be able to manufacture our product candidates at costs, or in sufficient quantities, or in a timely manner necessary to complete development of our product candidates or make commercially successful products. If we are unable to arrange for alternative third-party manufacturing sources, or to do so on commercially reasonable terms or in a timely manner, we may not be able to complete development of our product candidates, or market or distribute them. In addition, should the FDA or comparable regulatory authorities not agree with our product candidate specifications and comparability assessments for these materials, further clinical development of our product candidate could be substantially delayed and we would incur substantial additional expenses.

Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured product candidates ourselves, including reliance on the third party for regulatory compliance and quality assurance, the possibility that the third-party manufacturer does not maintain the financial resources to meet its obligations under the manufacturing agreement, the possibility of breach of the manufacturing agreement by the third party because of factors beyond our control, including a failure to manufacture our product candidates or any products we may eventually commercialize in accordance with our specifications, misappropriation of our proprietary information, including our trade secrets and know-how, and the possibility of termination or nonrenewal of the agreement by the third party, based on its own business priorities, at a time that is costly or damaging to us. In addition, the FDA and other regulatory authorities require that our product candidates and any products that we may eventually commercialize be manufactured according to cGMP, cGTP and similar regulatory jurisdictional standards. These requirements include, among other things, quality control, quality assurance and the maintenance of records and documentation. The FDA or similar foreign regulatory agencies may also implement new standards at any time or change their interpretations and enforcement of existing standards for manufacture, packaging or testing of products. We have limited control over our manufacturers’ compliance with these regulations and standards and although we monitor our manufacturers, we depend on them to provide honest and accurate information. Any failure by our third-

40


 

party manufacturers to comply with cGMP or cGTP or failure to scale up manufacturing processes, including any failure to deliver sufficient quantities of product candidates in a timely manner, could lead to a delay in, or failure to obtain, regulatory approval of any of our product candidates. In addition, such failure could be the basis for the FDA to issue a warning letter, withdraw approvals for product candidates previously granted to us, or take other regulatory or legal action, including recall or seizure of outside supplies of the product candidate, total or partial suspension of production, suspension of ongoing clinical studies, refusal to approve pending applications or supplemental applications, detention or product, refusal to permit the import or export of products, injunction or imposing civil and criminal penalties.

We depend on third party suppliers for key materials used to produce our product candidates. Any significant disruption in our supplier relationships could harm our business. Any significant delay in the supply of a product candidate for an ongoing clinical study could considerably delay initiation or completion of our clinical studies, product testing and potential regulatory approval of our product candidates. If raw materials or components cannot be purchased or fail to meet approved specifications, the commercial launch of our product candidates could be delayed, or there could be a shortage in supply, which could impair our ability to generate revenues from the sale of our product candidates.

Risks Related to Our Intellectual Property

If we are unable to obtain and maintain sufficient intellectual property protection for our product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our ability to commercialize our product candidates successfully and to compete effectively may be adversely affected.

We rely upon a combination of patents, trademarks, trade secrets and confidentiality agreements – both that we own or possess or that are owned or possessed by our partners that are in-licensed to us – to protect the intellectual property related to our technology and product candidates. When we refer to “our” technologies, inventions, patents, patent applications or other intellectual property rights, we are referring to both the rights that we own or possess as well as those that we in-license, many of which are critical to our intellectual property protection and our business. For example, the product candidates and platform technology we have licensed from our partners are protected primarily by patent or patent applications of our partners that we have licensed and as confidential know-how and trade secrets. If the intellectual property that we rely on is not adequately protected, competitors may be able to use our technologies and erode or negate any competitive advantage we may have.

The patentability of inventions and the validity, enforceability and scope of patents in the biotechnology field is uncertain because it involves complex legal, scientific and factual considerations, and it has in recent years been the subject of significant litigation. Moreover, the standards applied by the U.S. Patent and Trademark Office, or USPTO, and non-U.S. patent offices in granting patents are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in biotechnology patents.

There is no assurance that all potentially relevant prior art relating to our patents and patent applications is known to us or has been found in the instances where searching was done. We may be unaware of prior art that could be used to invalidate an issued patent or prevent a pending patent application from issuing as a patent. There also may be prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim of one of our patents or patent applications, which may, nonetheless, ultimately be found to affect the validity or enforceability of such claim. As a consequence of these and other factors, our patent applications may fail to result in issued patents with claims that cover our product candidates in the U.S. or in other countries.

Even if patents have issued or do successfully issue from patent applications, and even if these patents cover our product candidates, third parties may challenge the validity, enforceability or scope thereof, which may result in these patents being narrowed, invalidated or held to be unenforceable. No assurance can be given that if challenged, our patents would be declared by a court to be valid or enforceable.

Even if unchallenged, our patents and patent applications or other intellectual property rights may not adequately protect our intellectual property, provide exclusivity for our product candidates or prevent others from designing around our claims. The possibility exists that others will develop products on an independent basis which have the same effect as our product candidates and which do not infringe our patents or other intellectual property rights, or that others will design around the claims of patents that we have had issued that cover our product candidates. If the breadth or strength of protection provided by our patents and patent applications with respect to our product candidates is threatened, it could jeopardize our ability to commercialize our product candidates and dissuade companies from collaborating with us.

We may also desire to seek a license from a third party who owns intellectual property that may be useful for providing exclusivity for our product candidates, or for providing the ability to develop and commercialize a product candidate in an unrestricted manner. There is no guarantee that we will be able to obtain a license from such a third party on commercially reasonable terms, or at all.

41


 

In addition, the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.

We and our partners have filed a number of patent applications covering our product candidates or methods of using or making those product candidates. We cannot offer any assurances about which, if any, patents will be issued with respect to these pending patent applications, the breadth of any such patents that are ultimately issued or whether any issued patents will be found invalid and unenforceable or will be threatened by third parties. Because patent applications in the U.S. and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we or our partners were the first to file any patent application related to a product candidate. We or our partners may also become involved in proceedings regarding our patents, including patent infringement lawsuits, interference or derivation proceedings, oppositions, and inter partes and post-grant review proceedings before the USPTO the European Patent Office and other non-U.S. patent offices.

Even if granted, patents have a limited lifespan. In the U.S., the natural expiration of a patent generally occurs 20 years after it is filed. Although various extensions may be available if certain conditions are met, the life of a patent and the protection it affords is limited. If we encounter delays in our clinical studies or in obtaining regulatory approvals, the period of time during which we could exclusively market any of our product candidates under patent protection, if approved, could be reduced. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be vulnerable to competition from biosimilar products, as we may be unable to prevent competitors from entering the market with a product that is similar or identical to our product candidates.

Furthermore, the research resulting in certain of our licensed patent rights and technology was funded by the U.S. government. As a result, the government has certain rights to these patent rights and technology. When new technologies are developed with government funding, the government generally obtains certain rights in any resulting patents, including a non-exclusive license authorizing the government to practice the invention for or on behalf of the U.S. These rights may permit the government to disclose confidential information on which we rely to third parties and to exercise march-in rights to use or allow third parties to use our licensed technology. The government can exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations or to give preference to U.S. industry. In addition, our rights in any inventions that result from government-funded research may be subject to certain requirements to manufacture products embodying these inventions in the U.S.

If we are sued for infringing the intellectual property rights of third parties, the resulting litigation could be costly and time-consuming and could prevent or delay our development and commercialization efforts.

Our commercial success depends, in part, on us and our partners not infringing the patents and proprietary rights of third parties. There is a substantial amount of litigation and other adversarial proceedings, both within and outside the U.S., involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interference or derivation proceedings, oppositions, and inter partes and post-grant review proceedings before the USPTO and non-U.S. patent offices. Numerous U.S. and non-U.S. issued patents and pending patent applications owned by third parties exist in the fields in which we are developing and may develop our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of third parties’ patent rights, as it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform or predictable.

Third parties may assert infringement claims against us based on existing or future intellectual property rights, alleging that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacturing of our product candidates that we failed to identify. For example, patent applications covering our product candidates could have been filed by others without our knowledge, since these applications generally remain confidential for some period of time after their filing date. Even pending patent applications that have been published, including some of which we are aware, could be later amended in a manner that could cover our product candidates or their use or manufacture. In addition, we may have analyzed patents or patent applications of third parties that we believe are relevant to our activities and believe that we are free to operate in relation to any of our product candidates, but our competitors may obtain issued claims, including in patents we consider to be unrelated, which may block our efforts or potentially result in any of our product candidates or our activities infringing their claims.

42


 

If we or our partners are sued for patent infringement, we would need to demonstrate that our product candidates, products and methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid, and we may not be able to do this. Proving that a patent is invalid is difficult and even if we are successful in the relevant proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted from other activities. If any issued third-party patents were held by a court of competent jurisdiction to cover aspects of our materials, formulations, methods of manufacture or methods for treatment, we could be forced, including by court order, to cease developing, manufacturing or commercializing the relevant product candidate until the relevant patent expired. Alternatively, we may desire or be required to obtain a license from such third party in order to use the infringing technology and to continue developing, manufacturing or marketing the infringing product candidate. However, we may not be able to obtain any required license on commercially reasonably terms, or at all. Even if we were able to obtain a license, the rights may be nonexclusive, which could result in our competitors gaining access to the same intellectual property licensed to us.

We may face claims that we misappropriated the confidential information or trade secrets of a third party. If we are found to have misappropriated a third party’s trade secrets, we may be prevented from further using these trade secrets, which could limit our ability to develop our product candidates.

Defending against intellectual property claims could be costly and time consuming, regardless of the outcome. Thus, even if we were to ultimately prevail, or to settle before a final judgment, any litigation could burden us with substantial unanticipated costs. In addition, litigation or threatened litigation could result in significant demands on the time and attention of our management team, distracting them from the pursuit of other company business. During the course of any intellectual property litigation, there could be public announcements of the results of hearings, rulings on motions, and other interim proceedings in the litigation and these announcements may have negative impact on the perceived value of our product candidates, programs or intellectual property. In the event of a successful intellectual property claim against us, we may have to pay substantial damages, including treble damages and attorneys’ fees if we are found to have willfully infringed a patent, or to redesign our infringing product candidates, which may be impossible or require substantial time and monetary expenditure. In addition to paying monetary damages, we may lose valuable intellectual property rights or personnel and the parties making claims against us may obtain injunctive or other equitable relief, which could impose limitations on the conduct of our business. We may also elect to enter into license agreements in order to settle patent infringement claims prior to litigation, and any of these license agreements may require us to pay royalties and other fees that could be significant. As a result of all of the foregoing, any actual or threatened intellectual property claim could prevent us from developing or commercializing a product candidate or force us to cease some aspect of our business operations.

We may not be able to protect our intellectual property rights throughout the world.

Filing, prosecuting, enforcing and defending patents on all of our product candidates in all countries throughout the world would be prohibitively expensive. Our intellectual property rights in certain countries outside the U.S. may be less extensive than those in the U.S. In addition, the laws of certain foreign countries do not protect intellectual property rights to the same extent as laws in the U.S. Consequently, we and our partners may not be able to prevent third parties from practicing our inventions in countries outside the U.S., or from selling or importing infringing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection or where we do not have exclusive rights under the relevant patents to develop their own products and, further, may export otherwise-infringing products to territories where we and our partners have patent protection but where enforcement is not as strong as that in the U.S. These infringing products may compete with our product candidates in jurisdictions where we or our partners have no issued patents or where we do not have exclusive rights under the relevant patents, or our patent claims and other intellectual property rights may not be effective or sufficient to prevent them from so competing.

Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us and our partners to stop the infringement of our patents or marketing of competing products in violation of our intellectual property rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us or our partners. We or our partners may not prevail in any lawsuits that we or our licensors initiate, and even if we or our licensors are successful the damages or other remedies awarded, if any, may not be commercially meaningful.

43


 

We have in-licensed a significant portion of our intellectual property from our partners. If we breach any of our license agreements with these partners, we could lose the ability to continue the development and potential commercialization of one or more of our product candidates.

We hold rights under license agreements with our partners, including MSK, QIMR Berghofer and Moffitt that are important to our business. Our discovery and development platform is built, in part, around patent rights in-licensed from our partners. Under our existing license agreements, we are subject to various obligations, including diligence obligations with respect to development and commercialization activities, payment obligations upon achievement of certain milestones and royalties on product sales. If there is any conflict, dispute, disagreement or issue of nonperformance between us and our counterparties regarding our rights or obligations under these license agreements, including any conflict, dispute or disagreement arising from our failure to satisfy diligence or payment obligations, we may be liable to pay damages and our counterparties may have a right to terminate the affected license. The termination of any license agreement with one of our partners could materially adversely affect our ability to utilize the intellectual property that is subject to that license agreement in our drug discovery and development efforts, our ability to enter into future collaboration, licensing and/or marketing agreements for one or more affected product candidates and our ability to commercialize the affected product candidates. Furthermore, a disagreement under any of these license agreements may harm our relationship with the partner, which could have negative impacts on other aspects of our business.

We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time-consuming and unsuccessful and have a material adverse effect on the success of our business.

Third parties may infringe our patents or misappropriate or otherwise violate our intellectual property rights. Our patent applications cannot be enforced against third parties practicing the technology claimed in these applications unless and until a patent issues from the applications, and then only to the extent the issued claims cover the technology. In the future, we or our partners may elect to initiate legal proceedings to enforce or defend our or our partners’ intellectual property rights, to protect our or our partners’ trade secrets or to determine the validity or scope of our intellectual property rights. Any claims that we or our partners assert against perceived infringers could also provoke these parties to assert counterclaims against us or our partners alleging that we or our partners infringe their intellectual property rights or that our intellectual property rights are invalid.

Interference or derivation proceedings provoked by third parties, brought by us or our partners, or brought by the USPTO or any non-U.S. patent authority may be necessary to determine the priority of inventions or matters of inventorship with respect to our patents or patent applications. We or our partners may also become involved in other proceedings, such as reexamination or opposition proceedings, inter partes review, post-grant review or other pre-issuance or post-grant proceedings in the USPTO or its foreign counterparts relating to our intellectual property or the intellectual property of others. An unfavorable outcome in any of these proceedings could require us or our partners to cease using the related technology and commercializing our product candidates, or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us or our partners a license on commercially reasonable terms if any license is offered at all. Even if we or our licensors obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us or our licensors. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.

Any intellectual property proceedings can be expensive and time-consuming. Our or our partners’ adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we or our partners can. Accordingly, despite our or our partners’ efforts, we or our partners may not be able to prevent third parties from infringing upon or misappropriating our intellectual property rights, particularly in countries where the laws may not protect our rights as fully as in the U.S. Even if we are successful in the relevant proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted from other activities. We could be found liable for monetary damages, including treble damages and attorneys’ fees, if we are found to have willfully infringed a patent. In addition, in an infringement proceeding, a court may decide that one or more of our patents is invalid or unenforceable, in whole or in part, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly.

Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments.

44


 

If we are unable to protect the confidentiality of our trade secrets and other proprietary information, the value of our technology could be materially adversely affected and our business could be harmed.

In addition to seeking the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce, and other elements of our technology, discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. The T-cell immunotherapy product candidates and platform technology we have licensed from our partners are protected primarily as confidential know-how and trade secrets. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, including by enabling them to develop and commercialize products substantially similar to or competitive with our product candidates, thus eroding our competitive position in the market.

Trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements and invention assignment agreements with our employees, consultants, and outside scientific advisors, contractors and collaborators. These agreements are designed to protect our proprietary information. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, or outside scientific advisors might intentionally or inadvertently disclose our trade secrets or confidential, proprietary information to competitors. In addition, competitors may otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. If any of our confidential proprietary information were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position.

Enforcing a claim that a third party illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, the laws of certain foreign countries do not protect proprietary rights such as trade secrets to the same extent or in the same manner as the laws of the U.S. Misappropriation or unauthorized disclosure of our trade secrets to third parties could impair our competitive advantage in the market and could materially adversely affect our business, results of operations and financial condition.

Risks Related to Commercialization of Our Product Candidates

Our commercial success depends upon attaining significant market acceptance of our product candidates, if approved, among physicians, patients, healthcare payors and the medical community, including hospitals and outpatient clinics.

Even if we obtain regulatory approval for any of our product candidates that we may develop or acquire in the future, the product may not gain market acceptance among physicians, healthcare payors, patients or the medical community that supports our product development efforts, including hospitals and outpatient clinics. Market acceptance of any of our product candidates for which we receive approval depends on a number of factors, including:

 

the efficacy and safety of the product candidates as demonstrated in clinical studies;

 

the clinical indications and patient populations for which the product candidate is approved;

 

acceptance by physicians and patients of the drug as a safe and effective treatment;

 

the administrative and logistical burden of treating patients;

 

the adoption of novel cellular therapies by physicians, hospitals and third-party payors;

 

the potential and perceived advantages of product candidates over alternative treatments;

 

the safety of product candidates seen in a broader patient group, including its use outside the approved indications;

 

any restrictions on use together with other medications;

 

the prevalence and severity of any side effects;

 

product labeling or product insert requirements of the FDA or other regulatory authorities;

 

the timing of market introduction of our products as well as competitive products;

 

the development of manufacturing and distribution processes for our product candidates;

45


 

 

the cost of treatment in relation to alternative treatments;

 

the availability of coverage and adequate reimbursement from, and our ability to negotiate pricing with, third-party payors and government authorities;

 

relative convenience and ease of administration; and

 

the effectiveness of our sales and marketing efforts and those of our collaborators.

Even if we are able to commercialize our product candidates, the products may not receive coverage and adequate reimbursement from third-party payors in the U.S. and in other countries in which we seek to commercialize our products, which could harm our business.

Our ability to commercialize any product successfully will depend, in part, on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations.

Government authorities and third-party payors, such as private health insurers and health maintenance organizations, determine which medications they will cover and establish reimbursement levels. A primary trend in the healthcare industry is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Third-party payors may also seek additional clinical evidence, beyond the data required to obtain regulatory approval, demonstrating clinical benefits and value in specific patient populations before covering our products for those patients. We cannot be sure that coverage and adequate reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be. In some countries such as the U.S., greater cost-shifting from the payor to the patient is also a trend, and higher patient copayments or other administrative burdens could lead to reduced demand from patients or healthcare professionals. This could particularly be the case in a challenging economic climate, such as during the COVID-19 pandemic. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain regulatory approval, and ultimately our ability to successfully commercialize any product candidate for which we obtain regulatory approval.

There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may only be temporary. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the U.S. Coverage and reimbursement policies for drug products can differ significantly from payor to payor as there is no uniform policy of coverage and reimbursement for drug products among third-party payors in the U.S. Third-party payors in the U.S. often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. There may be significant delays in obtaining coverage and reimbursement as the process of determining coverage and reimbursement is often time consuming and costly which will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage or adequate reimbursement will be obtained. It is difficult to predict at this time what government authorities and third-party payors will decide with respect to coverage and reimbursement for our drug products. Our inability to promptly obtain coverage and profitable reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.

Current and future legislation, including potentially unfavorable pricing regulations or other healthcare reform initiatives, may increase the difficulty and cost for us to obtain regulatory approval of and commercialize our product candidates and affect the prices we may obtain.

The regulations that govern, among other things, regulatory approvals, coverage, pricing and reimbursement for new drug products vary widely from country to country. In the U.S. and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay regulatory approval of our product candidates, restrict or regulate post-approval activities and affect our ability to successfully sell any product candidates for which we obtain regulatory approval. In particular, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively, the Affordable Care Act, was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers, and continues to significantly impact the U.S. pharmaceutical

46


 

industry. The Affordable Care Act and its implementing regulations, among other things, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics, including our product candidates, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program, extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations, subjected manufacturers to new annual fees and taxes for certain branded prescription drugs, provided incentives to programs that increase the federal government’s comparative effectiveness research and established a new Medicare Part D coverage gap discount program.

Other legislative changes have been proposed and adopted in the U.S. since the Affordable Care Act was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by the U.S. Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation’s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect in April 2013, and, due to subsequent legislative amendments, will remain in effect through 2030 unless additional Congressional action is taken. The Coronavirus Aid, Relief and Economic Security Act, or CARES Act, which was signed into law in March 2020 and is designed to provide financial support and resources to individuals and businesses affected by the COVID-19 pandemic, suspended the 2% Medicare sequester from May 1, 2020 through December 31, 2020, and extended the sequester by one year, through 2030. In January 2013, the American Taxpayer Relief Act of 2012, or the ATRA, was enacted which, among other things, further reduced Medicare payments to several providers, including hospitals and outpatient clinics, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.

There remain judicial and Congressional challenges to numerous elements of the Affordable Care Act, as well as efforts by both the executive and legislative branches of the federal government to repeal or replace certain aspects of the Affordable Care Act. For example, the President signed Executive Orders designed to delay the implementation of certain provisions of the Affordable Care Act or otherwise circumvent some of the requirements for health insurance mandated by the Affordable Care Act. In addition, the U.S. Congress has considered legislation that would repeal or repeal and replace all or part of the Affordable Care Act. While the U.S. Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the Affordable Care Act, such as removing penalties, starting January 1, 2019, for not complying with the Affordable Care Act’s individual mandate to carry health insurance, eliminating the implementation of certain mandated fees, and increasing the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D. In December 2018, a Texas District Court Judge ruled that the Affordable Care Act is unconstitutional in its entirety because the “individual mandate” was repealed by Congress as part of the Tax Cuts and Jobs Act of 2017. In December 2019, the U.S. Court of Appeals for the 5th Circuit upheld the Texas District Court ruling that the individual mandate was unconstitutional and remanded the case back to the Texas District Court to determine whether the remaining provisions of the Affordable Care Act are invalid as well. In March 2020, the United States Supreme Court granted the petitions for writs of certiorari to review this case, and has allotted one hour for oral arguments, which are expected to occur in the fall of 2020.

It is unclear how this litigation and other efforts to repeal and replace the Affordable Care Act will impact the Affordable Care Act and our business. The U.S. Congress may consider and adopt other legislation to repeal and replace all or certain elements of the Affordable Care Act. Any other executive, legislative or judicial action to “repeal and replace” all or part of the Affordable Care Act may have the effect of limiting the amounts that government agencies will pay for healthcare products and services, which could result in reduced demand for our products or additional pricing pressure, or may lead to significant deregulation, which could make the introduction of competing products and technologies much easier. Policy changes, including potential modification or repeal of all or parts of the Affordable Care Act or the implementation of new healthcare legislation, could result in significant changes to the healthcare system which may adversely affect our business in unpredictable ways.

There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of governments, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare, including by imposing price controls, may adversely affect the demand for our product candidates for which we obtain regulatory approval and our ability to set a price that we believe is fair for our products. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors.

47


 

Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA or foreign regulations, guidance or interpretations will be changed, or what the impact of these changes on the regulatory approvals of our product candidates, if any, may be. In the U.S., the European Union and other potentially significant markets for our product candidates, government authorities and third-party payors are increasingly attempting to limit or regulate the price of medical products and services, particularly for new and innovative products and therapies, which has resulted in lower average selling prices for certain products in certain markets. For example, in the U.S., there have been several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. At the federal level, the U.S. presidential administration’s budget proposal for the fiscal year 2021 includes a $135 billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs. In March 2020, the administration sent “principles” for drug pricing to Congress, calling for legislation that would, among other things, cap Medicare Part D beneficiary out-of-pocket pharmacy expenses, provide an option to cap Medicare Part D beneficiary monthly out-of-pocket expenses, and place limits on pharmaceutical price increases. Additionally, in May 2018, the U.S. presidential administration previously laid out a “Blueprint” to lower drug prices and reduce out of pocket costs of drugs that contained additional proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs of drug products paid by consumers. HHS has solicited feedback on some of these measures and has implemented others under its existing authority. For example, in May 2019, CMS issued a final rule to allow Medicare Advantage plans the option to use step therapy for Part B drugs beginning January 1, 2020. This final rule codified CMS’s policy change that was effective January 1, 2019. Although some of these and other proposals may require additional authorization to become effective, members of Congress and the presidential administration have indicated that they will continue to seek new legislative or administrative measures to control drug costs. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, to encourage importation from other countries and bulk purchasing. It is also possible that additional governmental action is taken to address the COVID-19 pandemic. Furthermore, the increased emphasis on managed healthcare in the U.S. and on country and regional pricing and reimbursement controls in the European Union will put additional pressure on product pricing, reimbursement and usage, which may adversely affect our future product sales. These pressures can arise from rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and healthcare reform, pharmaceutical reimbursement policies and pricing in general.

In addition, there is significant uncertainty regarding the reimbursement status of newly approved healthcare products. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the cost-effectiveness of our products. If third-party payors do not consider our products to be cost-effective compared to other therapies, the payors may not cover our products after approved as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products on a profitable basis.

Price controls may be imposed in foreign markets, which may adversely affect our future profitability.

In some countries, particularly member states of the European Union, the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of regulatory approval for a product. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. In some countries, we, or our collaborators, may be required to conduct a clinical study or other studies that compare the cost-effectiveness of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be adversely affected.

48


 

We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.

We face competition from numerous pharmaceutical and biotechnology enterprises, as well as from academic institutions, government agencies and private and public research institutions for our current product candidates. Our commercial opportunities will be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer side effects or are less expensive than any products that we may develop. Additionally, our commercial opportunities will be reduced or eliminated if novel upstream products or changes in treatment protocols reduce the overall incidence or prevalence of our current or future target diseases. Competition could result in reduced sales and pricing pressure on our product candidates, if approved by applicable regulatory authorities. In addition, significant delays in the development of our product candidates could allow our competitors to bring products to market before us and impair any ability to commercialize our product candidates.

There are currently no FDA- or EMA-approved products for the treatment of EBV+ PTLD. However, some marketed products and therapies are used off-label in the treatment of EBV+ PTLD, such as rituximab and combination chemotherapy regimens. In addition, a number of companies and academic institutions are developing product candidates for EBV+ PTLD and other EBV-associated diseases including: Viracta Therapeutics, Inc., which is conducting a Phase 1b/2 clinical study for nanatinostat (formerly named tractinostat, or VRx-3996) in combination with antiviral drug valganciclovir in relapsed/refractory EBV+ lymphomas, AlloVir (formerly known as ViraCyte), which has completed a Phase 2 clinical study for Viralym-M (ALVR105), an allogeneic, multi-virus T-cell product that targets six viruses including EBV and is planning to initiate several Phase 3 studies in 2020 and Tessa Therapeutics Pte Ltd., or Tessa, which has a Phase 3 autologous EBV-specific T-cell therapy (TT10) and a preclinical product candidate that is an allogeneic CD30-targeted CAR EBV-specific T-cell therapy.

Competition in the MS market is high with at least eighteen therapies, including three generics, approved for the treatment of relapsing forms of MS, or RMS, including clinically isolated syndrome, relapsing-remitting disease, or RRMS, and active secondary progressive disease, in the U.S. and EU. There are many competitors in the RMS market, including major multi-national fully-integrated pharmaceutical companies and established biotechnology companies. Most recently, Zeposia® (ozanimod), marketed by Bristol Myers Squibb, and Vumerity™ (diroximel fumarate), marketed by Biogen, was approved in the U.S. for the treatment of RMS, and Mayzent® (siponimod), marketed by Novartis, was approved in the EU for the same indication. There are numerous development candidates in Phase 3 studies for RMS including TG Therapeutics’ anti-CD20 monoclonal antibody ublituximab and EMD Serono’s BTK inhibitor, evobrutinib. Novartis and J&J have completed Phase 3 studies of their anti-CD20 monoclonal antibody, ofatumumab, and sphingosine-1-phosphate receptor 1 (S1P1) modulator, ponesimod, respectively, and have sought regulatory approval for these candidates in the U.S. and EU.

Two therapies have been approved for the treatment of non-relapsing, progressive forms of MS. Ocrevus® is approved in the U.S. and EU for the treatment of PPMS. Mitoxantrone, which is now generic, is approved to treat SPMS, without relapses, in the U.S.

The SPMS and PPMS markets have active development pipelines and additional novel agents could be approved in the future. Several development candidates are being evaluated in Phase 3 studies for progressive forms of MS including primary and secondary progressive MS. These are MedDay’s MD-1003, a concentrated form of biotin, and AB Science’s masitinib, a tyrosine kinase inhibitor. Medicinova is planning to initiate a Phase 3 study of its PDE inhibitor, ibudilast (MN166) in patients with non-relapsing secondary progressive MS.

There are currently two CAR T therapies approved in the U.S. and EU, Novartis’ Kymriah® (tisagenlecleucel) and Gilead/Kite’s Yescarta® (axicabtagene ciloleucel). Bristol-Myers Squibb filed its BLA to the US FDA for lisocabtagene maraleucel (liso-cel) in December 2019. There are many CAR T therapies in development, and, although the majority are autologous, they include allogeneic and off-the-shelf cell therapies. There are multiple allogeneic CAR, or chimeric antigen receptor, platforms being developed with differences in donor cell type and technology approach to minimize instances of donor cells recognizing the patient’s body as foreign or rejection of the donor cells by the patient’s body. The majority of clinical stage allogeneic CAR programs utilize alpha beta T cells as the cell type and gene editing of the T-cell receptor and HLA as the preferred technology approach. It is possible that some of these other approaches will have more favorable characteristics than the approach we utilize, which would result in them being favored by potential partners or customers over our products. Depending on the diseases that we target in the future, we may face competition from both autologous and allogeneic CAR therapies and other modalities (e.g. small molecules, antibodies) in the indication of interest.

49


 

Many of the approved or commonly used drugs and therapies for our current or future target diseases, including EBV+ PTLD and MS, are well established and are widely accepted by physicians, patients and third-party payors. Some of these drugs are branded and subject to patent protection, and other drugs and nutritional supplements are available on a generic basis. Insurers and other third-party payors may encourage the use of generic products or specific branded products. We expect that, if any of our product candidates are approved, they will be priced at a significant premium over competitive generic products. Absent differentiated and compelling clinical evidence, pricing premiums may impede the adoption of our products over currently approved or commonly used therapies, which may adversely impact our business. In addition, many companies are developing new therapeutics, and we cannot predict what the standard of care will become as our products continue in clinical development.

Many of our competitors or potential competitors have significantly greater established presence in the market, financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical studies, obtaining regulatory approvals and marketing approved products than we do, and as a result may have a competitive advantage over us. Smaller or early-stage companies may also prove to be significant competitors, including through collaborative arrangements with large and established companies or if they are acquired by larger companies. These third parties compete with us in recruiting and retaining qualified scientific, commercial and management personnel, establishing clinical study sites and patient registration for clinical studies, as well as in acquiring technologies and technology licenses complementary to our programs or advantageous to our business.

As a result of these factors, these competitors may obtain regulatory approval of their products before we are able to obtain patent protection or other intellectual property rights, which will limit our ability to develop or commercialize our product candidates. Our competitors may also develop drugs that are safer, more effective, more widely used and cheaper than ours, and may also be more successful than us in manufacturing and marketing their products. These appreciable advantages could render our product candidates obsolete or noncompetitive before we can recover the expenses of development and commercialization.

We expect the product candidates we develop will be regulated as biological products, or biologics, and therefore they may be subject to competition sooner than anticipated.

The Biologics Price Competition and Innovation Act of 2009, or BPCIA, was enacted as part of the Affordable Care Act to establish an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as “interchangeable” based on its similarity to an approved biologic. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the reference product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when processes intended to implement BPCIA may be fully adopted by the FDA, any of these processes could have a material adverse effect on the future commercial prospects for our biological products.

We believe that any of the product candidates we develop that is approved in the U.S. as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider the subject product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.

In addition, the approval of a biologic product biosimilar to one of our products could have a material adverse impact on our business as it may be significantly less costly to bring to market and may be priced significantly lower than our products.

50


 

If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we may be unable to generate any revenue.

We are at any early stage of establishing an organization that will be responsible for the sale, marketing and distribution of pharmaceutical products and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. In order to market any products that may be approved by the FDA and comparable foreign regulatory authorities, we must build our sales, marketing, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. There are significant risks involved in building and managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may be competing with many companies that currently have extensive and well-funded sales and marketing operations. Without a sufficiently scaled, appropriately timed and trained internal commercial organization or the support of a third party to perform sales and marketing functions, we may be unable to compete successfully against these more established companies.

We may need to grow the size of our organization, and we may experience difficulties in managing this growth.

As of March 31, 2020, we had 409 employees. We have made the decision to grow the size of our organization in order to support our continued development and potential commercialization of our product candidates. In particular, we may need to add substantial numbers of additional personnel and other resources to support our development and potential commercialization of our product candidates. As our development and commercialization plans and strategies continue to develop, or as a result of any future acquisitions, our need for additional managerial, operational, manufacturing, sales, marketing, financial and other resources will increase. Our management, personnel and systems currently in place may not be adequate to support this future growth. Future growth would impose significant added responsibilities on members of management, including:

 

managing our preclinical and clinical studies effectively;

 

identifying, recruiting, maintaining, motivating and integrating additional employees;

 

managing our internal development efforts effectively while complying with our contractual obligations to licensors, licensees, contractors and other third parties;

 

improving our managerial, development, operational, information technology, and finance systems; and

 

expanding our facilities.

As our operations expand, we will also need to manage additional relationships with various strategic partners, suppliers and other third parties. Our future financial performance and our ability to commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we must be able to manage our development efforts and preclinical and clinical studies effectively and hire, train and integrate additional management, research and development, manufacturing, administrative and sales and marketing personnel. Our failure to accomplish any of these tasks could prevent us from successfully growing our company.

Risks Related to Our Business Generally

Our future success depends on our ability to retain our executive officers and to attract, retain and motivate qualified personnel.

We are highly dependent upon our executive officers and other key employees and the loss of the services of any of our executive officers or other key employees, including scientific, technical or management personnel, could impede the achievement of our corporate objectives.

Our success depends on our ability to recruit, retain, manage and motivate our employees. Although we enter into employment agreements or offer letters with our employees, these documents provide for “at-will” employment, which means that any of our employees could leave our employment at any time, with or without notice. Competition for skilled personnel in our industry and geographic regions is intense and may limit our ability to hire and retain qualified personnel on acceptable terms or at all. To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided equity awards that vest over time. The value to employees of equity awards may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies.

51


 

Our relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse, privacy and other laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.

Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain regulatory approval. Our current and future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we conduct research and would market, sell and distribute our products. As a pharmaceutical company, even though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, federal and state healthcare laws and regulations pertaining to fraud and abuse and patients’ rights are and will be applicable to our business. Restrictions under applicable federal and state healthcare laws and regulations that may affect our ability to operate include the following:

 

the federal healthcare Anti-Kickback Statute, which governs our marketing practices, educational programs, pricing policies, and relationships with healthcare providers or other entities, by prohibiting, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid;

 

federal civil and criminal false claims laws, including the civil False Claims Act, which can be enforced through civil whistleblower or qui tam actions, and civil monetary penalty laws impose criminal and civil penalties against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment or approval that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;

 

the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program and also created federal criminal laws that prohibit knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statements in connection with the delivery of or payment for healthcare benefits, items or services;

 

HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information held by covered entities and their business associates;

 

the federal physician sunshine requirements under the Affordable Care Act requires manufacturers of drugs, devices, biologics and medical supplies to report annually to CMS information related to payments and other transfers of value to physicians, as defined by this law, and teaching hospitals, and ownership and investment interests held by physicians and their immediate family members and applicable group purchasing organizations;

 

state and foreign laws and regulations that are analogous to the federal laws and regulations described in the preceding subsections of this risk factor, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; and

 

some state laws require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; some state laws require drug manufacturers to report information regarding pricing and marketing information related to payments and other transfers of value to physicians and other healthcare providers; some state and local laws require the registration of pharmaceutical sales representatives; and other state laws require the protection of the privacy and security of health information, which may differ from each other in significant ways and often are not preempted by HIPAA.

Efforts to ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from government-funded healthcare programs, such as Medicare and Medicaid, disgorgement, additional reporting requirements or oversight if we become subject to a corporate integrity agreement or similar agreement, and the curtailment or restructuring of our operations. If any physicians or other healthcare providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government-funded healthcare programs.

52


 

Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation.

We are exposed to the risk of employee fraud or other misconduct, including intentional failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, provide accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards we have established, comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report financial information or data accurately or disclose unauthorized activities to us. Employee misconduct could also involve the improper use of information obtained in the course of clinical studies, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions.

Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.

We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical studies and will face an even greater risk if we commercially sell any products that we may develop. Product liability claims may be brought against us by subjects enrolled in our clinical studies, patients, healthcare providers or others using, administering or selling our products. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:

 

decreased demand for any product candidates or products that we may develop;

 

termination of clinical study sites or entire study programs;

 

injury to our reputation and significant negative media attention;

 

withdrawal of clinical study participants;

 

significant costs to defend the related litigation;

 

substantial monetary awards to study subjects or patients;

 

loss of revenue;

 

diversion of management and scientific resources from our business operations; and

 

the inability to commercialize any products that we may develop.

We currently hold product liability insurance coverage at a level that we believe is customary for similarly situated companies and adequate to provide us with insurance coverage for foreseeable risks, but which may not be adequate to cover all liabilities that we may incur. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. We intend to expand our insurance coverage for products to include the sale of commercial products if we obtain regulatory approval for our product candidates in development, but we may be unable to obtain commercially reasonable product liability insurance for any products that receive regulatory approval. Large judgments have been awarded in class action lawsuits based on drugs that had unanticipated side effects. A successful product liability claim or series of claims brought against us, particularly if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business.

If we and our third-party manufacturers fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.

We and our third-party manufacturers are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our or our third-party manufacturers’ use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.

53


 

Although we maintain workers’ compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials with a policy limit that we believe is customary for similarly situated companies and adequate to provide us with insurance coverage for foreseeable risks, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological or hazardous materials.

In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions, which could adversely affect our business, financial condition, results of operations and prospects.

Our business and operations would suffer in the event of computer system failures or security breaches.

Our internal computer systems, and those of our partners, our CROs, our CMOs, and other business vendors on which we rely, are vulnerable to damage from computer viruses, unauthorized access, natural or man-made disasters, fire, terrorism, war and telecommunication and electrical failures. We exercise little or no control over these third parties, which increases our vulnerability to problems with their systems. Additionally, the increased usage of computers operated on home networks due to the shelter-in-place or similar restrictions related to the COVID-19 pandemic may make our systems more susceptible to security breaches. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our drug development programs. For example, the loss of clinical study data from completed, ongoing or planned clinical studies could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, the further development of our product candidates could be delayed and our business could be otherwise adversely affected.

Changes in tax laws or regulations that are applied adversely to us or our customers may have an adverse effect on our business, cash flows, financial condition or results of operations.

New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business and financial condition. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act, or the Tax Act, enacted many significant changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Act may affect us, and certain aspects of the Tax Act repealed or modified in future legislation. For example, the CARES Act modified certain provisions of the Tax Act. In addition, it is uncertain if and to what extent various states will conform to the Tax Act, the CARES Act or any other newly enacted federal tax legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses under the Tax Act or future reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future U.S. tax expense. However, given our valuation allowance position, the Tax Act is not expected to have a significant impact on our effective tax rate, cash tax expenses or net deferred tax assets.

Our ability to use net operating loss carryforwards to offset future taxable income, and our ability to use tax credit carryforwards, may be subject to certain limitations.

Our ability to use our federal and state net operating losses, or NOLs, to offset potential future taxable income and related income taxes that would otherwise be due is dependent upon our generation of future taxable income, and we cannot predict with certainty when, or whether, we will generate sufficient taxable income to use all of our NOLs.

As of December 31, 2019, we reported U.S. federal and state NOLs of approximately $547.7 million and $695.4 million, respectively. Our federal NOLs generated prior to 2018 aggregating to $77.1 million will continue to be governed by the NOL tax rules as they existed prior to the adoption of the Tax Act, which means that generally they will expire 20 years after they were generated if not used prior thereto. Many states have similar laws, and our state NOLs will begin to expire in 2032. Accordingly, these federal and state NOLs could expire unused and be unavailable to offset future income tax liabilities. Under the Tax Act, as modified by the CARES Act, federal NOLs incurred in 2018 and in future years may be carried forward indefinitely, but the utilization of such federal NOLs arising in taxable years beginning after 2020 is limited to 80% of current year taxable income. Not all states conform to the Tax Act or CARES Act and other states have varying conformity to the Tax Act or CARES Act.

54


 

In addition, under Section 382 of the Internal Revenue Code of 1986, as amended, or the Code, our ability to utilize these NOLs and other tax attributes, such as federal tax credits, in any taxable year may be limited if we have experienced an “ownership change.” Generally, a Section 382 ownership change occurs if one or more stockholders or groups of stockholders who owns at least 5% of a corporation’s stock increases its ownership by more than 50 percentage points over its lowest ownership percentage within a three-year testing period. Similar rules may apply under state tax laws. We completed a Section 382 study of transactions in our stock through December 31, 2019 and concluded that we have experienced ownership changes since inception that we believe under Section 382 of the Code will result in limitations in our ability to use certain of our NOLs and credits. In addition, we may experience subsequent ownership changes as a result of future equity offerings or other changes in the ownership of our stock, some of which are beyond our control. As a result, the amount of the NOLs and tax credit carryforwards presented in our financial statements could be limited and, in the case of NOLs generated in 2017 and before, may expire unused. Any such material limitation or expiration of our NOLs may harm our future operating results by effectively increasing our future tax obligations.

Business disruptions could seriously harm our future revenues and financial condition and increase our costs and expenses.

Our operations could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or manmade disasters or business interruptions, for which we are predominantly self-insured. Two of our corporate locations are located in California, an area prone to earthquakes and fires. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. We rely on third-party manufacturers to produce our product candidates. Our ability to obtain clinical supplies of product candidates could be disrupted, if the operations of these suppliers are affected by a man-made or natural disaster or other business interruption, including, for example, the COVID-19 pandemic.

Risks Related to Ownership of Our Common Stock

Our stock price has been and will likely continue to be volatile and may decline regardless of our operating performance.

Our stock price has fluctuated in the past and can be expected to be volatile in the future. From January 1, 2018 through March 31, 2020, the reported sale price of our common stock has fluctuated between $4.52 and $54.45 per share. The stock market in general and the market for biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. In particular, the COVID-19 pandemic has further heightened the volatility of the stock market for biopharmaceutical companies. As a result of this volatility, investors may experience losses on their investment in our common stock. The market price of our common stock may be influenced by many factors, including the following:

 

the success of competitive products or technologies;

 

regulatory actions with respect to our product candidates or products or our competitors’ product candidates or products;

 

actual or anticipated changes in our growth rate relative to our competitors;

 

announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments;

 

results of clinical studies of our product candidates or those of our competitors;

 

regulatory or legal developments in the U.S. and other countries;

 

developments or disputes concerning patent applications, issued patents or other proprietary rights;

 

the recruitment or departure of key personnel;

 

the level of expenses related to any of our product candidates or clinical development programs;

 

the results of our efforts to in-license or acquire additional product candidates or products;

 

actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;

 

variations in our financial results or those of companies that are perceived to be similar to us;

 

fluctuations in the valuation of companies perceived by investors to be comparable to us;

 

inconsistent trading volume levels of our shares;

 

announcement or expectation of additional financing efforts;

 

sales of our common stock by us, our insiders or our other stockholders;

55


 

 

changes in the structure of healthcare payment systems;

 

market conditions in the pharmaceutical and biotechnology sectors;

 

general economic, industry and market conditions; and

 

the other risks described in this “Risk Factors” section.

In addition, the stock markets in general, and the markets for biotechnology and pharmaceutical stocks in particular, have experienced significant volatility that has often been unrelated to the operating performance of particular companies, including very recently in connection with the ongoing COVID-19 pandemic, which has resulted in decreased stock prices for many companies. For example, negative publicity regarding drug pricing and price increases by pharmaceutical companies has negatively impacted, and may continue to negatively impact, the markets for biotechnology and pharmaceutical stocks. Likewise, as a result of significant changes in U.S. social, political, regulatory and economic conditions or in laws and policies governing foreign trade and healthcare spending and delivery, including the possible repeal and/or replacement of all or portions of the Affordable Care Act or changes in tariffs and other restrictions on free trade stemming from U.S. and foreign government policies, or for other reasons, the financial markets could experience significant volatility that could also negatively impact the markets for biotechnology and pharmaceutical stocks. These market fluctuations may adversely affect the trading price of our common stock.

In the past, class action litigation has often been instituted against companies whose securities have experienced periods of volatility in market price. Any such litigation brought against us could result in substantial costs and divert management’s attention and resources, which could result in delays of our clinical studies or commercialization efforts.

Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.

Our executive officers, directors and principal stockholders own a significant portion of our outstanding common stock. These stockholders may be able to determine the outcome of all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock. The interests of our significant stockholders may not always coincide with the interests of other stockholders and they may act in a manner that advances their best interests and not necessarily those of other stockholders, including seeking a premium value for their common stock, and might affect the market price for our common stock.

Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.

Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. Moreover, certain holders of shares of our common stock will have rights, subject to certain conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We have registered and intend to continue to register all shares of common stock that we may issue under our equity compensation plans. Once we register these shares, they can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates.

We have incurred and will continue to incur increased costs as a result of being a public company and our management expects to devote substantial time to public company compliance programs.

As a public company, we have incurred and will continue to incur significant legal, accounting and other expenses. We are subject to the reporting requirements of the Exchange Act, which require, among other things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and The Nasdaq Stock Market to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, the SEC has adopted and will adopt additional rules and regulations, such as mandatory “say on pay” voting requirements, that now apply to us. Stockholder activism, the current political environment and the potential for future regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate.

56


 

The rules and regulations applicable to public companies have substantially increased our legal and financial compliance costs and make some activities more time-consuming and costly. To the extent these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations. The increased costs will decrease our net income or increase our net loss and may require us to reduce costs in other areas of our business or increase the prices of our products or services.

Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be the sole source of potential gain for our stockholders.

We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for our stockholders for the foreseeable future.

Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.

We expect that significant additional capital will be needed in the future to continue our planned operations. To raise capital, we may sell substantial amounts of common stock or securities convertible into or exchangeable for common stock in one or more transactions at prices and in a manner we determine from time to time. These future issuances of common stock or common stock-related securities, together with the exercise of outstanding options or warrants, and any additional shares issued in connection with acquisitions or in-licenses, if any, may result in material dilution to our investors. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights, preferences and privileges senior to those of holders of our common stock. To the extent equity valuations, including the trading price of our common stock, are depressed as a result of economic disruptions and uncertainty concerning the COVID-19 pandemic or other factors, the potential magnitude of this dilution will increase. Pursuant to our equity incentive plans, our compensation committee is authorized to grant equity-based incentive awards to our employees, non-employee directors and consultants. Future grants of RSUs, options and other equity awards and issuances of common stock under our equity incentive plans will result in dilution and may have an adverse effect on the market price of our common stock.

Some terms of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders and may prevent attempts by our stockholders to replace or remove our current management.

Our amended and restated certificate of incorporation, or Certificate of Incorporation, and amended and restated bylaws, or Bylaws, as well as Delaware law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders, or remove our current management. These include terms that:

 

permit our board of directors to issue up to 20,000,000 shares of preferred stock, with any rights, preferences and privileges as they may designate;

 

provide that all vacancies on our board of directors, including as a result of newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;

 

establish that our board of directors is divided into three classes, with each class serving three-year staggered terms, which makes it more difficult to replace a majority of our directors in a short period of time;

 

require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent;

 

provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder’s notice;

 

not provide for cumulative voting rights, thereby allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election; and

 

provide that special meetings of our stockholders may be called only by our board of directors, the chairperson of our board of directors or our chief executive officer.

Any of the factors listed above may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, who are responsible for appointing the members of our management.

57


 

In addition, because we are incorporated in Delaware, we are governed by Section 203 of the Delaware General Corporation Law, which may discourage, delay or prevent someone from acquiring us or merging with us whether or not it is desired by or beneficial to our stockholders. Under Delaware law, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other things, the board of directors has approved the transaction. Any term of our Certificate of Incorporation or Bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock and could also affect the price that some investors are willing to pay for our common stock.

If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.

The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us and our business. In the event securities or industry analysts who cover us downgrade our stock or publish unfavorable research about us or our business, our stock price would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

58


 

Item 6. Exhibits

 

Exhibit

 

 

 

Incorporated by Reference

 

Filed

No.

 

Description of Exhibit

 

Form

 

File No.

 

Exhibit

 

Filing Date

 

Herewith

 

 

 

 

 

 

 

 

 

 

 

 

 

  3.1

 

Amended and Restated Certificate of Incorporation of Atara Biotherapeutics, Inc.

 

S-1

 

333-196936

 

3.2

 

6/20/2014

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  3.2

 

Amended and Restated Bylaws of Atara Biotherapeutics, Inc.

 

S-1

 

333-196936

 

3.4

 

6/20/2014

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

31.1

 

Certification by Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

31.2

 

Certification by Principal Financial and Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

32.1(1)

 

Certifications of Chief Executive Officer and Principal Financial and Accounting Officer pursuant to 18 U.S.C Section 1350 as adopted pursuant to Section 906 of The Sarbanes-Oxley Act of 2002.

 

 

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

101.INS

 

XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

 

 

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

101.SCH

 

Inline XBRL Schema Document

 

 

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

101.CAL

 

Inline XBRL Calculation Linkbase Document

 

 

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

101.LAB

 

Inline XBRL Labels Linkbase Document

 

 

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

101.PRE

 

Inline XBRL Presentation Linkbase Document

 

 

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

101.DEF

 

Inline XBRL Definition Linkbase Document.

 

 

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

104

 

The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, formatted in Inline XBRL.

 

 

 

 

 

 

 

 

 

X

 

*

Indicates management contract or compensatory plan or arrangement.

+

Portions of this exhibit have been omitted as being immaterial and would be competitively harmful if publicly disclosed.

 

(1)

The certifications attached as Exhibit 32.1 accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the Registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

 

59


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, Atara Biotherapeutics, Inc. has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

ATARA BIOTHERAPEUTICS, INC.

Date: May 6, 2020

 

 

 

 

 

 

 

 

 

By:

/s/ Pascal Touchon

 

 

Pascal Touchon

 

 

President and Chief Executive Officer

 

 

(Duly Authorized Officer and Principal

 

 

Executive Officer)

 

 

 

 

 

 

By:

/s/ Utpal Koppikar

 

 

Utpal Koppikar

 

 

Chief Financial Officer

 

 

(Duly Authorized Officer and Principal

 

 

Financial and Accounting Officer)

 

60

EX-31.1 2 atra-ex311_9.htm EX-31.1 atra-ex311_9.htm

 

Exhibit 31.1

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER

PURSUANT TO

SECURITIES EXCHANGE ACT RULES 13A-14(A) AND 15D-14(A)

I, Pascal Touchon, certify that:

1.

I have reviewed this Quarterly Report on Form 10-Q of Atara Biotherapeutics, Inc.;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 6, 2020

 

/s/ Pascal Touchon

Pascal Touchon

Chief Executive Officer

(Principal Executive Officer)

 

 

EX-31.2 3 atra-ex312_7.htm EX-31.2 atra-ex312_7.htm

 

Exhibit 31.2

CERTIFICATION OF THE PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER

PURSUANT TO

SECURITIES EXCHANGE ACT RULES 13A-14(A) AND 15D-14(A)

I, Utpal Koppikar certify that:

1.

I have reviewed this Quarterly Report on Form 10-Q of Atara Biotherapeutics, Inc.;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 6, 2020

 

/s/ Utpal Koppikar

Utpal Koppikar

Chief Financial Officer

(Principal Financial and Accounting Officer)

 

 

EX-32.1 4 atra-ex321_10.htm EX-32.1 atra-ex321_10.htm

 

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Atara Biotherapeutics, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2020, as filed with the Securities and Exchange Commission (the “Report”), Pascal Touchon, Chief Executive Officer of the Company, and Utpal Koppikar, Chief Financial Officer of the Company, respectively, do each hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 6, 2020

 

/s/ Pascal Touchon 

Pascal Touchon

Chief Executive Officer

(Principal Executive Officer)

 

/s/ Utpal Koppikar

Utpal Koppikar

Chief Financial Officer

(Principal Financial and Accounting Officer)

 

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

EX-101.SCH 5 atra-20200331.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical) (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100060 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Credit Losses link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Description of Business link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Net Loss per Common Share link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Financial Instruments link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Property and Equipment link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - License and Collaboration Agreements link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Net Loss per Common Share (Tables) link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Financial Instruments (Tables) link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Property and Equipment (Tables) link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Stockholders' Equity (Tables) link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Description of Business (Detail) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Net Loss per Common Share - Antidilutive Securities Excluded From Computation of Diluted Net Loss per Common Share (Detail) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Financial Instruments - Summary of Estimated Fair Value and Related Valuation Input Hierarchy of Available-for-Sale Securities (Detail) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Financial Instruments - Amortized Cost and Fair Value of Available-for-Sale Securities by Contractual Maturity (Detail) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Financial Instruments - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Financial Instruments - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Detail) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Property and Equipment - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - License and Collaboration Agreements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Stockholders' Equity - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Stockholders' Equity - Summary of RSU Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Stockholders' Equity - Schedule of Common Stock Reserved for Future Issuance Under Equity Incentive Plans (Detail) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Stockholders' Equity - Schedule of Stock-based Compensation Related to All Employee And Non-employee Stock Awards (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 6 atra-20200331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 atra-20200331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 atra-20200331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Current Reporting Status Entity Current Reporting Status Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Shell Company Entity Shell Company Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Title of 12(b) Security Security12b Title Security Exchange Name Security Exchange Name Entity Interactive Data Current Entity Interactive Data Current Document Quarterly Report Document Quarterly Report Document Transition Report Document Transition Report Accrued research and development expenses current. Statement Of Financial Position [Abstract] Assets Assets [Abstract] Current assets: Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Short-term investments Short Term Investments Restricted cash - short-term Restricted Cash Current Prepaid expenses and other current assets Prepaid Expense And Other Assets Current Total current assets Assets Current Property and equipment, net Property Plant And Equipment Net Operating lease assets Operating Lease Right Of Use Asset Restricted cash - long-term Restricted Cash Noncurrent Other assets Other Assets Noncurrent Total assets Assets Liabilities and stockholders’ equity Liabilities And Stockholders Equity [Abstract] Current liabilities: Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued compensation Employee Related Liabilities Current Accrued research and development expenses Accrued Research And Development Expenses Current Other current liabilities Other Liabilities Current Total current liabilities Liabilities Current Operating lease liabilities - long-term Operating Lease Liability Noncurrent Other long-term liabilities Other Liabilities Noncurrent Total liabilities Liabilities Commitments and contingencies (Note 7) Commitments And Contingencies Stockholders’ equity: Stockholders Equity [Abstract] Common stock—$0.0001 par value, 500,000 shares authorized as of March 31, 2020 and December 31, 2019; 58,940 and 56,806 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively Common Stock Value Additional paid-in capital Additional Paid In Capital Common Stock Accumulated other comprehensive income Accumulated Other Comprehensive Income Loss Net Of Tax Accumulated deficit Retained Earnings Accumulated Deficit Total stockholders’ equity Stockholders Equity Total liabilities and stockholders’ equity Liabilities And Stockholders Equity Common stock, par value Common Stock Par Or Stated Value Per Share Common stock, shares authorized Common Stock Shares Authorized Common stock, shares issued Common Stock Shares Issued Common stock, shares outstanding Common Stock Shares Outstanding Income Statement [Abstract] Operating expenses: Operating Expenses [Abstract] Research and development Research And Development Expense General and administrative General And Administrative Expense Total operating expenses Operating Expenses Loss from operations Operating Income Loss Interest and other income, net Other Nonoperating Income Expense Net loss Net Income Loss Other comprehensive (loss) gain: Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract] Unrealized (loss) gain on available-for-sale securities Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax Comprehensive loss Comprehensive Income Net Of Tax Net loss per common share: Earnings Per Share [Abstract] Basic and diluted net loss per common share Earnings Per Share Basic And Diluted Weighted-average shares outstanding used to calculate basic and diluted net loss per common share Weighted Average Number Of Share Outstanding Basic And Diluted Issuance of Common Stock, Net of Commissions and Offering Costs, Shares. Issuance of common stock, net of commissions and offering costs, value. Stock issued during period shares stock options exercised of pre-funded warrants. Stock issued during period value stock options exercised of pre funded warrants. Issuance of common stock pursuant to employee stock awards shares. Issuance of common stock pursuant to employee stock awards value. Statement Of Stockholders Equity [Abstract] Statement [Table] Statement [Table] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Common Stock Common Stock [Member] Additional Paid-in Capital Additional Paid In Capital [Member] Accumulated Other Comprehensive (Loss) Income Accumulated Other Comprehensive Income [Member] Accumulated Deficit Retained Earnings [Member] Sale of Stock Subsidiary Sale Of Stock [Axis] Sale of Stock Sale Of Stock Name Of Transaction [Domain] At the market offering. At The Market Offering At The Market Offering [Member] Statement [Line Items] Statement [Line Items] Beginning balance Beginning balance (in shares) Shares Outstanding Effect of the adoption of ASC topic 842 (Leases) Cumulative Effect Of New Accounting Principle In Period Of Adoption Beginning balance, as adjusted Stockholders Equity Including Portion Attributable To Noncontrolling Interest Adjusted Balance1 Issuance of common stock, net of commissions and offering costs, value Issuance Of Common Stock Net Of Commissions And Offering Costs Value Issuance of common stock, net of commissions and offering costs, shares Issuance Of Common Stock Net Of Commissions And Offering Costs Shares Exercise of pre-funded warrants Stock Issued During Period Value Stock Options Exercised Of Pre Funded Warrants Exercise of pre-funded warrants, shares Stock Issued During Period Shares Stock Options Exercised Of Pre Funded Warrants RSU settlements, net of shares withheld Restricted Stock Value Shares Issued Net Of Tax Withholdings RSU settlements, net of shares withheld, shares Restricted Stock Shares Issued Net Of Shares For Tax Withholdings Issuance of common stock pursuant to employee stock awards Issuance Of Common Stock Pursuant To Employee Stock Awards Value Issuance of common stock pursuant to employee stock awards, shares Issuance Of Common Stock Pursuant To Employee Stock Awards Shares Stock-based compensation expense Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Net loss Unrealized (loss) gain on available-for-sale securities Ending balance Ending balance (in shares) Stock issuance, discounts, commissions and offering costs Adjustments To Additional Paid In Capital Stock Issued Issuance Costs Non cash operating lease expense. Increase (decrease) in accrued research and development. Increase (decrease) in operating lease liabilities. Finance lease assets obtained in exchange for lease obligations. Accrued costs charged to stockholders' equity. Receivable for options exercised. Statement Of Cash Flows [Abstract] Operating activities Net Cash Provided By Used In Operating Activities [Abstract] Net loss Profit Loss Adjustments to reconcile net loss to net cash used in operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Stock-based compensation expense Share Based Compensation Depreciation and amortization expense Depreciation And Amortization Amortization (accretion) of investment premiums (discounts) Investment Income Net Amortization Of Discount And Premium Non-cash operating lease expense Non Cash Operating Lease Expense Asset retirement obligation accretion expense Accretion Expense Changes in operating assets and liabilities: Increase Decrease In Other Operating Assets And Liabilities Net [Abstract] Prepaid expenses and other current assets Increase Decrease In Prepaid Deferred Expense And Other Assets Other assets Increase Decrease In Other Operating Assets Accounts payable Increase Decrease In Accounts Payable Accrued compensation Increase Decrease In Employee Related Liabilities Accrued research and development expenses Increase Decrease In Accrued Research And Development Other current liabilities Increase Decrease In Other Current Liabilities Operating lease liabilities Increase Decrease In Operating Lease Liabilities Net cash used in operating activities Net Cash Provided By Used In Operating Activities Investing activities Net Cash Provided By Used In Investing Activities [Abstract] Purchases of short-term investments Payments To Acquire Short Term Investments Proceeds from maturities and sales of short-term investments Proceeds From Sale Maturity And Collection Of Shortterm Investments Purchases of property and equipment Payments To Acquire Property Plant And Equipment Net cash provided by investing activities Net Cash Provided By Used In Investing Activities Financing activities Net Cash Provided By Used In Financing Activities [Abstract] Proceeds from issuance of common stock through ATM facilities, net Proceeds From Issuance Of Common Stock Proceeds from employee stock awards Proceeds From Stock Plans Taxes paid related to net share settlement of restricted stock units Payments Related To Tax Withholding For Share Based Compensation Principal payments on finance lease obligations Finance Lease Principal Payments Other financing activities, net Proceeds From Payments For Other Financing Activities Net cash provided by (used in) financing activities Net Cash Provided By Used In Financing Activities Decrease in cash, cash equivalents and restricted cash Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect Cash, cash equivalents and restricted cash at beginning of period Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Cash, cash equivalents and restricted cash at end of period Non-cash investing and financing activities Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract] Property and equipment purchases included in accounts payable and other accrued liabilities Capital Expenditures Incurred But Not Yet Paid Finance lease assets obtained in exchange for lease obligations Finance Lease Assets Obtained In Exchange For Lease Obligations Accrued costs related to ATM facilities Accrued Costs Of Financing Activities Charged To Stockholders Equity Receivable for options exercised Receivable For Options Exercised Supplemental cash flow disclosure Supplemental Cash Flow Information [Abstract] Cash paid for interest Interest Paid Net Cash paid for income taxes Income Taxes Paid Net Credit Loss [Abstract] Credit Losses Credit Loss Financial Instrument [Text Block] The entire disclosure for the business description concept. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Organization Consolidation And Presentation Of Financial Statements [Abstract] Description of Business Business Description [Text Block] Accounting Policies [Abstract] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Net Loss per Common Share Earnings Per Share [Text Block] financial instruments disclosure. Financial Instruments Disclosure [Abstract] Financial Instruments Financial Instruments Disclosure [Text Block] Property Plant And Equipment [Abstract] Property and Equipment Property Plant And Equipment Disclosure [Text Block] License and Collaboration Agreements Collaborative Arrangement Disclosure [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments And Contingencies Disclosure [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Stockholders' Equity Stockholders Equity Note Disclosure [Text Block] Basis of Presentation Basis Of Accounting Policy Policy [Text Block] Liquidity and Going Concern. Liquidity and Going Concern Liquidity And Going Concern Policy [Text Block] Use of Estimates Use Of Estimates Recent Accounting Pronouncements New Accounting Pronouncements Policy Policy [Text Block] Antidilutive Securities Excluded From Computation of Diluted Net Loss per Common Share Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block] Summary of estimated fair value and related valuation input hierarchy of available-for-sale securities. Summary of Estimated Fair Value and Related Valuation Input Hierarchy of Available-for-Sale Securities Summary Of Estimated Fair Value And Related Valuation Input Hierarchy Of Available For Sale Securities Table [Text Block] Amortized Cost and Fair Value of Available for Sale Securities by Contractual Maturity Investments Classified By Contractual Maturity Date Table [Text Block] Reconciliation of Cash, Cash Equivalents and Restricted Cash Schedule Of Restricted Cash And Cash Equivalents [Text Block] Schedule of Property and Equipment Property Plant And Equipment [Text Block] Summary of RSU Activity Schedule Of Sharebased Compensation Restricted Stock And Restricted Stock Units Activity Table [Text Block] Summary of Stock Option Activity Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Common stock reserved for future issuance. Schedule of Common Stock Reserved for Future Issuance Under Equity Incentive Plans Common Stock Reserved For Future Issuance Table [Text Block] Schedule of Stock-based Compensation, Related to Employee and Nonemployee Stock Awards Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Entity incorporation state Entity incorporation date Entity Incorporation Date Of Incorporation Accumulated Deficit Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Antidilutive Securities Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis] Antidilutive Securities, Name Antidilutive Securities Name [Domain] Unvested RSUs Restricted Stock Units R S U [Member] Vested and Unvested Options Employee Stock Option [Member] Employee stock purchase plan. ESPP Share Purchase Rights Employee Stock Purchase Plan [Member] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of earnings per share Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Cash equivalents, amortized cost. Cash equivalents, accumulated gross unrealized gain, before tax. Cash equivalents, accumulated gross unrealized loss, before tax. Cash equivalents, fair value. Schedule Of Available For Sale Securities [Table] Schedule Of Available For Sale Securities [Table] Measurement Frequency Fair Value By Measurement Frequency [Axis] Measurement Frequency Fair Value Measurement Frequency [Domain] Fair Value, Measurements, Recurring Fair Value Measurements Recurring [Member] Investment Type Investment Type [Axis] Investments Investment Type Categorization [Member] Money Market Funds Money Market Funds [Member] U.S. Treasury Obligations U S Treasury Securities [Member] Government Agency Obligations U S Government Agencies Shortterm Debt Securities [Member] Corporate Debt Obligations Corporate Debt Securities [Member] Commercial Paper Commercial Paper [Member] Asset-Backed Securities Asset Backed Securities [Member] Certificates of Deposit Certificates Of Deposit [Member] Amounts Classified As Cash Equivalents Cash Equivalents [Member] Amounts Classified As Short-Term Investments Short Term Investments [Member] Fair Value Hierarchy and NAV Fair Value By Fair Value Hierarchy Level [Axis] Fair Value Hierarchy and NAV Fair Value Measurements Fair Value Hierarchy [Domain] Level 1 Fair Value Inputs Level1 [Member] Level 2 Fair Value Inputs Level2 [Member] Schedule of Available-for-sale Securities [Line Items] Schedule Of Available For Sale Securities [Line Items] Total Amortized Cost Available For Sale Debt Securities Amortized Cost Basis Total Unrealized Gain Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Total Unrealized Loss Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Total Fair Value Available For Sale Securities Debt Securities Total Amortized Cost Cash Equivalents Amortized Cost Total Unrealized Gain Cash Equivalents Accumulated Gross Unrealized Gain Before Tax Total Unrealized Loss Cash Equivalents Accumulated Gross Unrealized Loss Before Tax Total Fair Value Cash Equivalents Fair Value Amortized cost Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis [Abstract] Maturing within one year, Amortized cost Available For Sale Securities Debt Maturities Within One Year Amortized Cost Maturing in one to five years, Amortized cost Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost Total available-for-sale securities, Amortized cost Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis Estimated Fair value Available For Sale Securities Debt Maturities Fair Value [Abstract] Maturing within one year, Estimated fair value Available For Sale Securities Debt Maturities Within One Year Fair Value Maturing in one to five years, Estimated fair value Available For Sale Securities Debt Maturities After One Through Five Years Fair Value Total available-for-sale securities, Estimated fair value Write off of accrued interest receivable. Accrued interest receivable Interest Receivable Write off, of accrued interest receivable Write Off Of Accrued Interest Receivable Restricted Cash Restricted Cash Total cash, cash equivalents and restricted cash Schedule Of Property Plant And Equipment [Table] Schedule Of Property Plant And Equipment [Table] Property, Plant and Equipment, Type Property Plant And Equipment By Type [Axis] Property, Plant and Equipment, Type Property Plant And Equipment Type [Domain] Leasehold Improvements Leasehold Improvements [Member] Lab Equipment Equipment [Member] Machinery and Equipment Machinery And Equipment [Member] Computer equipment and software. Computer Equipment and Software Computer Equipment And Software [Member] Furniture and Fixtures Furniture And Fixtures [Member] Construction in Progress Construction In Progress [Member] Property Plant And Equipment [Line Items] Property Plant And Equipment [Line Items] Property and equipment, gross Property Plant And Equipment Gross Less: accumulated depreciation and amortization Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Property and equipment, net Property Plant And Equipment Net By Type [Abstract] Potential milestone payments payable. License, collaboration and manufacturing agreements. License Collaboration And Manufacturing Agreements [Abstract] License, collaboration and manufacturing agreements. Schedule of license, collaboration and manufacturing agreements. Schedule Of License Collaboration And Manufacturing Agreements [Table] Schedule Of License Collaboration And Manufacturing Agreements [Table] Collaborative Arrangement and Arrangement Other than Collaborative Type Of Arrangement [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Arrangements And Nonarrangement Transactions [Member] MSK agreement. MSK Agreements Memorial Sloan Kettering Cancer Center Agreement [Member] License Collaboration And Manufacturing Agreements [Line Items] License Collaboration And Manufacturing Agreements [Line Items] Potential milestone payments payable Potential Milestone Payments Payable Payments for research and development. Payments for research and development Payments For Research And Development Carrying amount as of the balance sheet date of obligations due all licensors. Contractual obligations due to MSK and QIMR Due To Licensors Current And Noncurrent Accrued termination charges. Accrued termination charges Accrued Termination Charges Liabilities related to indemnification agreements. Liabilities related to indemnification agreements Liabilities Related To Indemnification Agreements Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Underwritten public offering. Underwritten Public Offering Underwritten Public Offering [Member] Warrant Warrant [Member] Statistical Measurement Range [Axis] Statistical Measurement Range [Member] Maximum Maximum [Member] Minimum Minimum [Member] Counterparty Name Counterparty Name [Axis] Counterparty Name Repurchase Agreement Counterparty Name [Domain] Cowen and Company Limited Liability Company. Cowen Cowen And Company Limited Liability Company [Member] Two thousand nineteen at the market offering. 2019 ATM Facility Two Thousand Nineteen At The Market Offering [Member] Two thousand twenty at the market offering. 2020 ATM Facility Two Thousand Twenty At The Market Offering [Member] Award Type Award Type [Axis] Award Type Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Restricted Stock Units (RSUs) Employees and non-employees. Employees And Non Employees Employees And Non Employees [Member] Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation Deferred Compensation Arrangement With Individual Share Based Payments By Type Of Deferred Compensation [Axis] Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation Equity Based Arrangements Individual Contracts Type Of Deferred Compensation [Domain] Expire from date of grant. From Date Of Grant From Date Of Grant [Member] Title of Individual Title Of Individual [Axis] Title of Individual Title Of Individual With Relationship To Entity [Domain] Ten percent share holder. 10% Shareholder Ten Percent Share Holder [Member] Plan Name Plan Name [Axis] Plan Name Plan Name [Domain] Two thousand and fourteen equity incentive plan. 2014 Equity Incentive Plan Two Thousand And Fourteen Equity Incentive Plan [Member] Inducement plan. Inducement Plan Inducement Plan [Member] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Authorized capital stock Capital Units Authorized Preferred stock, par value Preferred Stock Par Or Stated Value Per Share Preferred stock, shares authorized Preferred Stock Shares Authorized Preferred stock, shares outstanding Preferred Stock Shares Outstanding Class of warrant or right, term. Maximum ownership percentage. Prior notice period to increase or decrease maximum ownership percentage. Number of securities called by each warrant Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right Warrants, exercise price Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 Warrants, term Class Of Warrant Or Right Term Maximum ownership Percentage Maximum Ownership Percentage Prior notice period Prior Notice Period To Increase Or Decrease Maximum Ownership Percentage Warrants outstanding Class Of Warrant Or Right Outstanding Aggregate Offering Price of common stock. Percentage of commission to be paid on gross sales proceeds of common stock sold. Common stock aggregate offering price Aggregate Offering Price Of Common Stock Percentage of commission to be paid on gross sales proceeds of common stock sold Percentage Of Commission To Be Paid On Gross Sales Proceeds Of Common Stock Sold Common stock value remained available to be sold. Common stock average price. Proceeds from issuance of common stock gross. Common stock, shares issued Stock Issued During Period Shares New Issues Common stock average price Common Stock Average Price Proceeds from sale of common stock, gross Proceeds From Issuance Of Common Stock Gross Proceeds from sale of common stock, net Common stock value remaining to be sold Common Stock Value Remained Available To Be Sold Shareholders ownership percent. Share based compensation arrangement by share based payment award equity instruments options and restricted stock units outstanding. Share based compensation, vesting period Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 Percentage of employees purchase price of common stock Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent Stock option granted description terms Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award Ownership percent Shareholder Ownership Percent Share based compensation award expiration period Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period Shares of common stock, reserved for issuance Common Stock Capital Shares Reserved For Future Issuance Aggregate number of awards available for grant to be issued Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Outstanding options and RSUs Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options And Restricted Stock Units Outstanding Shares, Unvested as of December 31, 2019 Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number Shares, Granted Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Shares, Forfeited Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period Shares, Vested Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Shares, Outstanding as of March 31, 2020 Weighted Average Grant Date Fair Value, Unvested as of December 31, 2019 Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value, Granted Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value, Forfeited Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value, Vested Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value, Outstanding as of March 31, 2020 Unrecognized stock-based compensation expense Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options Unrecognized stock-based compensation weighted average recognition period Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 Stock options, issued Stock Issued During Period Shares Share Based Compensation Gross 2014 EIP and Inducement Plan. 2014 EIP and Inducement Plan Two Thousand Fourteen Equity Incentive Plan And Inducement Plan [Member] Outstanding, Shares, beginning balance Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Granted, Shares Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Exercised, Shares Stock Issued During Period Shares Stock Options Exercised Forfeited or expired, Shares Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Outstanding, Shares, ending balance Outstanding, Weighted Average Exercise Price, beginning balance Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Granted, Weighted Average Exercise Price Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Exercised, Weighted Average Exercise Price Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price Forfeited or expired, Weighted Average Exercise price Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price Outstanding, Weighted Average Exercise Price, ending balance Outstanding, Weighted Average Remaining Contractual Term Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Aggregate intrinsic value Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Unrecognized stock-based compensation Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options Common Stock Including Additional Paid In Capital Net Of Discount [Abstract] Schedule Of Stock By Class [Table] Schedule Of Stock By Class [Table] Two thousand eighteen inducement plan. 2018 Inducement Plan Two Thousand Eighteen Inducement Plan [Member] Two thousand fourteen employee stock purchase plan. 2014 Employee Stock Purchase Plan Two Thousand Fourteen Employee Stock Purchase Plan [Member] Class Of Stock [Line Items] Class Of Stock [Line Items] Total reserved shares of common stock Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Income Statement Location Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Research and development Research And Development Expense [Member] General and administrative General And Administrative Expense [Member] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Total stock-based compensation expense Allocated Share Based Compensation Expense EX-101.PRE 9 atra-20200331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 R4.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Operating expenses:    
Research and development $ 57,659 $ 48,668
General and administrative 17,038 19,223
Total operating expenses 74,697 67,891
Loss from operations (74,697) (67,891)
Interest and other income, net 1,188 1,634
Net loss (73,509) (66,257)
Other comprehensive (loss) gain:    
Unrealized (loss) gain on available-for-sale securities (16) 378
Comprehensive loss $ (73,525) $ (65,879)
Net loss per common share:    
Basic and diluted net loss per common share $ (1.20) $ (1.44)
Weighted-average shares outstanding used to calculate basic and diluted net loss per common share 61,208 46,124
XML 11 R8.htm IDEA: XBRL DOCUMENT v3.20.1
Description of Business
3 Months Ended
Mar. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
Description of Business

1.

Description of Business

Atara Biotherapeutics, Inc. (“Atara”, “we”, “our” or “the Company”) was incorporated in August 2012 in Delaware. Atara is a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases, including solid tumors, hematologic cancers and autoimmune disease.

We have several T-cell immunotherapies in clinical development and are progressing multiple next-generation allogeneic chimeric antigen receptor T-cell (“CAR T”) programs.

We have licensed rights to T-cell product candidates from Memorial Sloan Kettering Cancer Center (“MSK”), rights related to our next-generation CAR T programs from MSK and from Moffitt Cancer Center, and rights to know-how and technology from the Council of the Queensland Institute of Medical Research (“QIMR Berghofer”). See Note 6 for further information.

 

XML 12 R30.htm IDEA: XBRL DOCUMENT v3.20.1
License and Collaboration Agreements - Additional Information (Detail) - USD ($)
3 Months Ended
Mar. 31, 2019
Mar. 31, 2020
Dec. 31, 2019
License Collaboration And Manufacturing Agreements [Line Items]      
Contractual obligations due to MSK and QIMR   $ 0 $ 0
MSK Agreements      
License Collaboration And Manufacturing Agreements [Line Items]      
Potential milestone payments payable   $ 33,000,000.0  
Payments for research and development $ 12,500,000    
XML 13 R34.htm IDEA: XBRL DOCUMENT v3.20.1
Stockholders' Equity - Summary of Stock Option Activity (Detail) - 2014 EIP and Inducement Plan
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2020
USD ($)
$ / shares
shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Outstanding, Shares, beginning balance | shares 6,934,262
Granted, Shares | shares 1,489,925
Exercised, Shares | shares (93,719)
Forfeited or expired, Shares | shares (233,997)
Outstanding, Shares, ending balance | shares 8,096,471
Outstanding, Weighted Average Exercise Price, beginning balance | $ / shares $ 28.25
Granted, Weighted Average Exercise Price | $ / shares 12.91
Exercised, Weighted Average Exercise Price | $ / shares 14.19
Forfeited or expired, Weighted Average Exercise price | $ / shares 32.28
Outstanding, Weighted Average Exercise Price, ending balance | $ / shares $ 25.47
Outstanding, Weighted Average Remaining Contractual Term 6 years 6 months
Aggregate intrinsic value | $ $ 0
XML 14 R17.htm IDEA: XBRL DOCUMENT v3.20.1
Net Loss per Common Share (Tables)
3 Months Ended
Mar. 31, 2020
Earnings Per Share [Abstract]  
Antidilutive Securities Excluded From Computation of Diluted Net Loss per Common Share

The following table represents the potential common shares issuable pursuant to outstanding securities as of the related period end dates that were excluded from the computation of diluted net loss per common share, as their inclusion would have an antidilutive effect:

 

 

As of March 31,

 

 

2020

 

 

2019

 

Unvested RSUs

 

3,630,713

 

 

 

1,860,374

 

Vested and unvested options

 

8,096,471

 

 

 

6,842,443

 

ESPP share purchase rights

 

178,397

 

 

 

37,538

 

Total

 

11,905,581

 

 

 

8,740,355

 

 

XML 15 R13.htm IDEA: XBRL DOCUMENT v3.20.1
License and Collaboration Agreements
3 Months Ended
Mar. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
License and Collaboration Agreements

6.

License and Collaboration Agreements

MSK Agreements – In June 2015, we entered into an exclusive license agreement with MSK for three clinical stage T-cell therapies. We are required to make additional payments of up to $33.0 million to MSK based on achievement of specified regulatory and sales-related milestones, as well as mid-single-digit percentage tiered royalty payments based on future sales of products resulting from the development of the licensed product candidates, if any. In addition, under certain circumstances, we are required to make certain minimum annual royalty payments to MSK, which are creditable against earned royalties owed for the same annual period. We are also required to pay a low double-digit percentage of any consideration we receive for sublicensing the licensed rights. The license agreement expires on a product-by-product and country-by-country basis on the later of: (i) expiration of the last licensed patent rights related to each licensed product, (ii) expiration of any market exclusivity period granted by law with respect to each licensed product, and (iii) a specified number of years after the first commercial sale of the licensed product in each country. Upon expiration of the license agreement, Atara will retain non-exclusive rights to the licensed products.

In May 2018 and December 2018, we licensed additional technology from MSK. In connection with the effectiveness of the December 2018 license agreement, we made upfront cash payments of $12.5 million in the first quarter of 2019, which were recorded as research and development expense in our consolidated statement of operations and comprehensive loss in the fourth quarter of 2018. We are obligated to make additional milestone payments based on achievement of specified development, regulatory and sales-related milestones, as well as mid-single-digit percentage tiered royalty payments based on future sales of products resulting from the development of the licensed product candidates, if any.

QIMR Berghofer Agreements – In October 2015, we entered into an exclusive license agreement and a research and development collaboration agreement with QIMR Berghofer. Under the terms of the license agreement, we obtained an exclusive, worldwide license to develop and commercialize allogeneic T-cell therapy programs utilizing technology and know-how developed by QIMR Berghofer. In September 2016, the exclusive license agreement and research and development collaboration agreement were amended and restated. Under the amended and restated agreements, we obtained an exclusive, worldwide license to develop and commercialize additional T-cell programs, as well as the option to license additional technology. We exercised this option in June 2018. We further amended and restated our license agreement and research and development collaboration agreements with QIMR Berghofer in August 2019 to eliminate our license to certain rights related to cytomegalovirus. Our current license agreement also provides for various milestone and royalty payments to QIMR Berghofer based on future product sales, if any. Under the terms of our current research and development collaboration agreement, we are also required to reimburse the cost of agreed-upon development activities related to programs developed under the collaboration. These payments are expensed on a straight-line basis over the related development periods. The agreement also provides for various milestone payments to QIMR Berghofer based on achievement of certain developmental and regulatory milestones.

From time to time, we have entered into other license and collaboration agreements with other parties. For example, we licensed additional rights related to our MSK-partnered next-generation CAR T programs from MSK in May 2018 and we licensed rights related to our next-generation CAR T programs from Moffitt Cancer Center in August 2018, and we agreed to collaborate through sponsored research in connection with each of these licenses. We also licensed rights related to our MSK-partnered next generation CAR T programs from the National Institutes of Health in December 2018.

Milestones and royalties under each of the above agreements are contingent upon future events and will be recorded as expense when it is probable that the milestones will be achieved or royalties are due. As of March 31, 2020 and December 31, 2019, there were no outstanding obligations for milestones and royalties under our license and collaboration agreements.

Cognate Agreement - In December 2019, we entered into a Commercial Manufacturing Services Agreement (the “Manufacturing Agreement”) with Cognate BioServices, Inc. (“Cognate”) to supersede the Development and Manufacturing Agreement that was entered into with Cognate in August 2015 and amended in December 2017, May 2018, November 2018, June 2019 and November 2019. Pursuant to the Manufacturing Agreement, Cognate provides manufacturing services for certain of our product candidates. The initial term of the Manufacturing Agreement is from January 1, 2020 until December 31, 2021 and is renewable with Cognate’s approval for an additional one-year period. We may terminate the Manufacturing Agreement for convenience on six months’ written notice to Cognate, or immediately if Cognate is unable to perform the services under the Manufacturing Agreement or fails to obtain or maintain certain necessary approvals. The Manufacturing Agreement includes standard mutual termination rights for uncured breach or insolvency, or a force majeure event preventing the performance of services for at least ninety days.

EXCEL 16 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 17 R25.htm IDEA: XBRL DOCUMENT v3.20.1
Financial Instruments - Amortized Cost and Fair Value of Available-for-Sale Securities by Contractual Maturity (Detail) - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Amortized cost    
Maturing within one year, Amortized cost $ 174,851 $ 214,085
Maturing in one to five years, Amortized cost 38,071 42,993
Total available-for-sale securities, Amortized cost 212,922 257,078
Estimated Fair value    
Maturing within one year, Estimated fair value 174,853 214,199
Maturing in one to five years, Estimated fair value 38,274 43,100
Total available-for-sale securities, Estimated fair value $ 213,127 $ 257,299
XML 18 R21.htm IDEA: XBRL DOCUMENT v3.20.1
Description of Business (Detail)
3 Months Ended
Mar. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
Entity incorporation state DE
Entity incorporation date Aug. 01, 2012
XML 19 R29.htm IDEA: XBRL DOCUMENT v3.20.1
Property and Equipment - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Property Plant And Equipment Net By Type [Abstract]    
Depreciation and amortization expense $ 1,949 $ 1,648
XML 20 atra-10q_20200331_htm.xml IDEA: XBRL DOCUMENT 0001604464 2020-01-01 2020-03-31 0001604464 2020-04-30 0001604464 2020-03-31 0001604464 2019-12-31 0001604464 2019-01-01 2019-03-31 0001604464 us-gaap:CommonStockMember 2019-12-31 0001604464 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001604464 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001604464 us-gaap:RetainedEarningsMember 2019-12-31 0001604464 us-gaap:CommonStockMember atra:AtTheMarketOfferingMember 2020-01-01 2020-03-31 0001604464 us-gaap:AdditionalPaidInCapitalMember atra:AtTheMarketOfferingMember 2020-01-01 2020-03-31 0001604464 atra:AtTheMarketOfferingMember 2020-01-01 2020-03-31 0001604464 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001604464 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001604464 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001604464 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001604464 us-gaap:CommonStockMember 2020-03-31 0001604464 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001604464 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001604464 us-gaap:RetainedEarningsMember 2020-03-31 0001604464 us-gaap:CommonStockMember 2018-12-31 0001604464 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001604464 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001604464 us-gaap:RetainedEarningsMember 2018-12-31 0001604464 2018-12-31 0001604464 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001604464 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001604464 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001604464 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001604464 us-gaap:CommonStockMember 2019-03-31 0001604464 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001604464 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001604464 us-gaap:RetainedEarningsMember 2019-03-31 0001604464 2019-03-31 0001604464 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-03-31 0001604464 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-03-31 0001604464 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001604464 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-03-31 0001604464 atra:EmployeeStockPurchasePlanMember 2020-01-01 2020-03-31 0001604464 atra:EmployeeStockPurchasePlanMember 2019-01-01 2019-03-31 0001604464 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2020-03-31 0001604464 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2020-03-31 0001604464 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember 2020-03-31 0001604464 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-03-31 0001604464 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-03-31 0001604464 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2020-03-31 0001604464 us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001604464 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2020-03-31 0001604464 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-12-31 0001604464 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-12-31 0001604464 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember 2019-12-31 0001604464 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001604464 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0001604464 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-12-31 0001604464 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2019-12-31 0001604464 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001604464 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2019-12-31 0001604464 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashEquivalentsMember 2020-03-31 0001604464 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashEquivalentsMember 2019-12-31 0001604464 2019-01-01 2019-12-31 0001604464 us-gaap:LeaseholdImprovementsMember 2020-03-31 0001604464 us-gaap:LeaseholdImprovementsMember 2019-12-31 0001604464 us-gaap:EquipmentMember 2020-03-31 0001604464 us-gaap:EquipmentMember 2019-12-31 0001604464 us-gaap:MachineryAndEquipmentMember 2020-03-31 0001604464 us-gaap:MachineryAndEquipmentMember 2019-12-31 0001604464 atra:ComputerEquipmentAndSoftwareMember 2020-03-31 0001604464 atra:ComputerEquipmentAndSoftwareMember 2019-12-31 0001604464 us-gaap:FurnitureAndFixturesMember 2020-03-31 0001604464 us-gaap:FurnitureAndFixturesMember 2019-12-31 0001604464 us-gaap:ConstructionInProgressMember 2020-03-31 0001604464 us-gaap:ConstructionInProgressMember 2019-12-31 0001604464 atra:MemorialSloanKetteringCancerCenterAgreementMember 2020-03-31 0001604464 atra:MemorialSloanKetteringCancerCenterAgreementMember 2019-01-01 2019-03-31 0001604464 us-gaap:WarrantMember atra:UnderwrittenPublicOfferingMember 2019-07-18 0001604464 us-gaap:WarrantMember atra:UnderwrittenPublicOfferingMember 2019-07-18 2019-07-18 0001604464 srt:MaximumMember us-gaap:WarrantMember atra:UnderwrittenPublicOfferingMember 2019-07-18 2019-07-18 0001604464 srt:MinimumMember us-gaap:WarrantMember atra:UnderwrittenPublicOfferingMember 2019-07-18 2019-07-18 0001604464 atra:UnderwrittenPublicOfferingMember 2020-03-31 0001604464 atra:CowenAndCompanyLimitedLiabilityCompanyMember srt:MaximumMember atra:AtTheMarketOfferingMember 2019-02-25 0001604464 atra:CowenAndCompanyLimitedLiabilityCompanyMember srt:MaximumMember atra:AtTheMarketOfferingMember 2020-02-28 0001604464 atra:CowenAndCompanyLimitedLiabilityCompanyMember srt:MaximumMember atra:AtTheMarketOfferingMember 2019-02-25 2019-02-25 0001604464 atra:CowenAndCompanyLimitedLiabilityCompanyMember srt:MaximumMember atra:AtTheMarketOfferingMember 2020-02-28 2020-02-28 0001604464 atra:CowenAndCompanyLimitedLiabilityCompanyMember atra:AtTheMarketOfferingMember 2020-01-01 2020-03-31 0001604464 atra:CowenAndCompanyLimitedLiabilityCompanyMember atra:AtTheMarketOfferingMember 2020-01-03 2020-01-03 0001604464 atra:CowenAndCompanyLimitedLiabilityCompanyMember atra:TwoThousandNineteenAtTheMarketOfferingMember 2020-03-31 0001604464 atra:CowenAndCompanyLimitedLiabilityCompanyMember atra:TwoThousandTwentyAtTheMarketOfferingMember 2020-03-31 0001604464 us-gaap:RestrictedStockUnitsRSUMember atra:FromDateOfGrantMember 2020-01-01 2020-03-31 0001604464 srt:MinimumMember 2020-01-01 2020-03-31 0001604464 srt:MinimumMember atra:TenPercentShareHolderMember 2020-01-01 2020-03-31 0001604464 atra:EmployeesAndNonEmployeesMember 2020-01-01 2020-03-31 0001604464 srt:MinimumMember atra:EmployeesAndNonEmployeesMember 2020-01-01 2020-03-31 0001604464 srt:MaximumMember atra:EmployeesAndNonEmployeesMember 2020-01-01 2020-03-31 0001604464 atra:TwoThousandAndFourteenEquityIncentivePlanMember 2020-03-31 0001604464 atra:InducementPlanMember 2020-03-31 0001604464 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0001604464 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-03-31 0001604464 us-gaap:RestrictedStockUnitsRSUMember 2020-03-31 0001604464 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0001604464 atra:TwoThousandFourteenEquityIncentivePlanAndInducementPlanMember 2019-12-31 0001604464 atra:TwoThousandFourteenEquityIncentivePlanAndInducementPlanMember 2020-01-01 2020-03-31 0001604464 atra:TwoThousandFourteenEquityIncentivePlanAndInducementPlanMember 2020-03-31 0001604464 us-gaap:EmployeeStockOptionMember 2020-03-31 0001604464 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001604464 atra:TwoThousandEighteenInducementPlanMember 2020-03-31 0001604464 atra:TwoThousandFourteenEmployeeStockPurchasePlanMember 2020-03-31 0001604464 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001604464 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-03-31 0001604464 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-03-31 0001604464 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-03-31 shares iso4217:USD iso4217:USD shares pure false Q1 0001604464 --12-31 Large Accelerated Filer 2012-08-01 P6Y6M 10-Q true 2020-03-31 2020 false 001-36548 ATARA BIOTHERAPEUTICS, INC. DE 46-0920988 611 Gateway Blvd. Suite 900 South San Francisco CA 94080 650 278-8930 Common Stock, par value $0.0001 per share ATRA NASDAQ Yes Yes false false false 58952045 70203000 74317000 144428000 184792000 194000 194000 14392000 13689000 229217000 272992000 54442000 54176000 13691000 14007000 1200000 1200000 997000 567000 299547000 342942000 8079000 7963000 9676000 14706000 7827000 8341000 5938000 5733000 31520000 36743000 13809000 14136000 1396000 1282000 46725000 52161000 0.0001 0.0001 500000000 500000000 58940000 58940000 56806000 56806000 6000 6000 1144082000 1108516000 204000 220000 -891470000 -817961000 252822000 290781000 299547000 342942000 57659000 48668000 17038000 19223000 74697000 67891000 -74697000 -67891000 1188000 1634000 -73509000 -66257000 -16000 378000 -73525000 -65879000 -1.20 -1.44 61208000 46124000 56806000 6000 1108516000 220000 -817961000 290781000 704000 1528000 22987000 22987000 57000 455000 1395000 1395000 94000 1330000 1330000 12644000 12644000 -73509000 -73509000 -16000 -16000 58940000 6000 1144082000 204000 -891470000 252822000 45951000 5000 866541000 -340000 -527349000 338857000 364000 364000 45951000 5000 866541000 -340000 -526985000 339221000 197000 4575000 4575000 159000 2898000 2898000 12269000 12269000 -66257000 -66257000 378000 378000 46307000 5000 877133000 38000 -593242000 283934000 -73509000 -66257000 12644000 12269000 1949000 1648000 -42000 458000 364000 331000 19000 17000 1888000 1434000 209000 -38000 -590000 2672000 -5030000 -3177000 -514000 -13016000 -169000 -2572000 -153000 -261000 -67044000 -70200000 56851000 7427000 97157000 75819000 1333000 796000 38973000 67596000 24277000 0 1330000 2747000 1395000 4575000 90000 98000 -165000 0 23957000 -1926000 -4114000 -4530000 75711000 62092000 71597000 57562000 1098000 666000 281000 0 112000 0 0 151000 17000 0 0 0 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Description of Business<span style="font-weight:normal;"> </span></p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Atara Biotherapeutics, Inc. (“Atara”, “we”, “our” or “the Company”) was incorporated in August 2012 in Delaware. <span style="Background-color:#FFFFFF;color:#000000;">Atara is a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to </span>develop transformative therapies for patients with severe diseases, including solid tumors, hematologic <span style="Background-color:#FFFFFF;color:#000000;">cancers and autoimmune disease.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We have several T-cell immunotherapies in clinical development and are progressing multiple next-generation allogeneic chimeric antigen receptor T-cell (“CAR T”) programs. </span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have licensed rights to T-cell product candidates from Memorial Sloan Kettering Cancer Center (“MSK”), rights related to our next-generation CAR T programs from MSK and from Moffitt Cancer Center, and rights to know-how and technology from the <span style="Background-color:#FFFFFF;color:#000000;">Council of the Queensland Institute of Medical Research</span> (“QIMR Berghofer”). See Note 6 for further information.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> DE <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Summary of Significant Accounting Policies </p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Basis of Presentation</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited condensed consolidated financial statements include the accounts of Atara and its wholly-owned subsidiaries and have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These condensed consolidated financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, except for the adoption of <span style="color:#000000;">accounting pronouncements relating to credit losses on financial instruments, implementation of cloud computing arrangements, and simplification of income tax accounting, effective January 1, 2020, as discussed below.</span> In the opinion of management, the condensed consolidated financial statements reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair presentation of the Company’s consolidated financial statements. The results of operations for any interim period are not necessarily indicative of the results to be expected for the full year or any other future period. The condensed consolidated balance sheet as of December 31, 2019 has been derived from audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete consolidated financial statements.</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Going Concern </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with Accounting Standards Codification (“ASC”) 205-40, Going Concern, we have evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern for one year from the date the accompanying financial statements are issued. We have incurred significant operating losses since inception and have relied on public and private equity financings to fund our operations. As of March 31, 2020, we had an accumulated deficit of $891.5 million.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we continue to incur losses, our transition to profitability will depend on the successful development, approval and commercialization of product candidates and on the achievement of sufficient revenues to support our cost structure. We may never achieve profitability, and unless and until we do, we will need to continue to raise additional capital. We expect that our cash, cash equivalents and short-term investments as of March 31, 2020 will be sufficient to fund our planned operations into the second quarter of 2021. However, the uncertainties inherent in the Company’s future operations and in our ability to obtain additional funding raise substantial doubt about our ability to continue as a going concern beyond one year from the date these financial statements are issued. The interim condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. We currently plan to raise additional funding as required, based on the status of our development programs and our projected cash flows. We may also need to pursue the sale or sublicense of rights to the Company’s programs and assets on terms potentially unfavorable to us. If we are unable to obtain additional funding, we will be forced to delay, limit, reduce or terminate preclinical studies, clinical studies or other development activities for one or more of our product candidates.</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions, and judgments that affect the amounts reported in the financial statements and accompanying notes. Significant estimates relied upon in preparing these financial statements include estimates related to clinical trial and other accruals, stock-based compensation expense and income taxes. Actual results could differ materially from those estimates. </p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers the applicability and impact of any Accounting Standards Update (“ASU”) issued by the Financial Accounting Standards Board (“FASB”). Other than the ASUs we adopted effective January 1, 2020 and listed below, all other ASUs were assessed and determined to be either not applicable or are expected to have minimal impact on our consolidated financial statements.</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adoption of New Accounting Pronouncements</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We adopted ASU No. 2016-13 (as amended by ASUs 2018-19, 2019-04, 2019-05 and 2019-11), <span style="font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span>, prospectively on January 1, 2020. Under this new guidance, a company is required to estimate credit losses on certain types of financial instruments using an expected-loss model, replacing the current incurred-loss model, and record the estimate through an allowance for credit losses. We do not hold material amounts of the types of financial instruments impacted by this guidance on our balance sheet. The guidance also establishes a new impairment model for available-for-sale debt securities. The adoption did not have a material impact on our condensed consolidated balance sheet or our condensed consolidated statements of operations and comprehensive loss, changes in stockholders’ equity, and cash flows for the three months ended March 31, 2020 and 2019.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We adopted ASU No. 2018-15, <span style="font-style:italic;">Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span>, effective January 1, 2020, electing a prospective adoption method. The new standard requires that certain implementation costs for cloud computing arrangements are capitalized and amortized over the term of associated hosted cloud computing arrangement service. Capitalized implementation costs are classified in the same line on the balance sheet as amounts prepaid for hosted cloud computing arrangement service, or prepaid expenses and other assets. The amortization of the capitalized asset is presented in the same line on the statement of operations and comprehensive loss as the fees for the associated hosted cloud computing arrangement service and not included with depreciation or amortization expense related to property and equipment or intangible assets. Cash flows related to capitalized implementation costs are presented consistent with the presentation of cash flows for fees related to the hosted cloud computing arrangement service, or cash flows used in operating activities. The adoption did not have a material impact on our condensed consolidated balance sheet or our condensed consolidated statements of operations and comprehensive loss, changes in stockholders’ equity, and cash flows for the three months ended March 31, 2020 and 2019.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We adopted ASU No. 2019-12, <span style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span>, as of January 1, 2020, which eliminates certain exceptions related to the general principles in ASC 740 and makes amendments to other areas with the intention of simplifying various aspects related to accounting for income taxes. The provisions of the ASU that are applicable to Atara are applied on a prospective basis. The adoption did not have a material impact on our condensed consolidated balance sheet or our condensed consolidated statements of operations and comprehensive loss, changes in stockholders’ equity, and cash flows for the three months ended March 31, 2020 and 2019.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Basis of Presentation</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited condensed consolidated financial statements include the accounts of Atara and its wholly-owned subsidiaries and have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These condensed consolidated financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, except for the adoption of <span style="color:#000000;">accounting pronouncements relating to credit losses on financial instruments, implementation of cloud computing arrangements, and simplification of income tax accounting, effective January 1, 2020, as discussed below.</span> In the opinion of management, the condensed consolidated financial statements reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair presentation of the Company’s consolidated financial statements. The results of operations for any interim period are not necessarily indicative of the results to be expected for the full year or any other future period. The condensed consolidated balance sheet as of December 31, 2019 has been derived from audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete consolidated financial statements.</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Going Concern </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with Accounting Standards Codification (“ASC”) 205-40, Going Concern, we have evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern for one year from the date the accompanying financial statements are issued. We have incurred significant operating losses since inception and have relied on public and private equity financings to fund our operations. As of March 31, 2020, we had an accumulated deficit of $891.5 million.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we continue to incur losses, our transition to profitability will depend on the successful development, approval and commercialization of product candidates and on the achievement of sufficient revenues to support our cost structure. We may never achieve profitability, and unless and until we do, we will need to continue to raise additional capital. We expect that our cash, cash equivalents and short-term investments as of March 31, 2020 will be sufficient to fund our planned operations into the second quarter of 2021. However, the uncertainties inherent in the Company’s future operations and in our ability to obtain additional funding raise substantial doubt about our ability to continue as a going concern beyond one year from the date these financial statements are issued. The interim condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. We currently plan to raise additional funding as required, based on the status of our development programs and our projected cash flows. We may also need to pursue the sale or sublicense of rights to the Company’s programs and assets on terms potentially unfavorable to us. If we are unable to obtain additional funding, we will be forced to delay, limit, reduce or terminate preclinical studies, clinical studies or other development activities for one or more of our product candidates.</p> -891500000 <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions, and judgments that affect the amounts reported in the financial statements and accompanying notes. Significant estimates relied upon in preparing these financial statements include estimates related to clinical trial and other accruals, stock-based compensation expense and income taxes. Actual results could differ materially from those estimates. </p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers the applicability and impact of any Accounting Standards Update (“ASU”) issued by the Financial Accounting Standards Board (“FASB”). Other than the ASUs we adopted effective January 1, 2020 and listed below, all other ASUs were assessed and determined to be either not applicable or are expected to have minimal impact on our consolidated financial statements.</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adoption of New Accounting Pronouncements</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We adopted ASU No. 2016-13 (as amended by ASUs 2018-19, 2019-04, 2019-05 and 2019-11), <span style="font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span>, prospectively on January 1, 2020. Under this new guidance, a company is required to estimate credit losses on certain types of financial instruments using an expected-loss model, replacing the current incurred-loss model, and record the estimate through an allowance for credit losses. We do not hold material amounts of the types of financial instruments impacted by this guidance on our balance sheet. The guidance also establishes a new impairment model for available-for-sale debt securities. The adoption did not have a material impact on our condensed consolidated balance sheet or our condensed consolidated statements of operations and comprehensive loss, changes in stockholders’ equity, and cash flows for the three months ended March 31, 2020 and 2019.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We adopted ASU No. 2018-15, <span style="font-style:italic;">Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span>, effective January 1, 2020, electing a prospective adoption method. The new standard requires that certain implementation costs for cloud computing arrangements are capitalized and amortized over the term of associated hosted cloud computing arrangement service. Capitalized implementation costs are classified in the same line on the balance sheet as amounts prepaid for hosted cloud computing arrangement service, or prepaid expenses and other assets. The amortization of the capitalized asset is presented in the same line on the statement of operations and comprehensive loss as the fees for the associated hosted cloud computing arrangement service and not included with depreciation or amortization expense related to property and equipment or intangible assets. Cash flows related to capitalized implementation costs are presented consistent with the presentation of cash flows for fees related to the hosted cloud computing arrangement service, or cash flows used in operating activities. The adoption did not have a material impact on our condensed consolidated balance sheet or our condensed consolidated statements of operations and comprehensive loss, changes in stockholders’ equity, and cash flows for the three months ended March 31, 2020 and 2019.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We adopted ASU No. 2019-12, <span style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span>, as of January 1, 2020, which eliminates certain exceptions related to the general principles in ASC 740 and makes amendments to other areas with the intention of simplifying various aspects related to accounting for income taxes. The provisions of the ASU that are applicable to Atara are applied on a prospective basis. The adoption did not have a material impact on our condensed consolidated balance sheet or our condensed consolidated statements of operations and comprehensive loss, changes in stockholders’ equity, and cash flows for the three months ended March 31, 2020 and 2019.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"/>Net Loss per Common Share</p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock and pre-funded warrants outstanding during the period, without consideration of common share equivalents. Diluted net loss per common share is computed by dividing net loss by the weighted-average number of shares of common stock, pre-funded warrants and common share equivalents outstanding for the period. The pre-funded warrants are included in the computation of basic and diluted net loss per common share as the exercise price is negligible and the pre-funded warrants are fully vested and exercisable. Common share equivalents are only included in the calculation of diluted net loss per common share when their effect is dilutive.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Potential dilutive securities, which include unvested restricted stock units (“RSUs”), unvested performance-based RSUs for which established performance criteria have been achieved as of the end of the respective periods, vested and unvested options to purchase common stock and shares to be issued under our employee stock purchase plan (“ESPP”), have been excluded from the computation of diluted net loss per share as the effect is antidilutive. Therefore, the denominator used to calculate both basic and diluted net loss per common share is the same in all periods presented.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table represents the potential common shares issuable pursuant to outstanding securities as of the related period end dates that were excluded from the computation of diluted net loss per common share, as their inclusion would have an antidilutive effect:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.9%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of March 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.9%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.9%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested RSUs</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,630,713</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,860,374</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.9%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and unvested options</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,096,471</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,842,443</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.9%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ESPP share purchase rights</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">178,397</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,538</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.9%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,905,581</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,740,355</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"> </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table represents the potential common shares issuable pursuant to outstanding securities as of the related period end dates that were excluded from the computation of diluted net loss per common share, as their inclusion would have an antidilutive effect:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.9%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of March 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.9%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.9%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested RSUs</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,630,713</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,860,374</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.9%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and unvested options</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,096,471</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,842,443</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.9%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ESPP share purchase rights</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">178,397</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,538</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.9%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,905,581</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,740,355</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"> </p> 3630713 1860374 8096471 6842443 178397 37538 11905581 8740355 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4.</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"/>Financial Instruments</p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our financial assets are measured at fair value <span style="color:#000000;">on a recurring basis using the following hierarchy to prioritize valuation inputs,</span> in accordance with applicable U.S. GAAP: </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1:</span></p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Quoted prices in active markets for identical assets or liabilities that we have the ability to access</p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2:</span></p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Observable market-based inputs or unobservable inputs that are corroborated by market data such as quoted prices, interest rates and yield curves</p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3:</span></p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Inputs that are unobservable data points that are not corroborated by market data</p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We review the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels of certain securities within the fair value hierarchy. We recognize transfers into and out of levels within the fair value hierarchy in the period in which the actual event or change in circumstances that caused the transfer occurs. There have been no transfers between Level 1, Level 2 and Level 3 in any periods presented.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets and liabilities are considered Level 2 when their fair values are determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis. U.S. Treasury, government agency and corporate debt obligations, commercial paper and asset-backed securities are valued primarily using market prices of comparable securities, bid/ask quotes, interest rate yields and prepayment spreads and are included in Level 2.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets and liabilities are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies, or similar techniques, and at least one significant model assumption or input is unobservable. We have no Level 3 financial assets or liabilities. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables summarize the estimated fair value and related valuation input hierarchy of our available-for-sale securities as of each period end:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2020:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Input Level</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gain</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.9%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,382</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,382</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury obligations</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,993</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">318</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,311</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government agency obligations</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,686</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,693</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt obligations</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,121</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(210</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,003</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,471</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,471</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.68%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Asset-backed securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,269</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,267</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total available-for-sale securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">212,922</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">421</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(216</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">213,127</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.68%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: amounts classified as cash equivalents</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(68,689</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(68,699</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.68%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts classified as short-term investments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144,233</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">411</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(216</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144,428</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Input Level</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gain</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.9%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,554</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,554</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury obligations</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,805</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,850</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government agency obligations</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,151</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,151</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt obligations</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,512</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,682</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,290</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,290</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Asset-backed securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,266</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,272</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.68%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certificates of deposit</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">500</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">500</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total available-for-sale securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">257,078</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">233</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">257,299</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.68%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: amounts classified as cash equivalents</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(72,507</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(72,507</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.68%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts classified as short-term investments</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">184,571</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">233</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">184,792</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amortized cost and fair value of our available-for-sale securities by contractual maturity were as follows: </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.78%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman Bold;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.28%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.28%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.78%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturing within one year</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">174,851</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">174,853</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214,085</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214,199</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.78%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturing in one to five years</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,071</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,274</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,993</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,100</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.78%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total available-for-sale securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">212,922</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">213,127</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">257,078</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">257,299</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2020, no significant facts or circumstances were present to indicate a deterioration in the creditworthiness of the issuers of the available-for-sale securities we hold, and the Company has no requirement or intention to sell these securities before maturity or recovery of their amortized cost basis. We considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic and determined that our investments were not significantly impacted. For all securities with a fair value less than its amortized cost basis, we determined the decline in fair value below amortized cost basis to be immaterial and non-credit related, and therefore no allowance for losses has been recorded. <span style="color:#000000;">During </span>the three months ended March 31, 2020 and 2019<span style="color:#000000;">, we did not recognize any impairment losses on our investments. </span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have elected the practical expedient to exclude the applicable accrued interest from both the fair value and the amortized cost basis of our available-for-sale securities for purposes of identifying and measuring an impairment. We present accrued interest receivable related to our available-for-sale securities in prepaid expenses and other current assets, separate from short-term investments on our condensed consolidated balance sheet. As of March 31, 2020 and December 31, 2019, accrued interest receivable was $0.8 million and $0.9 million, respectively. Our accounting policy is to not measure an allowance for credit losses for accrued interest receivables and to write-off any uncollectible accrued interest receivable as a reversal of interest income in a timely manner, which we consider to be in the period in which we determine the accrued interest will not be collected by us. We have not written off any accrued interest receivables for the three months ended March 31, 2020 and 2019.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, restricted cash collateralized by money market funds is a financial asset measured at fair value and is a Level 1 financial instrument under the fair value hierarchy. As of March 31, 2020 and December 31, 2019, restricted cash was $1.4 million. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a reconciliation of cash, cash equivalents and restricted cash within the condensed consolidated balance sheets that sum to the total of the same such amounts in the condensed consolidated statement of cash flows:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,203</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,317</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash - short term</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">194</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">194</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash - long term</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,200</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,200</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents and restricted cash</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,597</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,711</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"> </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables summarize the estimated fair value and related valuation input hierarchy of our available-for-sale securities as of each period end:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2020:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Input Level</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gain</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.9%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,382</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,382</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury obligations</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,993</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">318</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,311</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government agency obligations</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,686</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,693</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt obligations</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,121</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(210</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,003</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,471</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,471</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.68%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Asset-backed securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,269</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,267</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total available-for-sale securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">212,922</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">421</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(216</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">213,127</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.68%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: amounts classified as cash equivalents</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(68,689</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(68,699</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.68%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts classified as short-term investments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144,233</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">411</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(216</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144,428</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Input Level</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gain</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.9%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,554</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,554</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury obligations</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,805</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,850</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government agency obligations</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,151</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,151</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt obligations</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,512</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,682</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,290</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,290</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Asset-backed securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,266</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,272</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.68%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certificates of deposit</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">500</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">500</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.68%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total available-for-sale securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">257,078</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">233</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">257,299</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.68%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: amounts classified as cash equivalents</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(72,507</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(72,507</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.68%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts classified as short-term investments</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">184,571</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">233</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">184,792</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 42382000 0 0 42382000 58993000 318000 0 59311000 6686000 9000 2000 6693000 85121000 92000 210000 85003000 14471000 0 0 14471000 5269000 2000 4000 5267000 212922000 421000 216000 213127000 68689000 10000 0 68699000 144233000 411000 216000 144428000 63554000 0 0 63554000 52805000 46000 1000 52850000 6151000 1000 1000 6151000 100512000 180000 10000 100682000 26290000 0 0 26290000 7266000 6000 7272000 500000 0 0 500000 257078000 233000 12000 257299000 72507000 0 0 72507000 184571000 233000 12000 184792000 <p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amortized cost and fair value of our available-for-sale securities by contractual maturity were as follows: </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.78%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman Bold;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.28%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.28%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.78%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.78%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturing within one year</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">174,851</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">174,853</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214,085</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214,199</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.78%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturing in one to five years</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,071</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,274</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,993</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,100</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.78%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total available-for-sale securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">212,922</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">213,127</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">257,078</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">257,299</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 174851000 174853000 214085000 214199000 38071000 38274000 42993000 43100000 212922000 213127000 257078000 257299000 800000 900000 0 0 1400000 1400000 <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a reconciliation of cash, cash equivalents and restricted cash within the condensed consolidated balance sheets that sum to the total of the same such amounts in the condensed consolidated statement of cash flows:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,203</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,317</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash - short term</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">194</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">194</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash - long term</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,200</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,200</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents and restricted cash</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,597</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,711</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 70203000 74317000 194000 194000 1200000 1200000 71597000 75711000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Property and Equipment </p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consisted of the following as of each period end:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,703</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,028</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,060</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,815</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Machinery and equipment</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,074</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,832</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment and software</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,797</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,299</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,764</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,356</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,116</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, gross</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,009</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,854</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation and amortization</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,567</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,678</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,442</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,176</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization expense was $1.9 million and $1.6 million for the three months ended March 31, 2020 and 2019. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consisted of the following as of each period end:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,703</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,028</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,060</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,815</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Machinery and equipment</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,074</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,832</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment and software</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,797</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,299</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,764</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,356</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,116</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, gross</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,009</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,854</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation and amortization</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,567</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,678</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,442</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,176</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 49703000 49028000 7060000 6815000 4074000 3832000 3797000 3299000 2019000 1764000 1356000 1116000 68009000 65854000 13567000 11678000 54442000 54176000 1900000 1600000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6.</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">License and Collaboration Agreements </p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MSK Agreements – <span style="font-weight:normal;">In June 2015, we entered into an exclusive license agreement with MSK for three clinical stage T-cell therapies.</span><span style="color:#000000;font-weight:normal;"> We are required to make </span><span style="font-weight:normal;">additional payments of up to $33.0 million to MSK based on achievement of specified regulatory and sales-related milestones, </span><span style="color:#000000;font-weight:normal;">as well as </span><span style="font-weight:normal;">mid-single-digit percentage tiered royalty payments based on </span><span style="color:#000000;font-weight:normal;">future sales of products resulting from the development of the licensed product candidates, if any. </span><span style="Background-color:#FFFFFF;color:#000000;font-weight:normal;">In addition, under certain circumstances, we are required to make certain minimum annual royalty payments to MSK, which are creditable against earned royalties owed for the same annual period. We are also required to pay a low double-digit percentage of any consideration we receive for sublicensing the licensed rights. </span><span style="color:#000000;font-weight:normal;">The license agreement expires on a product-by-product and country-by-country basis on the later of: (i) expiration of the last licensed patent rights related to each licensed product, (ii) expiration of any market exclusivity period granted by law with respect to each licensed product, and (iii) a specified number of years after the first commercial sale of the licensed product in each country. Upon expiration of the license agreement, Atara will retain non-exclusive rights to the licensed products. </span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2018 and December 2018, we licensed additional technology from MSK. In connection with the effectiveness of the December 2018 license agreement, we made upfront cash payments of $12.5 million in the first quarter of 2019, which were recorded as research and development expense in our consolidated statement of operations and comprehensive loss in the fourth quarter of 2018. We are obligated to make additional milestone payments based on achievement of specified development, regulatory and sales-related milestones, <span style="color:#000000;">as well as </span>mid-single-digit percentage tiered royalty payments based on <span style="color:#000000;">future sales of products resulting from the development of the licensed product candidates, if any</span>.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">QIMR Berghofer Agreements – </span><span style="font-weight:normal;">In October 2015, we entered into an exclusive license agreement and a research and development collaboration agreement with </span><span style="font-weight:normal;">QIMR</span><span style="font-weight:normal;"> Berghofer.</span><span style="font-weight:normal;"> </span><span style="font-weight:normal;">Under the terms of the license agreement, we obtained an exclusive, worldwide license to develop and commercialize allogeneic T-cell therapy programs utilizing technology and know-how developed by QIMR Berghofer. In September 2016, the exclusive license agreement and research and development collaboration agreement were amended and restated. Under the amended and restated agreements, we obtained an exclusive, worldwide license to develop and commercialize additional T-cell programs</span><span style="font-weight:normal;">,</span><span style="font-weight:normal;"> as well as the option to license additional technology. We exercised this option in June 2018. </span><span style="font-weight:normal;">We further amended and restated our license agreement and research and development collaboration agreements with QIMR Berghofer in August 2019 to eliminate our license to certain rights related to cytomegalovirus. Our current </span><span style="font-weight:normal;">license agreement also provides for various milestone and royalty payments to QIMR Berghofer based on future product sales, if any.</span><span style="font-weight:normal;"> Under the terms of our current research and development collaboration agreement, we are also required to reimburse the cost of agreed-upon development activities related to programs developed under the collaboration. These payments are expensed on a straight-line basis over the related development periods. The agreement also provides for various milestone payments to QIMR Berghofer based on achievement of certain developmental and regulatory milestones.</span></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we have entered into other license and collaboration agreements with other parties. For example, we licensed additional rights related to our MSK-partnered next-generation CAR T programs from MSK in May 2018 and we licensed rights related to our next-generation CAR T programs from Moffitt Cancer Center in August 2018, and we agreed to collaborate through sponsored research in connection with each of these licenses. We also licensed rights related to our MSK-partnered next generation CAR T programs from the National Institutes of Health in December 2018.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Milestones and royalties under each of the above agreements are contingent upon future events and will be recorded as expense when it is probable that the milestones will be achieved or royalties are due. As of March 31, 2020 and December 31, 2019, there were no outstanding obligations for milestones and royalties under our license and collaboration agreements.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cognate Agreement<span style="font-weight:normal;"> - In December 2019, we entered into a Commercial Manufacturing Services Agreement (the “Manufacturing Agreement”) with Cognate BioServices, Inc. (“Cognate”) to supersede the Development and Manufacturing Agreement that was entered into with Cognate in August 2015 and amended in December 2017, May 2018, November 2018, June 2019 and November 2019. Pursuant to the Manufacturing Agreement, Cognate provides manufacturing services for certain of our product candidates. The initial term of the Manufacturing Agreement is from January 1, 2020 until December 31, 2021 and is renewable with Cognate’s approval for an additional one-year period. We may terminate the Manufacturing Agreement for convenience on six months’ written notice to Cognate, or immediately if Cognate is unable to perform the services under the Manufacturing Agreement or fails to obtain or maintain certain necessary approvals. The Manufacturing Agreement includes standard mutual termination rights for uncured breach or insolvency, or a force majeure event preventing the performance of services for at least ninety days.</span></p> 33000000.0 12500000 0 0 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Commitments and Contingencies</p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">License and Collaboration Agreements </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Potential payments related to our license and collaboration agreements, including milestone and royalty payments, are detailed in Note 6.</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other Research and Development Agreements</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may enter into contracts in the normal course of business with clinical research organizations <span style="color:#000000;">for clinical trials, with contract manufacturing </span>organizations for <span style="color:#000000;">clinical supplies, and with other vendors for pre-clinical studies, supplies and other services for our operating purposes. These contracts generally provide for termination on </span>notice. As of March 31, 2020 and December 31, 2019, there were immaterial and no amounts accrued related to contract termination charges or minimum purchase volumes not being met, respectively.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Indemnification Agreements </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the normal course of business, we enter into contracts and agreements that contain a variety of representations and warranties and provide for indemnification for certain liabilities. The exposure under these agreements is unknown because it involves claims that may be made against us in the future but have not yet been made. To date, we have not paid any claims or been required to defend any action related to our indemnification obligations. However, we may record charges in the future as a result of these indemnification obligations. We also have indemnification obligations to our directors and executive officers for specified events or occurrences, subject to some limits, while they are serving at our request in such capacities. There have been no claims to date and we believe the fair value of these indemnification agreements is minimal. Accordingly, we did not record liabilities for these agreements as of March 31, 2020 and December 31, 2019. </p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contingencies</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may be involved in legal proceedings, as well as demands, claims and threatened litigation, which arise in the normal course of our business or otherwise. The ultimate outcome of any litigation is uncertain and unfavorable outcomes could have a negative impact on our results of operations and financial condition. Regardless of outcome, litigation can have an adverse impact on us because of the defense costs, diversion of management resources and other factors. We are not currently involved in any material legal proceedings.</p> 0 0 0 0 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Stockholders’ Equity</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our authorized capital stock consists of 520,000,000 shares, all with a par value of $0.0001 per share, of which 500,000,000 shares are designated as common stock and 20,000,000 shares are designated as preferred stock. <span style="color:#000000;">There were no shares of preferred stock outstanding as of March 31</span>, 2020 and December 31, 2019.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:6pt;"> </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of our July 2019 underwritten public offering, we issued and sold pre-funded warrants to purchase shares of common stock. Each pre-funded warrant entitles the holder to purchase one share of common stock at an exercise price of $0.0001 per share and expires seven years from the date of issuance. These warrants were recorded as a component of stockholders’ equity within additional paid-in capital. Per the terms of the warrant agreement, a holder of the outstanding warrants is not entitled to exercise any portion of any pre-funded warrant if, upon exercise of the warrant, the holder’s ownership (together with its affiliates) of our common stock or combined voting power of our securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% after giving effect to the exercise (“Maximum Ownership Percentage”). Upon at least 61 days’ prior notice to us by the holder, any holder may increase or decrease the Maximum Ownership Percentage to any other percentage not to exceed 19.99%. As of March 31, 2020, 2,888,526 pre-funded warrants were outstanding.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ATM Facilities</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2019, we entered into a sales agreement (the “2019 ATM Facility”) with Cowen and Company, LLC (“Cowen”), which provides for the sale, in our sole discretion, of shares of our common stock, in the aggregate offering price of up to $100.0 million through Cowen, as our sales agent.<span style="color:#000000;"> The issuance and sale of these shares by us pursuant to the 2019 ATM Facility are deemed “at the market” offerings as defined in Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”), and are registered under the Securities Act. </span>We pay a commission of up to 3.0% of gross sales proceeds of any common stock sold under the 2019 ATM Facility.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2020, we entered into a new sales agreement (the “2020 ATM Facility”) with Cowen, which provides for the sale, in our sole discretion, of shares of our common stock having an aggregate offering price of up to $100.0 million through Cowen, as our sales agent. The 2020 ATM Facility is separate from and does not replace the 2019 ATM Facility in any way. The issuance and sale of these shares by us pursuant to the 2020 ATM Facility are deemed “at the market” offerings and are registered under the Securities Act of 1933, as amended. We will pay a commission of up to 3.0% of gross sales proceeds of any common stock sold under the 2020 ATM Facility.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three months ended March 31, 2020, we sold an aggregate of 1,528,216 shares of common stock under the 2019 ATM Facility, at an average price of $15.50 per share, for gross proceeds of $23.7 million and net proceeds of $23.1 million, after deducting commissions and other offering expenses payable by us. Additionally, on January 3, 2020, we received net proceeds of approximately $1.2 million from sales of shares of common stock under the 2019 ATM Facility that occurred during 2019. As of March 31, 2020, $25.9 million and $100.0 million of common stock remained available to be sold under the 2019 ATM Facility and 2020 ATM Facility, respectively, subject to certain conditions as specified in the agreement.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Equity Incentive Plans </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the 2014 Equity Incentive Plan, as amended (“2014 EIP”), we may grant stock options, restricted stock awards (“RSAs”) and RSUs to employees, directors, consultants and other service providers. RSUs generally vest over four years. In the first quarter of 2020, we granted performance-based RSUs to certain of our employees that provide for the issuance of common stock if specified Company performance criteria related to our clinical programs are achieved. The number of performance-based RSUs that ultimately vests depends upon if, when and which performance criteria are achieved, as well as the employee’s continuous service, as defined in the 2014 EIP, through the date of vesting. The fair value of performance-based RSUs is determined as the closing stock price on the date of grant.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options are granted at prices no less than </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% of the estimated fair value of the shares on the date of grant as determined by the board of directors, provided, however, that </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the exercise price of an option granted to a </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% shareholder cannot be less than </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% of the estimated fair value of the shares on the date of grant. Options granted generally vest over </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">four years</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and expire in </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">seven to ten years</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> As of </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 31</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, a total of </span>14,316,451<span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of common stock were reserved for issuance under the 2014 EIP, of which </span>2,483,425<span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares were available for future grant and </span>11,833,026<span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares were subject to outstanding options and RSUs</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, including performance-based RSUs</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2018, we adopted the 2018 Inducement Plan (“Inducement Plan”), under which we may grant options, stock appreciation rights, RSAs and RSUs to new employees. As of March 31, 2020, 1,196,086 shares of common stock were reserved for issuance under the Inducement Plan, of which 272,336 shares were available for future grant and 923,750 shares were subject to outstanding options and RSUs.</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Restricted Stock Units</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of RSU activity under our 2014 EIP and Inducement Plan:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.82%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.58%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RSUs</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.82%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.58%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.82%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested as of December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.46%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,910,764</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.93</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.82%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.46%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,387,890</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.15</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.82%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.46%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(85,851</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.66</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.82%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.58%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(552,498</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.04</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.82%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested as of March 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.58%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,660,305</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.56</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2020, there was $63.9 million of unrecognized stock-based compensation expense related to RSUs that is expected to be recognized over a weighted average period of 2.9 years. This excludes unrecognized stock-based compensation expense for performance-based RSUs that were deemed not probable of vesting in accordance with U.S GAAP.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stock Options </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of stock option activity under our 2014 EIP and Inducement Plan. The table below also includes the activity relating to options for 275,000 shares of our common stock which were issued in 2017 outside of these plans:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:85%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.52%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual Term</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate Intrinsic</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,934,262</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.25</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,489,925</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.91</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(93,719</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.19</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.52%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited or expired</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(233,997</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.2%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.28</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.12%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.12%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.52%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of March 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,096,471</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.2%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.47</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.12%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000459">6.5</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.12%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Aggregate intrinsic value represents the difference between the closing stock price of our common stock on March 31, 2020 and the exercise price of outstanding, in-the-money options. As of March 31, 2020, there was $71.1 million of unrecognized stock-based compensation expense related to stock options that is expected to be recognized over a weighted average period of 3.0 years. </p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Reserved Shares</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following shares of common stock were reserved for future issuance under our equity incentive plans as of March 31, 2020:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.74%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.24%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total Shares</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Reserved</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.74%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2014 Equity Incentive Plan</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,316,451</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.74%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018 Inducement Plan</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,196,086</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2014 Employee Stock Purchase Plan</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,233,317</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.74%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total reserved shares of common stock</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,745,854</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Stock-based Compensation Expense</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense related to all employee and non-employee stock awards was as follows:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.3%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.68%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.3%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.68%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,650</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,065</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,994</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,204</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.3%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,644</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,269</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"> </p> 520000000 0.0001 0.0001 500000000 20000000 0 0 1 0.0001 P7Y 0.0999 P61D 0.1999 2888526000 100000000.0 0.030 100000000.0 0.030 1528216 15.50 23700000 23100000 1200000 25900000 100000000.0 P4Y 1 the exercise price of an option granted to a 10% shareholder cannot be less than 110% of the estimated fair value of the shares on the date of grant. Options granted generally vest over four years and expire in seven to ten years. 0.10 1.10 P4Y P7Y P10Y 14316451 2483425 11833026 1196086 272336 923750 <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of RSU activity under our 2014 EIP and Inducement Plan:</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.82%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.58%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RSUs</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.82%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.58%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.82%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested as of December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.46%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,910,764</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.93</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.82%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.46%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,387,890</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.15</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.82%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.46%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(85,851</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.66</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.82%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.58%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(552,498</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.04</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.82%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested as of March 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.58%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,660,305</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.56</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> 1910764 26.93 3387890 12.15 85851 18.66 552498 25.04 4660305 16.56 63900000 P2Y10M24D <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of stock option activity under our 2014 EIP and Inducement Plan. The table below also includes the activity relating to options for 275,000 shares of our common stock which were issued in 2017 outside of these plans:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:85%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.52%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual Term</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate Intrinsic</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,934,262</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.25</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,489,925</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.91</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.52%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(93,719</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.19</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.52%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited or expired</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(233,997</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.2%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.28</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.12%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.12%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.52%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of March 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,096,471</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.2%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.47</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.12%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000459">6.5</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.12%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 275000 6934262 28.25 1489925 12.91 93719 14.19 233997 32.28 8096471 25.47 0 71100000 P3Y <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following shares of common stock were reserved for future issuance under our equity incentive plans as of March 31, 2020:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.74%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.24%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total Shares</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Reserved</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.74%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2014 Equity Incentive Plan</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,316,451</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:81.74%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018 Inducement Plan</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,196,086</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2014 Employee Stock Purchase Plan</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,233,317</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:81.74%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total reserved shares of common stock</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,745,854</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> 14316451 1196086 1233317 16745854 <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense related to all employee and non-employee stock awards was as follows:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.3%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.68%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.3%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.68%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,650</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.76%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,065</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,994</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,204</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.3%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,644</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,269</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"> </p> 7650000 6065000 4994000 6204000 12644000 12269000 XML 21 R28.htm IDEA: XBRL DOCUMENT v3.20.1
Property and Equipment - Schedule of Property and Equipment (Detail) - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Property Plant And Equipment [Line Items]    
Property and equipment, gross $ 68,009 $ 65,854
Less: accumulated depreciation and amortization (13,567) (11,678)
Property and equipment, net 54,442 54,176
Leasehold Improvements    
Property Plant And Equipment [Line Items]    
Property and equipment, gross 49,703 49,028
Lab Equipment    
Property Plant And Equipment [Line Items]    
Property and equipment, gross 7,060 6,815
Machinery and Equipment    
Property Plant And Equipment [Line Items]    
Property and equipment, gross 4,074 3,832
Computer Equipment and Software    
Property Plant And Equipment [Line Items]    
Property and equipment, gross 3,797 3,299
Furniture and Fixtures    
Property Plant And Equipment [Line Items]    
Property and equipment, gross 2,019 1,764
Construction in Progress    
Property Plant And Equipment [Line Items]    
Property and equipment, gross $ 1,356 $ 1,116
XML 22 R24.htm IDEA: XBRL DOCUMENT v3.20.1
Financial Instruments - Summary of Estimated Fair Value and Related Valuation Input Hierarchy of Available-for-Sale Securities (Detail) - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Schedule of Available-for-sale Securities [Line Items]    
Total Fair Value $ 213,127 $ 257,299
Fair Value, Measurements, Recurring    
Schedule of Available-for-sale Securities [Line Items]    
Total Amortized Cost 212,922 257,078
Total Unrealized Gain 421 233
Total Unrealized Loss (216) (12)
Total Fair Value 213,127 257,299
Fair Value, Measurements, Recurring | Money Market Funds | Level 1    
Schedule of Available-for-sale Securities [Line Items]    
Total Amortized Cost 42,382 63,554
Total Unrealized Gain 0 0
Total Unrealized Loss 0 0
Total Fair Value 42,382 63,554
Fair Value, Measurements, Recurring | U.S. Treasury Obligations | Level 2    
Schedule of Available-for-sale Securities [Line Items]    
Total Amortized Cost 58,993 52,805
Total Unrealized Gain 318 46
Total Unrealized Loss 0 (1)
Total Fair Value 59,311 52,850
Fair Value, Measurements, Recurring | Government Agency Obligations | Level 2    
Schedule of Available-for-sale Securities [Line Items]    
Total Amortized Cost 6,686 6,151
Total Unrealized Gain 9 1
Total Unrealized Loss (2) (1)
Total Fair Value 6,693 6,151
Fair Value, Measurements, Recurring | Corporate Debt Obligations | Level 2    
Schedule of Available-for-sale Securities [Line Items]    
Total Amortized Cost 85,121 100,512
Total Unrealized Gain 92 180
Total Unrealized Loss (210) (10)
Total Fair Value 85,003 100,682
Fair Value, Measurements, Recurring | Commercial Paper | Level 2    
Schedule of Available-for-sale Securities [Line Items]    
Total Amortized Cost 14,471 26,290
Total Unrealized Gain 0 0
Total Unrealized Loss 0 0
Total Fair Value 14,471 26,290
Fair Value, Measurements, Recurring | Asset-Backed Securities | Level 2    
Schedule of Available-for-sale Securities [Line Items]    
Total Amortized Cost 5,269 7,266
Total Unrealized Gain 2 6
Total Unrealized Loss (4)  
Total Fair Value 5,267 7,272
Fair Value, Measurements, Recurring | Certificates of Deposit | Level 2    
Schedule of Available-for-sale Securities [Line Items]    
Total Amortized Cost   500
Total Unrealized Gain   0
Total Unrealized Loss   0
Total Fair Value   500
Fair Value, Measurements, Recurring | Amounts Classified As Cash Equivalents    
Schedule of Available-for-sale Securities [Line Items]    
Total Amortized Cost (68,689) (72,507)
Total Unrealized Gain (10) 0
Total Unrealized Loss 0 0
Total Fair Value (68,699) (72,507)
Fair Value, Measurements, Recurring | Amounts Classified As Short-Term Investments    
Schedule of Available-for-sale Securities [Line Items]    
Total Amortized Cost 144,233 184,571
Total Unrealized Gain 411 233
Total Unrealized Loss (216) (12)
Total Fair Value $ 144,428 $ 184,792
XML 24 R20.htm IDEA: XBRL DOCUMENT v3.20.1
Stockholders' Equity (Tables)
3 Months Ended
Mar. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]  
Summary of RSU Activity

The following is a summary of RSU activity under our 2014 EIP and Inducement Plan:

 

 

RSUs

 

 

 

Shares

 

 

Weighted

Average

Grant Date Fair Value

 

Unvested as of December 31, 2019

 

 

1,910,764

 

 

$

26.93

 

Granted

 

 

3,387,890

 

 

$

12.15

 

Forfeited

 

 

(85,851

)

 

$

18.66

 

Vested

 

 

(552,498

)

 

$

25.04

 

Unvested as of March 31, 2020

 

 

4,660,305

 

 

$

16.56

 

 

Summary of Stock Option Activity

The following is a summary of stock option activity under our 2014 EIP and Inducement Plan. The table below also includes the activity relating to options for 275,000 shares of our common stock which were issued in 2017 outside of these plans:

 

 

 

Shares

 

 

Weighted Average

Exercise Price

 

 

Weighted Average

Remaining

Contractual Term

(Years)

 

 

Aggregate Intrinsic

Value

(in thousands)

 

Outstanding as of December 31, 2019

 

 

6,934,262

 

 

$

28.25

 

 

 

 

 

 

 

 

 

Granted

 

 

1,489,925

 

 

 

12.91

 

 

 

 

 

 

 

 

 

Exercised

 

 

(93,719

)

 

 

14.19

 

 

 

 

 

 

 

 

 

Forfeited or expired

 

 

(233,997

)

 

 

32.28

 

 

 

 

 

 

 

 

 

Outstanding as of March 31, 2020

 

 

8,096,471

 

 

$

25.47

 

 

 

6.5

 

 

$

-

 

Schedule of Common Stock Reserved for Future Issuance Under Equity Incentive Plans

The following shares of common stock were reserved for future issuance under our equity incentive plans as of March 31, 2020:

 

 

Total Shares

Reserved

 

2014 Equity Incentive Plan

 

14,316,451

 

2018 Inducement Plan

 

1,196,086

 

2014 Employee Stock Purchase Plan

 

1,233,317

 

Total reserved shares of common stock

 

16,745,854

 

 

Schedule of Stock-based Compensation, Related to Employee and Nonemployee Stock Awards

Total stock-based compensation expense related to all employee and non-employee stock awards was as follows:

 

 

Three Months Ended March 31,

 

 

2020

 

 

2019

 

 

(in thousands)

 

Research and development

$

7,650

 

 

$

6,065

 

General and administrative

 

4,994

 

 

 

6,204

 

Total stock-based compensation expense

$

12,644

 

 

$

12,269

 

 

XML 25 R9.htm IDEA: XBRL DOCUMENT v3.20.1
Summary of Significant Accounting Policies
3 Months Ended
Mar. 31, 2020
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

2.

Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements include the accounts of Atara and its wholly-owned subsidiaries and have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These condensed consolidated financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, except for the adoption of accounting pronouncements relating to credit losses on financial instruments, implementation of cloud computing arrangements, and simplification of income tax accounting, effective January 1, 2020, as discussed below. In the opinion of management, the condensed consolidated financial statements reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair presentation of the Company’s consolidated financial statements. The results of operations for any interim period are not necessarily indicative of the results to be expected for the full year or any other future period. The condensed consolidated balance sheet as of December 31, 2019 has been derived from audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete consolidated financial statements.

Liquidity and Going Concern

In accordance with Accounting Standards Codification (“ASC”) 205-40, Going Concern, we have evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern for one year from the date the accompanying financial statements are issued. We have incurred significant operating losses since inception and have relied on public and private equity financings to fund our operations. As of March 31, 2020, we had an accumulated deficit of $891.5 million.

As we continue to incur losses, our transition to profitability will depend on the successful development, approval and commercialization of product candidates and on the achievement of sufficient revenues to support our cost structure. We may never achieve profitability, and unless and until we do, we will need to continue to raise additional capital. We expect that our cash, cash equivalents and short-term investments as of March 31, 2020 will be sufficient to fund our planned operations into the second quarter of 2021. However, the uncertainties inherent in the Company’s future operations and in our ability to obtain additional funding raise substantial doubt about our ability to continue as a going concern beyond one year from the date these financial statements are issued. The interim condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. We currently plan to raise additional funding as required, based on the status of our development programs and our projected cash flows. We may also need to pursue the sale or sublicense of rights to the Company’s programs and assets on terms potentially unfavorable to us. If we are unable to obtain additional funding, we will be forced to delay, limit, reduce or terminate preclinical studies, clinical studies or other development activities for one or more of our product candidates.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions, and judgments that affect the amounts reported in the financial statements and accompanying notes. Significant estimates relied upon in preparing these financial statements include estimates related to clinical trial and other accruals, stock-based compensation expense and income taxes. Actual results could differ materially from those estimates.

Recent Accounting Pronouncements

The Company considers the applicability and impact of any Accounting Standards Update (“ASU”) issued by the Financial Accounting Standards Board (“FASB”). Other than the ASUs we adopted effective January 1, 2020 and listed below, all other ASUs were assessed and determined to be either not applicable or are expected to have minimal impact on our consolidated financial statements.

Adoption of New Accounting Pronouncements

We adopted ASU No. 2016-13 (as amended by ASUs 2018-19, 2019-04, 2019-05 and 2019-11), Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, prospectively on January 1, 2020. Under this new guidance, a company is required to estimate credit losses on certain types of financial instruments using an expected-loss model, replacing the current incurred-loss model, and record the estimate through an allowance for credit losses. We do not hold material amounts of the types of financial instruments impacted by this guidance on our balance sheet. The guidance also establishes a new impairment model for available-for-sale debt securities. The adoption did not have a material impact on our condensed consolidated balance sheet or our condensed consolidated statements of operations and comprehensive loss, changes in stockholders’ equity, and cash flows for the three months ended March 31, 2020 and 2019.

We adopted ASU No. 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, effective January 1, 2020, electing a prospective adoption method. The new standard requires that certain implementation costs for cloud computing arrangements are capitalized and amortized over the term of associated hosted cloud computing arrangement service. Capitalized implementation costs are classified in the same line on the balance sheet as amounts prepaid for hosted cloud computing arrangement service, or prepaid expenses and other assets. The amortization of the capitalized asset is presented in the same line on the statement of operations and comprehensive loss as the fees for the associated hosted cloud computing arrangement service and not included with depreciation or amortization expense related to property and equipment or intangible assets. Cash flows related to capitalized implementation costs are presented consistent with the presentation of cash flows for fees related to the hosted cloud computing arrangement service, or cash flows used in operating activities. The adoption did not have a material impact on our condensed consolidated balance sheet or our condensed consolidated statements of operations and comprehensive loss, changes in stockholders’ equity, and cash flows for the three months ended March 31, 2020 and 2019.

We adopted ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, as of January 1, 2020, which eliminates certain exceptions related to the general principles in ASC 740 and makes amendments to other areas with the intention of simplifying various aspects related to accounting for income taxes. The provisions of the ASU that are applicable to Atara are applied on a prospective basis. The adoption did not have a material impact on our condensed consolidated balance sheet or our condensed consolidated statements of operations and comprehensive loss, changes in stockholders’ equity, and cash flows for the three months ended March 31, 2020 and 2019.

XML 26 R5.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
Total
At The Market Offering
Common Stock
Common Stock
At The Market Offering
Additional Paid-in Capital
Additional Paid-in Capital
At The Market Offering
Accumulated Other Comprehensive (Loss) Income
Accumulated Deficit
Beginning balance at Dec. 31, 2018 $ 338,857   $ 5   $ 866,541   $ (340) $ (527,349)
Beginning balance (in shares) at Dec. 31, 2018     45,951          
Effect of the adoption of ASC topic 842 (Leases) at Dec. 31, 2018 364             364
Beginning balance, as adjusted at Dec. 31, 2018 339,221   $ 5   866,541   (340) (526,985)
RSU settlements, net of shares withheld (4,575)       (4,575)      
RSU settlements, net of shares withheld, shares     197          
Issuance of common stock pursuant to employee stock awards 2,898       2,898      
Issuance of common stock pursuant to employee stock awards, shares     159          
Stock-based compensation expense 12,269       12,269      
Net loss (66,257)             (66,257)
Unrealized (loss) gain on available-for-sale securities 378           378  
Ending balance at Mar. 31, 2019 283,934   $ 5   877,133   38 (593,242)
Ending balance (in shares) at Mar. 31, 2019     46,307          
Beginning balance at Dec. 31, 2019 290,781   $ 6   1,108,516   220 (817,961)
Beginning balance (in shares) at Dec. 31, 2019     56,806          
Issuance of common stock, net of commissions and offering costs, value   $ 22,987       $ 22,987    
Issuance of common stock, net of commissions and offering costs, shares       1,528        
Exercise of pre-funded warrants, shares     57          
RSU settlements, net of shares withheld (1,395)       (1,395)      
RSU settlements, net of shares withheld, shares     455          
Issuance of common stock pursuant to employee stock awards 1,330       1,330      
Issuance of common stock pursuant to employee stock awards, shares     94          
Stock-based compensation expense 12,644       12,644      
Net loss (73,509)             (73,509)
Unrealized (loss) gain on available-for-sale securities (16)           (16)  
Ending balance at Mar. 31, 2020 $ 252,822   $ 6   $ 1,144,082   $ 204 $ (891,470)
Ending balance (in shares) at Mar. 31, 2020     58,940          
XML 27 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Document and Entity Information - shares
3 Months Ended
Mar. 31, 2020
Apr. 30, 2020
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Mar. 31, 2020  
Document Fiscal Year Focus 2020  
Document Fiscal Period Focus Q1  
Trading Symbol ATRA  
Entity Registrant Name ATARA BIOTHERAPEUTICS, INC.  
Entity Central Index Key 0001604464  
Entity Current Reporting Status Yes  
Current Fiscal Year End Date --12-31  
Entity Filer Category Large Accelerated Filer  
Entity Shell Company false  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Common Stock, Shares Outstanding   58,952,045
Entity File Number 001-36548  
Entity Tax Identification Number 46-0920988  
Entity Address, Address Line One 611 Gateway Blvd.  
Entity Address, Address Line Two Suite 900  
Entity Address, City or Town South San Francisco  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 94080  
City Area Code 650  
Local Phone Number 278-8930  
Entity Incorporation, State or Country Code DE  
Title of 12(b) Security Common Stock, par value $0.0001 per share  
Security Exchange Name NASDAQ  
Entity Interactive Data Current Yes  
Document Quarterly Report true  
Document Transition Report false  
XML 28 R31.htm IDEA: XBRL DOCUMENT v3.20.1
Commitments and Contingencies - Additional Information (Detail) - USD ($)
Mar. 31, 2020
Dec. 31, 2019
Commitments And Contingencies Disclosure [Abstract]    
Accrued termination charges $ 0 $ 0
Liabilities related to indemnification agreements $ 0 $ 0
XML 29 R35.htm IDEA: XBRL DOCUMENT v3.20.1
Stockholders' Equity - Schedule of Common Stock Reserved for Future Issuance Under Equity Incentive Plans (Detail)
Mar. 31, 2020
shares
Class Of Stock [Line Items]  
Total reserved shares of common stock 16,745,854
2014 Equity Incentive Plan  
Class Of Stock [Line Items]  
Total reserved shares of common stock 14,316,451
2018 Inducement Plan  
Class Of Stock [Line Items]  
Total reserved shares of common stock 1,196,086
2014 Employee Stock Purchase Plan  
Class Of Stock [Line Items]  
Total reserved shares of common stock 1,233,317
XML 30 R16.htm IDEA: XBRL DOCUMENT v3.20.1
Summary of Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2020
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements include the accounts of Atara and its wholly-owned subsidiaries and have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These condensed consolidated financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, except for the adoption of accounting pronouncements relating to credit losses on financial instruments, implementation of cloud computing arrangements, and simplification of income tax accounting, effective January 1, 2020, as discussed below. In the opinion of management, the condensed consolidated financial statements reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair presentation of the Company’s consolidated financial statements. The results of operations for any interim period are not necessarily indicative of the results to be expected for the full year or any other future period. The condensed consolidated balance sheet as of December 31, 2019 has been derived from audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete consolidated financial statements.

Liquidity and Going Concern

Liquidity and Going Concern

In accordance with Accounting Standards Codification (“ASC”) 205-40, Going Concern, we have evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern for one year from the date the accompanying financial statements are issued. We have incurred significant operating losses since inception and have relied on public and private equity financings to fund our operations. As of March 31, 2020, we had an accumulated deficit of $891.5 million.

As we continue to incur losses, our transition to profitability will depend on the successful development, approval and commercialization of product candidates and on the achievement of sufficient revenues to support our cost structure. We may never achieve profitability, and unless and until we do, we will need to continue to raise additional capital. We expect that our cash, cash equivalents and short-term investments as of March 31, 2020 will be sufficient to fund our planned operations into the second quarter of 2021. However, the uncertainties inherent in the Company’s future operations and in our ability to obtain additional funding raise substantial doubt about our ability to continue as a going concern beyond one year from the date these financial statements are issued. The interim condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. We currently plan to raise additional funding as required, based on the status of our development programs and our projected cash flows. We may also need to pursue the sale or sublicense of rights to the Company’s programs and assets on terms potentially unfavorable to us. If we are unable to obtain additional funding, we will be forced to delay, limit, reduce or terminate preclinical studies, clinical studies or other development activities for one or more of our product candidates.

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions, and judgments that affect the amounts reported in the financial statements and accompanying notes. Significant estimates relied upon in preparing these financial statements include estimates related to clinical trial and other accruals, stock-based compensation expense and income taxes. Actual results could differ materially from those estimates.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

The Company considers the applicability and impact of any Accounting Standards Update (“ASU”) issued by the Financial Accounting Standards Board (“FASB”). Other than the ASUs we adopted effective January 1, 2020 and listed below, all other ASUs were assessed and determined to be either not applicable or are expected to have minimal impact on our consolidated financial statements.

Adoption of New Accounting Pronouncements

We adopted ASU No. 2016-13 (as amended by ASUs 2018-19, 2019-04, 2019-05 and 2019-11), Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, prospectively on January 1, 2020. Under this new guidance, a company is required to estimate credit losses on certain types of financial instruments using an expected-loss model, replacing the current incurred-loss model, and record the estimate through an allowance for credit losses. We do not hold material amounts of the types of financial instruments impacted by this guidance on our balance sheet. The guidance also establishes a new impairment model for available-for-sale debt securities. The adoption did not have a material impact on our condensed consolidated balance sheet or our condensed consolidated statements of operations and comprehensive loss, changes in stockholders’ equity, and cash flows for the three months ended March 31, 2020 and 2019.

We adopted ASU No. 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, effective January 1, 2020, electing a prospective adoption method. The new standard requires that certain implementation costs for cloud computing arrangements are capitalized and amortized over the term of associated hosted cloud computing arrangement service. Capitalized implementation costs are classified in the same line on the balance sheet as amounts prepaid for hosted cloud computing arrangement service, or prepaid expenses and other assets. The amortization of the capitalized asset is presented in the same line on the statement of operations and comprehensive loss as the fees for the associated hosted cloud computing arrangement service and not included with depreciation or amortization expense related to property and equipment or intangible assets. Cash flows related to capitalized implementation costs are presented consistent with the presentation of cash flows for fees related to the hosted cloud computing arrangement service, or cash flows used in operating activities. The adoption did not have a material impact on our condensed consolidated balance sheet or our condensed consolidated statements of operations and comprehensive loss, changes in stockholders’ equity, and cash flows for the three months ended March 31, 2020 and 2019.

We adopted ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, as of January 1, 2020, which eliminates certain exceptions related to the general principles in ASC 740 and makes amendments to other areas with the intention of simplifying various aspects related to accounting for income taxes. The provisions of the ASU that are applicable to Atara are applied on a prospective basis. The adoption did not have a material impact on our condensed consolidated balance sheet or our condensed consolidated statements of operations and comprehensive loss, changes in stockholders’ equity, and cash flows for the three months ended March 31, 2020 and 2019.

XML 31 R12.htm IDEA: XBRL DOCUMENT v3.20.1
Property and Equipment
3 Months Ended
Mar. 31, 2020
Property Plant And Equipment [Abstract]  
Property and Equipment

5.

Property and Equipment

Property and equipment consisted of the following as of each period end:

 

 

 

March 31,

 

 

December 31,

 

 

 

2020

 

 

2019

 

 

 

(in thousands)

 

Leasehold improvements

 

$

49,703

 

 

$

49,028

 

Lab equipment

 

 

7,060

 

 

 

6,815

 

Machinery and equipment

 

 

4,074

 

 

 

3,832

 

Computer equipment and software

 

 

3,797

 

 

 

3,299

 

Furniture and fixtures

 

 

2,019

 

 

 

1,764

 

Construction in progress

 

 

1,356

 

 

 

1,116

 

Property and equipment, gross

 

 

68,009

 

 

 

65,854

 

Less: accumulated depreciation and amortization

 

 

(13,567

)

 

 

(11,678

)

Property and equipment, net

 

$

54,442

 

 

$

54,176

 

 

Depreciation and amortization expense was $1.9 million and $1.6 million for the three months ended March 31, 2020 and 2019.

XML 33 R26.htm IDEA: XBRL DOCUMENT v3.20.1
Financial Instruments - Additional Information (Detail) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Financial Instruments Disclosure [Abstract]    
Accrued interest receivable $ 800,000 $ 900,000
Write off, of accrued interest receivable 0 0
Restricted Cash $ 1,400,000 $ 1,400,000
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.20.1
Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Accounting Policies [Abstract]    
Accumulated Deficit $ 891,470 $ 817,961
XML 35 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 110 271 1 false 46 0 false 4 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.atarabio.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) Sheet http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) Statements 3 false false R4.htm 100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 100040 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) Sheet http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 100050 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical) (Unaudited) Sheet http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParentheticalUnaudited Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical) (Unaudited) Statements 6 false false R7.htm 100060 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 100080 - Disclosure - Description of Business Sheet http://www.atarabio.com/20200331/taxonomy/role/DisclosureDescriptionOfBusiness Description of Business Notes 8 false false R9.htm 100090 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.atarabio.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 100100 - Disclosure - Net Loss per Common Share Sheet http://www.atarabio.com/20200331/taxonomy/role/DisclosureNetLossPerCommonShare Net Loss per Common Share Notes 10 false false R11.htm 100110 - Disclosure - Financial Instruments Sheet http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstruments Financial Instruments Notes 11 false false R12.htm 100120 - Disclosure - Property and Equipment Sheet http://www.atarabio.com/20200331/taxonomy/role/DisclosurePropertyAndEquipment Property and Equipment Notes 12 false false R13.htm 100130 - Disclosure - License and Collaboration Agreements Sheet http://www.atarabio.com/20200331/taxonomy/role/DisclosureLicenseAndCollaborationAgreements License and Collaboration Agreements Notes 13 false false R14.htm 100140 - Disclosure - Commitments and Contingencies Sheet http://www.atarabio.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 14 false false R15.htm 100150 - Disclosure - Stockholders' Equity Sheet http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquity Stockholders' Equity Notes 15 false false R16.htm 100160 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.atarabio.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.atarabio.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies 16 false false R17.htm 100170 - Disclosure - Net Loss per Common Share (Tables) Sheet http://www.atarabio.com/20200331/taxonomy/role/DisclosureNetLossPerCommonShareTables Net Loss per Common Share (Tables) Tables http://www.atarabio.com/20200331/taxonomy/role/DisclosureNetLossPerCommonShare 17 false false R18.htm 100180 - Disclosure - Financial Instruments (Tables) Sheet http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsTables Financial Instruments (Tables) Tables http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstruments 18 false false R19.htm 100190 - Disclosure - Property and Equipment (Tables) Sheet http://www.atarabio.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentTables Property and Equipment (Tables) Tables http://www.atarabio.com/20200331/taxonomy/role/DisclosurePropertyAndEquipment 19 false false R20.htm 100200 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquity 20 false false R21.htm 100210 - Disclosure - Description of Business (Detail) Sheet http://www.atarabio.com/20200331/taxonomy/role/DisclosureDescriptionOfBusinessDetail Description of Business (Detail) Details http://www.atarabio.com/20200331/taxonomy/role/DisclosureDescriptionOfBusiness 21 false false R22.htm 100220 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.atarabio.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail Summary of Significant Accounting Policies - Additional Information (Detail) Details 22 false false R23.htm 100230 - Disclosure - Net Loss per Common Share - Antidilutive Securities Excluded From Computation of Diluted Net Loss per Common Share (Detail) Sheet http://www.atarabio.com/20200331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail Net Loss per Common Share - Antidilutive Securities Excluded From Computation of Diluted Net Loss per Common Share (Detail) Details 23 false false R24.htm 100240 - Disclosure - Financial Instruments - Summary of Estimated Fair Value and Related Valuation Input Hierarchy of Available-for-Sale Securities (Detail) Sheet http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail Financial Instruments - Summary of Estimated Fair Value and Related Valuation Input Hierarchy of Available-for-Sale Securities (Detail) Details 24 false false R25.htm 100250 - Disclosure - Financial Instruments - Amortized Cost and Fair Value of Available-for-Sale Securities by Contractual Maturity (Detail) Sheet http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsAmortizedCostAndFairValueOfAvailableForSaleSecuritiesByContractualMaturityDetail Financial Instruments - Amortized Cost and Fair Value of Available-for-Sale Securities by Contractual Maturity (Detail) Details 25 false false R26.htm 100260 - Disclosure - Financial Instruments - Additional Information (Detail) Sheet http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail Financial Instruments - Additional Information (Detail) Details 26 false false R27.htm 100270 - Disclosure - Financial Instruments - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail) Sheet http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetail Financial Instruments - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail) Details 27 false false R28.htm 100280 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Detail) Sheet http://www.atarabio.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail Property and Equipment - Schedule of Property and Equipment (Detail) Details 28 false false R29.htm 100290 - Disclosure - Property and Equipment - Additional Information (Detail) Sheet http://www.atarabio.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetail Property and Equipment - Additional Information (Detail) Details 29 false false R30.htm 100300 - Disclosure - License and Collaboration Agreements - Additional Information (Detail) Sheet http://www.atarabio.com/20200331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail License and Collaboration Agreements - Additional Information (Detail) Details 30 false false R31.htm 100310 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.atarabio.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 31 false false R32.htm 100320 - Disclosure - Stockholders' Equity - Additional Information (Detail) Sheet http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail Stockholders' Equity - Additional Information (Detail) Details 32 false false R33.htm 100330 - Disclosure - Stockholders' Equity - Summary of RSU Activity (Detail) Sheet http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquitySummaryOfRSUActivityDetail Stockholders' Equity - Summary of RSU Activity (Detail) Details 33 false false R34.htm 100340 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Detail) Sheet http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail Stockholders' Equity - Summary of Stock Option Activity (Detail) Details 34 false false R35.htm 100350 - Disclosure - Stockholders' Equity - Schedule of Common Stock Reserved for Future Issuance Under Equity Incentive Plans (Detail) Sheet http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceUnderEquityIncentivePlansDetail Stockholders' Equity - Schedule of Common Stock Reserved for Future Issuance Under Equity Incentive Plans (Detail) Details 35 false false R36.htm 100360 - Disclosure - Stockholders' Equity - Schedule of Stock-based Compensation Related to All Employee And Non-employee Stock Awards (Detail) Sheet http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationRelatedToAllEmployeeAndNonEmployeeStockAwardsDetail Stockholders' Equity - Schedule of Stock-based Compensation Related to All Employee And Non-employee Stock Awards (Detail) Details 36 false false All Reports Book All Reports atra-10q_20200331.htm atra-20200331.xsd atra-20200331_cal.xml atra-20200331_def.xml atra-20200331_lab.xml atra-20200331_pre.xml atra-ex311_9.htm atra-ex312_7.htm atra-ex321_10.htm http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/srt/2019-01-31 http://fasb.org/us-gaap/2019-01-31 true true XML 36 R7.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Operating activities    
Net loss $ (73,509) $ (66,257)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation expense 12,644 12,269
Depreciation and amortization expense 1,949 1,648
Amortization (accretion) of investment premiums (discounts) 42 (458)
Non-cash operating lease expense 364 331
Asset retirement obligation accretion expense 19 17
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets (1,888) (1,434)
Other assets (209) 38
Accounts payable (590) 2,672
Accrued compensation (5,030) (3,177)
Accrued research and development expenses (514) (13,016)
Other current liabilities (169) (2,572)
Operating lease liabilities (153) (261)
Net cash used in operating activities (67,044) (70,200)
Investing activities    
Purchases of short-term investments (56,851) (7,427)
Proceeds from maturities and sales of short-term investments 97,157 75,819
Purchases of property and equipment (1,333) (796)
Net cash provided by investing activities 38,973 67,596
Financing activities    
Proceeds from issuance of common stock through ATM facilities, net 24,277 0
Proceeds from employee stock awards 1,330 2,747
Taxes paid related to net share settlement of restricted stock units (1,395) (4,575)
Principal payments on finance lease obligations (90) (98)
Other financing activities, net (165) 0
Net cash provided by (used in) financing activities 23,957 (1,926)
Decrease in cash, cash equivalents and restricted cash (4,114) (4,530)
Cash, cash equivalents and restricted cash at beginning of period 75,711 62,092
Cash, cash equivalents and restricted cash at end of period 71,597 57,562
Non-cash investing and financing activities    
Property and equipment purchases included in accounts payable and other accrued liabilities 1,098 666
Finance lease assets obtained in exchange for lease obligations 281 0
Accrued costs related to ATM facilities 112 0
Receivable for options exercised 0 151
Supplemental cash flow disclosure    
Cash paid for interest 17 0
Cash paid for income taxes $ 0 $ 0
XML 37 R3.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) - $ / shares
Mar. 31, 2020
Dec. 31, 2019
Statement Of Financial Position [Abstract]    
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 500,000,000 500,000,000
Common stock, shares issued 58,940,000 56,806,000
Common stock, shares outstanding 58,940,000 56,806,000
XML 38 R14.htm IDEA: XBRL DOCUMENT v3.20.1
Commitments and Contingencies
3 Months Ended
Mar. 31, 2020
Commitments And Contingencies Disclosure [Abstract]  
Commitments and Contingencies

7.

Commitments and Contingencies

License and Collaboration Agreements

Potential payments related to our license and collaboration agreements, including milestone and royalty payments, are detailed in Note 6.

Other Research and Development Agreements

We may enter into contracts in the normal course of business with clinical research organizations for clinical trials, with contract manufacturing organizations for clinical supplies, and with other vendors for pre-clinical studies, supplies and other services for our operating purposes. These contracts generally provide for termination on notice. As of March 31, 2020 and December 31, 2019, there were immaterial and no amounts accrued related to contract termination charges or minimum purchase volumes not being met, respectively.

 

Indemnification Agreements

In the normal course of business, we enter into contracts and agreements that contain a variety of representations and warranties and provide for indemnification for certain liabilities. The exposure under these agreements is unknown because it involves claims that may be made against us in the future but have not yet been made. To date, we have not paid any claims or been required to defend any action related to our indemnification obligations. However, we may record charges in the future as a result of these indemnification obligations. We also have indemnification obligations to our directors and executive officers for specified events or occurrences, subject to some limits, while they are serving at our request in such capacities. There have been no claims to date and we believe the fair value of these indemnification agreements is minimal. Accordingly, we did not record liabilities for these agreements as of March 31, 2020 and December 31, 2019.

Contingencies

From time to time, we may be involved in legal proceedings, as well as demands, claims and threatened litigation, which arise in the normal course of our business or otherwise. The ultimate outcome of any litigation is uncertain and unfavorable outcomes could have a negative impact on our results of operations and financial condition. Regardless of outcome, litigation can have an adverse impact on us because of the defense costs, diversion of management resources and other factors. We are not currently involved in any material legal proceedings.

XML 39 R10.htm IDEA: XBRL DOCUMENT v3.20.1
Net Loss per Common Share
3 Months Ended
Mar. 31, 2020
Earnings Per Share [Abstract]  
Net Loss per Common Share

3.

Net Loss per Common Share

Basic net loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock and pre-funded warrants outstanding during the period, without consideration of common share equivalents. Diluted net loss per common share is computed by dividing net loss by the weighted-average number of shares of common stock, pre-funded warrants and common share equivalents outstanding for the period. The pre-funded warrants are included in the computation of basic and diluted net loss per common share as the exercise price is negligible and the pre-funded warrants are fully vested and exercisable. Common share equivalents are only included in the calculation of diluted net loss per common share when their effect is dilutive.

Potential dilutive securities, which include unvested restricted stock units (“RSUs”), unvested performance-based RSUs for which established performance criteria have been achieved as of the end of the respective periods, vested and unvested options to purchase common stock and shares to be issued under our employee stock purchase plan (“ESPP”), have been excluded from the computation of diluted net loss per share as the effect is antidilutive. Therefore, the denominator used to calculate both basic and diluted net loss per common share is the same in all periods presented.

The following table represents the potential common shares issuable pursuant to outstanding securities as of the related period end dates that were excluded from the computation of diluted net loss per common share, as their inclusion would have an antidilutive effect:

 

 

As of March 31,

 

 

2020

 

 

2019

 

Unvested RSUs

 

3,630,713

 

 

 

1,860,374

 

Vested and unvested options

 

8,096,471

 

 

 

6,842,443

 

ESPP share purchase rights

 

178,397

 

 

 

37,538

 

Total

 

11,905,581

 

 

 

8,740,355

 

 

XML 40 R18.htm IDEA: XBRL DOCUMENT v3.20.1
Financial Instruments (Tables)
3 Months Ended
Mar. 31, 2020
Financial Instruments Disclosure [Abstract]  
Summary of Estimated Fair Value and Related Valuation Input Hierarchy of Available-for-Sale Securities

The following tables summarize the estimated fair value and related valuation input hierarchy of our available-for-sale securities as of each period end:

 

 

 

 

 

Total

 

 

Total

 

 

Total

 

 

Total

 

 

 

 

 

Amortized

 

 

Unrealized

 

 

Unrealized

 

 

Estimated

 

As of March 31, 2020:

 

Input Level

 

Cost

 

 

Gain

 

 

Loss

 

 

Fair Value

 

 

 

 

 

(in thousands)

 

Money market funds

 

Level 1

 

$

42,382

 

 

$

 

 

$

 

 

$

42,382

 

U.S. Treasury obligations

 

Level 2

 

 

58,993

 

 

 

318

 

 

 

 

 

 

59,311

 

Government agency obligations

 

Level 2

 

 

6,686

 

 

 

9

 

 

 

(2

)

 

 

6,693

 

Corporate debt obligations

 

Level 2

 

 

85,121

 

 

 

92

 

 

 

(210

)

 

 

85,003

 

Commercial paper

 

Level 2

 

 

14,471

 

 

 

 

 

 

 

 

 

14,471

 

Asset-backed securities

 

Level 2

 

 

5,269

 

 

 

2

 

 

 

(4

)

 

 

5,267

 

Total available-for-sale securities

 

 

 

 

212,922

 

 

 

421

 

 

 

(216

)

 

 

213,127

 

Less: amounts classified as cash equivalents

 

 

 

 

(68,689

)

 

 

(10

)

 

 

 

 

 

(68,699

)

Amounts classified as short-term investments

 

 

 

$

144,233

 

 

$

411

 

 

$

(216

)

 

$

144,428

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total

 

 

Total

 

 

Total

 

 

Total

 

 

 

 

 

Amortized

 

 

Unrealized

 

 

Unrealized

 

 

Estimated

 

As of December 31, 2019:

 

Input Level

 

Cost

 

 

Gain

 

 

Loss

 

 

Fair Value

 

 

 

 

 

(in thousands)

 

Money market funds

 

Level 1

 

$

63,554

 

 

$

 

 

$

 

 

$

63,554

 

U.S. Treasury obligations

 

Level 2

 

 

52,805

 

 

 

46

 

 

 

(1

)

 

 

52,850

 

Government agency obligations

 

Level 2

 

 

6,151

 

 

 

1

 

 

 

(1

)

 

 

6,151

 

Corporate debt obligations

 

Level 2

 

 

100,512

 

 

 

180

 

 

 

(10

)

 

 

100,682

 

Commercial paper

 

Level 2

 

 

26,290

 

 

 

 

 

 

 

 

 

26,290

 

Asset-backed securities

 

Level 2

 

 

7,266

 

 

 

6

 

 

 

 

 

 

 

7,272

 

Certificates of deposit

 

Level 2

 

 

500

 

 

 

 

 

 

 

 

 

500

 

Total available-for-sale securities

 

 

 

 

257,078

 

 

 

233

 

 

 

(12

)

 

 

257,299

 

Less: amounts classified as cash equivalents

 

 

 

 

(72,507

)

 

 

 

 

 

 

 

 

(72,507

)

Amounts classified as short-term investments

 

 

 

$

184,571

 

 

$

233

 

 

$

(12

)

 

$

184,792

 

Amortized Cost and Fair Value of Available for Sale Securities by Contractual Maturity

The amortized cost and fair value of our available-for-sale securities by contractual maturity were as follows:

 

 

As of March 31, 2020

 

 

As of December 31, 2019

 

 

Amortized

 

 

Estimated

 

 

Amortized

 

 

Estimated

 

 

Cost

 

 

Fair Value

 

 

Cost

 

 

Fair Value

 

 

(in thousands)

 

 

(in thousands)

 

Maturing within one year

$

174,851

 

 

$

174,853

 

 

$

214,085

 

 

$

214,199

 

Maturing in one to five years

 

38,071

 

 

 

38,274

 

 

 

42,993

 

 

 

43,100

 

Total available-for-sale securities

$

212,922

 

 

$

213,127

 

 

$

257,078

 

 

$

257,299

 

Reconciliation of Cash, Cash Equivalents and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents and restricted cash within the condensed consolidated balance sheets that sum to the total of the same such amounts in the condensed consolidated statement of cash flows:

 

 

 

March 31,

 

 

December 31,

 

 

 

2020

 

 

2019

 

 

 

(in thousands)

 

Cash and cash equivalents

 

$

70,203

 

 

$

74,317

 

Restricted cash - short term

 

 

194

 

 

 

194

 

Restricted cash - long term

 

 

1,200

 

 

 

1,200

 

Total cash, cash equivalents and restricted cash

 

$

71,597

 

 

$

75,711

 

XML 41 R33.htm IDEA: XBRL DOCUMENT v3.20.1
Stockholders' Equity - Summary of RSU Activity (Detail) - Unvested RSUs
3 Months Ended
Mar. 31, 2020
$ / shares
shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Shares, Unvested as of December 31, 2019 | shares 1,910,764
Shares, Granted | shares 3,387,890
Shares, Forfeited | shares (85,851)
Shares, Vested | shares (552,498)
Shares, Outstanding as of March 31, 2020 | shares 4,660,305
Weighted Average Grant Date Fair Value, Unvested as of December 31, 2019 | $ / shares $ 26.93
Weighted Average Grant Date Fair Value, Granted | $ / shares 12.15
Weighted Average Grant Date Fair Value, Forfeited | $ / shares 18.66
Weighted Average Grant Date Fair Value, Vested | $ / shares 25.04
Weighted Average Grant Date Fair Value, Outstanding as of March 31, 2020 | $ / shares $ 16.56
ZIP 42 0001564590-20-021960-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-20-021960-xbrl.zip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

  •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�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end XML 43 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 44 R6.htm IDEA: XBRL DOCUMENT v3.20.1
    Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical) (Unaudited)
    $ in Thousands
    3 Months Ended
    Mar. 31, 2020
    USD ($)
    At The Market Offering | Common Stock  
    Stock issuance, discounts, commissions and offering costs $ 704
    XML 45 R2.htm IDEA: XBRL DOCUMENT v3.20.1
    Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
    $ in Thousands
    Mar. 31, 2020
    Dec. 31, 2019
    Current assets:    
    Cash and cash equivalents $ 70,203 $ 74,317
    Short-term investments 144,428 184,792
    Restricted cash - short-term 194 194
    Prepaid expenses and other current assets 14,392 13,689
    Total current assets 229,217 272,992
    Property and equipment, net 54,442 54,176
    Operating lease assets 13,691 14,007
    Restricted cash - long-term 1,200 1,200
    Other assets 997 567
    Total assets 299,547 342,942
    Current liabilities:    
    Accounts payable 8,079 7,963
    Accrued compensation 9,676 14,706
    Accrued research and development expenses 7,827 8,341
    Other current liabilities 5,938 5,733
    Total current liabilities 31,520 36,743
    Operating lease liabilities - long-term 13,809 14,136
    Other long-term liabilities 1,396 1,282
    Total liabilities 46,725 52,161
    Commitments and contingencies (Note 7)
    Stockholders’ equity:    
    Common stock—$0.0001 par value, 500,000 shares authorized as of March 31, 2020 and December 31, 2019; 58,940 and 56,806 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively 6 6
    Additional paid-in capital 1,144,082 1,108,516
    Accumulated other comprehensive income 204 220
    Accumulated deficit (891,470) (817,961)
    Total stockholders’ equity 252,822 290,781
    Total liabilities and stockholders’ equity $ 299,547 $ 342,942
    XML 46 R19.htm IDEA: XBRL DOCUMENT v3.20.1
    Property and Equipment (Tables)
    3 Months Ended
    Mar. 31, 2020
    Property Plant And Equipment [Abstract]  
    Schedule of Property and Equipment

    Property and equipment consisted of the following as of each period end:

     

     

     

    March 31,

     

     

    December 31,

     

     

     

    2020

     

     

    2019

     

     

     

    (in thousands)

     

    Leasehold improvements

     

    $

    49,703

     

     

    $

    49,028

     

    Lab equipment

     

     

    7,060

     

     

     

    6,815

     

    Machinery and equipment

     

     

    4,074

     

     

     

    3,832

     

    Computer equipment and software

     

     

    3,797

     

     

     

    3,299

     

    Furniture and fixtures

     

     

    2,019

     

     

     

    1,764

     

    Construction in progress

     

     

    1,356

     

     

     

    1,116

     

    Property and equipment, gross

     

     

    68,009

     

     

     

    65,854

     

    Less: accumulated depreciation and amortization

     

     

    (13,567

    )

     

     

    (11,678

    )

    Property and equipment, net

     

    $

    54,442

     

     

    $

    54,176

     

    XML 47 R15.htm IDEA: XBRL DOCUMENT v3.20.1
    Stockholders' Equity
    3 Months Ended
    Mar. 31, 2020
    Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]  
    Stockholders' Equity

    8.

    Stockholders’ Equity

    Our authorized capital stock consists of 520,000,000 shares, all with a par value of $0.0001 per share, of which 500,000,000 shares are designated as common stock and 20,000,000 shares are designated as preferred stock. There were no shares of preferred stock outstanding as of March 31, 2020 and December 31, 2019.

     

    As part of our July 2019 underwritten public offering, we issued and sold pre-funded warrants to purchase shares of common stock. Each pre-funded warrant entitles the holder to purchase one share of common stock at an exercise price of $0.0001 per share and expires seven years from the date of issuance. These warrants were recorded as a component of stockholders’ equity within additional paid-in capital. Per the terms of the warrant agreement, a holder of the outstanding warrants is not entitled to exercise any portion of any pre-funded warrant if, upon exercise of the warrant, the holder’s ownership (together with its affiliates) of our common stock or combined voting power of our securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% after giving effect to the exercise (“Maximum Ownership Percentage”). Upon at least 61 days’ prior notice to us by the holder, any holder may increase or decrease the Maximum Ownership Percentage to any other percentage not to exceed 19.99%. As of March 31, 2020, 2,888,526 pre-funded warrants were outstanding.

     

    ATM Facilities

     

    In February 2019, we entered into a sales agreement (the “2019 ATM Facility”) with Cowen and Company, LLC (“Cowen”), which provides for the sale, in our sole discretion, of shares of our common stock, in the aggregate offering price of up to $100.0 million through Cowen, as our sales agent. The issuance and sale of these shares by us pursuant to the 2019 ATM Facility are deemed “at the market” offerings as defined in Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”), and are registered under the Securities Act. We pay a commission of up to 3.0% of gross sales proceeds of any common stock sold under the 2019 ATM Facility.

     

    In February 2020, we entered into a new sales agreement (the “2020 ATM Facility”) with Cowen, which provides for the sale, in our sole discretion, of shares of our common stock having an aggregate offering price of up to $100.0 million through Cowen, as our sales agent. The 2020 ATM Facility is separate from and does not replace the 2019 ATM Facility in any way. The issuance and sale of these shares by us pursuant to the 2020 ATM Facility are deemed “at the market” offerings and are registered under the Securities Act of 1933, as amended. We will pay a commission of up to 3.0% of gross sales proceeds of any common stock sold under the 2020 ATM Facility.

     

    During the three months ended March 31, 2020, we sold an aggregate of 1,528,216 shares of common stock under the 2019 ATM Facility, at an average price of $15.50 per share, for gross proceeds of $23.7 million and net proceeds of $23.1 million, after deducting commissions and other offering expenses payable by us. Additionally, on January 3, 2020, we received net proceeds of approximately $1.2 million from sales of shares of common stock under the 2019 ATM Facility that occurred during 2019. As of March 31, 2020, $25.9 million and $100.0 million of common stock remained available to be sold under the 2019 ATM Facility and 2020 ATM Facility, respectively, subject to certain conditions as specified in the agreement.

     

    Equity Incentive Plans

    Under the terms of the 2014 Equity Incentive Plan, as amended (“2014 EIP”), we may grant stock options, restricted stock awards (“RSAs”) and RSUs to employees, directors, consultants and other service providers. RSUs generally vest over four years. In the first quarter of 2020, we granted performance-based RSUs to certain of our employees that provide for the issuance of common stock if specified Company performance criteria related to our clinical programs are achieved. The number of performance-based RSUs that ultimately vests depends upon if, when and which performance criteria are achieved, as well as the employee’s continuous service, as defined in the 2014 EIP, through the date of vesting. The fair value of performance-based RSUs is determined as the closing stock price on the date of grant.

    Stock options are granted at prices no less than 100% of the estimated fair value of the shares on the date of grant as determined by the board of directors, provided, however, that the exercise price of an option granted to a 10% shareholder cannot be less than 110% of the estimated fair value of the shares on the date of grant. Options granted generally vest over four years and expire in seven to ten years. As of March 31, 2020, a total of 14,316,451 shares of common stock were reserved for issuance under the 2014 EIP, of which 2,483,425 shares were available for future grant and 11,833,026 shares were subject to outstanding options and RSUs, including performance-based RSUs.

    In February 2018, we adopted the 2018 Inducement Plan (“Inducement Plan”), under which we may grant options, stock appreciation rights, RSAs and RSUs to new employees. As of March 31, 2020, 1,196,086 shares of common stock were reserved for issuance under the Inducement Plan, of which 272,336 shares were available for future grant and 923,750 shares were subject to outstanding options and RSUs.

    Restricted Stock Units

    The following is a summary of RSU activity under our 2014 EIP and Inducement Plan:

     

     

     

    RSUs

     

     

     

    Shares

     

     

    Weighted

    Average

    Grant Date Fair Value

     

    Unvested as of December 31, 2019

     

     

    1,910,764

     

     

    $

    26.93

     

    Granted

     

     

    3,387,890

     

     

    $

    12.15

     

    Forfeited

     

     

    (85,851

    )

     

    $

    18.66

     

    Vested

     

     

    (552,498

    )

     

    $

    25.04

     

    Unvested as of March 31, 2020

     

     

    4,660,305

     

     

    $

    16.56

     

     

    As of March 31, 2020, there was $63.9 million of unrecognized stock-based compensation expense related to RSUs that is expected to be recognized over a weighted average period of 2.9 years. This excludes unrecognized stock-based compensation expense for performance-based RSUs that were deemed not probable of vesting in accordance with U.S GAAP.

     

    Stock Options

    The following is a summary of stock option activity under our 2014 EIP and Inducement Plan. The table below also includes the activity relating to options for 275,000 shares of our common stock which were issued in 2017 outside of these plans:

     

     

     

    Shares

     

     

    Weighted Average

    Exercise Price

     

     

    Weighted Average

    Remaining

    Contractual Term

    (Years)

     

     

    Aggregate Intrinsic

    Value

    (in thousands)

     

    Outstanding as of December 31, 2019

     

     

    6,934,262

     

     

    $

    28.25

     

     

     

     

     

     

     

     

     

    Granted

     

     

    1,489,925

     

     

     

    12.91

     

     

     

     

     

     

     

     

     

    Exercised

     

     

    (93,719

    )

     

     

    14.19

     

     

     

     

     

     

     

     

     

    Forfeited or expired

     

     

    (233,997

    )

     

     

    32.28

     

     

     

     

     

     

     

     

     

    Outstanding as of March 31, 2020

     

     

    8,096,471

     

     

    $

    25.47

     

     

     

    6.5

     

     

    $

    -

     

     

    Aggregate intrinsic value represents the difference between the closing stock price of our common stock on March 31, 2020 and the exercise price of outstanding, in-the-money options. As of March 31, 2020, there was $71.1 million of unrecognized stock-based compensation expense related to stock options that is expected to be recognized over a weighted average period of 3.0 years.

    Reserved Shares

    The following shares of common stock were reserved for future issuance under our equity incentive plans as of March 31, 2020:

     

     

    Total Shares

    Reserved

     

    2014 Equity Incentive Plan

     

    14,316,451

     

    2018 Inducement Plan

     

    1,196,086

     

    2014 Employee Stock Purchase Plan

     

    1,233,317

     

    Total reserved shares of common stock

     

    16,745,854

     

     

    Stock-based Compensation Expense

    Total stock-based compensation expense related to all employee and non-employee stock awards was as follows:

     

     

    Three Months Ended March 31,

     

     

    2020

     

     

    2019

     

     

    (in thousands)

     

    Research and development

    $

    7,650

     

     

    $

    6,065

     

    General and administrative

     

    4,994

     

     

     

    6,204

     

    Total stock-based compensation expense

    $

    12,644

     

     

    $

    12,269

     

     

    XML 48 R11.htm IDEA: XBRL DOCUMENT v3.20.1
    Financial Instruments
    3 Months Ended
    Mar. 31, 2020
    Financial Instruments Disclosure [Abstract]  
    Financial Instruments

    4.

    Financial Instruments

    Our financial assets are measured at fair value on a recurring basis using the following hierarchy to prioritize valuation inputs, in accordance with applicable U.S. GAAP:

     

    Level 1:

    Quoted prices in active markets for identical assets or liabilities that we have the ability to access

     

    Level 2:

    Observable market-based inputs or unobservable inputs that are corroborated by market data such as quoted prices, interest rates and yield curves

     

    Level 3:

    Inputs that are unobservable data points that are not corroborated by market data

    We review the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels of certain securities within the fair value hierarchy. We recognize transfers into and out of levels within the fair value hierarchy in the period in which the actual event or change in circumstances that caused the transfer occurs. There have been no transfers between Level 1, Level 2 and Level 3 in any periods presented.

    Financial assets and liabilities are considered Level 2 when their fair values are determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis. U.S. Treasury, government agency and corporate debt obligations, commercial paper and asset-backed securities are valued primarily using market prices of comparable securities, bid/ask quotes, interest rate yields and prepayment spreads and are included in Level 2.

    Financial assets and liabilities are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies, or similar techniques, and at least one significant model assumption or input is unobservable. We have no Level 3 financial assets or liabilities.

    The following tables summarize the estimated fair value and related valuation input hierarchy of our available-for-sale securities as of each period end:

     

     

     

     

     

    Total

     

     

    Total

     

     

    Total

     

     

    Total

     

     

     

     

     

    Amortized

     

     

    Unrealized

     

     

    Unrealized

     

     

    Estimated

     

    As of March 31, 2020:

     

    Input Level

     

    Cost

     

     

    Gain

     

     

    Loss

     

     

    Fair Value

     

     

     

     

     

    (in thousands)

     

    Money market funds

     

    Level 1

     

    $

    42,382

     

     

    $

     

     

    $

     

     

    $

    42,382

     

    U.S. Treasury obligations

     

    Level 2

     

     

    58,993

     

     

     

    318

     

     

     

     

     

     

    59,311

     

    Government agency obligations

     

    Level 2

     

     

    6,686

     

     

     

    9

     

     

     

    (2

    )

     

     

    6,693

     

    Corporate debt obligations

     

    Level 2

     

     

    85,121

     

     

     

    92

     

     

     

    (210

    )

     

     

    85,003

     

    Commercial paper

     

    Level 2

     

     

    14,471

     

     

     

     

     

     

     

     

     

    14,471

     

    Asset-backed securities

     

    Level 2

     

     

    5,269

     

     

     

    2

     

     

     

    (4

    )

     

     

    5,267

     

    Total available-for-sale securities

     

     

     

     

    212,922

     

     

     

    421

     

     

     

    (216

    )

     

     

    213,127

     

    Less: amounts classified as cash equivalents

     

     

     

     

    (68,689

    )

     

     

    (10

    )

     

     

     

     

     

    (68,699

    )

    Amounts classified as short-term investments

     

     

     

    $

    144,233

     

     

    $

    411

     

     

    $

    (216

    )

     

    $

    144,428

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Total

     

     

    Total

     

     

    Total

     

     

    Total

     

     

     

     

     

    Amortized

     

     

    Unrealized

     

     

    Unrealized

     

     

    Estimated

     

    As of December 31, 2019:

     

    Input Level

     

    Cost

     

     

    Gain

     

     

    Loss

     

     

    Fair Value

     

     

     

     

     

    (in thousands)

     

    Money market funds

     

    Level 1

     

    $

    63,554

     

     

    $

     

     

    $

     

     

    $

    63,554

     

    U.S. Treasury obligations

     

    Level 2

     

     

    52,805

     

     

     

    46

     

     

     

    (1

    )

     

     

    52,850

     

    Government agency obligations

     

    Level 2

     

     

    6,151

     

     

     

    1

     

     

     

    (1

    )

     

     

    6,151

     

    Corporate debt obligations

     

    Level 2

     

     

    100,512

     

     

     

    180

     

     

     

    (10

    )

     

     

    100,682

     

    Commercial paper

     

    Level 2

     

     

    26,290

     

     

     

     

     

     

     

     

     

    26,290

     

    Asset-backed securities

     

    Level 2

     

     

    7,266

     

     

     

    6

     

     

     

     

     

     

     

    7,272

     

    Certificates of deposit

     

    Level 2

     

     

    500

     

     

     

     

     

     

     

     

     

    500

     

    Total available-for-sale securities

     

     

     

     

    257,078

     

     

     

    233

     

     

     

    (12

    )

     

     

    257,299

     

    Less: amounts classified as cash equivalents

     

     

     

     

    (72,507

    )

     

     

     

     

     

     

     

     

    (72,507

    )

    Amounts classified as short-term investments

     

     

     

    $

    184,571

     

     

    $

    233

     

     

    $

    (12

    )

     

    $

    184,792

     

     

    The amortized cost and fair value of our available-for-sale securities by contractual maturity were as follows:

     

     

    As of March 31, 2020

     

     

    As of December 31, 2019

     

     

    Amortized

     

     

    Estimated

     

     

    Amortized

     

     

    Estimated

     

     

    Cost

     

     

    Fair Value

     

     

    Cost

     

     

    Fair Value

     

     

    (in thousands)

     

     

    (in thousands)

     

    Maturing within one year

    $

    174,851

     

     

    $

    174,853

     

     

    $

    214,085

     

     

    $

    214,199

     

    Maturing in one to five years

     

    38,071

     

     

     

    38,274

     

     

     

    42,993

     

     

     

    43,100

     

    Total available-for-sale securities

    $

    212,922

     

     

    $

    213,127

     

     

    $

    257,078

     

     

    $

    257,299

     

     

    As of March 31, 2020, no significant facts or circumstances were present to indicate a deterioration in the creditworthiness of the issuers of the available-for-sale securities we hold, and the Company has no requirement or intention to sell these securities before maturity or recovery of their amortized cost basis. We considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic and determined that our investments were not significantly impacted. For all securities with a fair value less than its amortized cost basis, we determined the decline in fair value below amortized cost basis to be immaterial and non-credit related, and therefore no allowance for losses has been recorded. During the three months ended March 31, 2020 and 2019, we did not recognize any impairment losses on our investments.

    We have elected the practical expedient to exclude the applicable accrued interest from both the fair value and the amortized cost basis of our available-for-sale securities for purposes of identifying and measuring an impairment. We present accrued interest receivable related to our available-for-sale securities in prepaid expenses and other current assets, separate from short-term investments on our condensed consolidated balance sheet. As of March 31, 2020 and December 31, 2019, accrued interest receivable was $0.8 million and $0.9 million, respectively. Our accounting policy is to not measure an allowance for credit losses for accrued interest receivables and to write-off any uncollectible accrued interest receivable as a reversal of interest income in a timely manner, which we consider to be in the period in which we determine the accrued interest will not be collected by us. We have not written off any accrued interest receivables for the three months ended March 31, 2020 and 2019.

    In addition, restricted cash collateralized by money market funds is a financial asset measured at fair value and is a Level 1 financial instrument under the fair value hierarchy. As of March 31, 2020 and December 31, 2019, restricted cash was $1.4 million. 

    The following table provides a reconciliation of cash, cash equivalents and restricted cash within the condensed consolidated balance sheets that sum to the total of the same such amounts in the condensed consolidated statement of cash flows:

     

     

     

    March 31,

     

     

    December 31,

     

     

     

    2020

     

     

    2019

     

     

     

    (in thousands)

     

    Cash and cash equivalents

     

    $

    70,203

     

     

    $

    74,317

     

    Restricted cash - short term

     

     

    194

     

     

     

    194

     

    Restricted cash - long term

     

     

    1,200

     

     

     

    1,200

     

    Total cash, cash equivalents and restricted cash

     

    $

    71,597

     

     

    $

    75,711

     

     

    XML 49 R32.htm IDEA: XBRL DOCUMENT v3.20.1
    Stockholders' Equity - Additional Information (Detail) - USD ($)
    3 Months Ended 12 Months Ended
    Feb. 28, 2020
    Jan. 03, 2020
    Jul. 18, 2019
    Feb. 25, 2019
    Mar. 31, 2020
    Mar. 31, 2019
    Dec. 31, 2017
    Dec. 31, 2019
    Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
    Authorized capital stock         520,000,000      
    Common stock, par value         $ 0.0001     $ 0.0001
    Common stock, shares authorized         500,000,000     500,000,000
    Preferred stock, par value         $ 0.0001      
    Preferred stock, shares authorized         20,000,000      
    Preferred stock, shares outstanding         0     0
    Proceeds from sale of common stock, net         $ 24,277,000 $ 0    
    Stock option granted description terms         the exercise price of an option granted to a 10% shareholder cannot be less than 110% of the estimated fair value of the shares on the date of grant. Options granted generally vest over four years and expire in seven to ten years.      
    Ownership percent         10.00%      
    Shares of common stock, reserved for issuance         16,745,854      
    2014 Equity Incentive Plan                
    Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
    Shares of common stock, reserved for issuance         14,316,451      
    Aggregate number of awards available for grant to be issued         2,483,425      
    Outstanding options and RSUs         11,833,026      
    Inducement Plan                
    Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
    Shares of common stock, reserved for issuance         1,196,086      
    Aggregate number of awards available for grant to be issued         272,336      
    Outstanding options and RSUs         923,750      
    Restricted Stock Units (RSUs)                
    Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
    Unrecognized stock-based compensation expense         $ 63,900,000      
    Unrecognized stock-based compensation weighted average recognition period         2 years 10 months 24 days      
    Restricted Stock Units (RSUs) | From Date Of Grant                
    Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
    Share based compensation, vesting period         4 years      
    Employees And Non Employees                
    Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
    Share based compensation, vesting period         4 years      
    Vested and Unvested Options                
    Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
    Unrecognized stock-based compensation weighted average recognition period         3 years      
    Stock options, issued             275,000  
    Unrecognized stock-based compensation         $ 71,100,000      
    Maximum | Employees And Non Employees                
    Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
    Share based compensation award expiration period         10 years      
    Minimum                
    Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
    Percentage of employees purchase price of common stock         100.00%      
    Minimum | 10% Shareholder                
    Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
    Percentage of employees purchase price of common stock         110.00%      
    Minimum | Employees And Non Employees                
    Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
    Share based compensation award expiration period         7 years      
    Underwritten Public Offering                
    Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
    Warrants outstanding         2,888,526,000      
    Underwritten Public Offering | Warrant                
    Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
    Number of securities called by each warrant     1          
    Warrants, exercise price     $ 0.0001          
    Warrants, term     7 years          
    Maximum ownership Percentage     9.99%          
    Underwritten Public Offering | Warrant | Maximum                
    Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
    Maximum ownership Percentage     19.99%          
    Underwritten Public Offering | Warrant | Minimum                
    Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
    Prior notice period     61 days          
    At The Market Offering | Cowen                
    Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
    Common stock, shares issued         1,528,216      
    Common stock average price         $ 15.50      
    Proceeds from sale of common stock, gross         $ 23,700,000      
    Proceeds from sale of common stock, net   $ 1,200,000     23,100,000      
    At The Market Offering | Maximum | Cowen                
    Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
    Common stock aggregate offering price $ 100,000,000.0     $ 100,000,000.0        
    Percentage of commission to be paid on gross sales proceeds of common stock sold 3.00%     3.00%        
    2019 ATM Facility | Cowen                
    Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
    Common stock value remaining to be sold         25,900,000      
    2020 ATM Facility | Cowen                
    Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
    Common stock value remaining to be sold         $ 100,000,000.0      
    XML 50 R36.htm IDEA: XBRL DOCUMENT v3.20.1
    Stockholders' Equity - Schedule of Stock-based Compensation Related to All Employee And Non-employee Stock Awards (Detail) - USD ($)
    $ in Thousands
    3 Months Ended
    Mar. 31, 2020
    Mar. 31, 2019
    Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]    
    Total stock-based compensation expense $ 12,644 $ 12,269
    Research and development    
    Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]    
    Total stock-based compensation expense 7,650 6,065
    General and administrative    
    Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]    
    Total stock-based compensation expense $ 4,994 $ 6,204
    XML 51 R27.htm IDEA: XBRL DOCUMENT v3.20.1
    Financial Instruments - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail) - USD ($)
    $ in Thousands
    Mar. 31, 2020
    Dec. 31, 2019
    Mar. 31, 2019
    Dec. 31, 2018
    Financial Instruments Disclosure [Abstract]        
    Cash and cash equivalents $ 70,203 $ 74,317    
    Restricted cash - short-term 194 194    
    Restricted cash - long-term 1,200 1,200    
    Total cash, cash equivalents and restricted cash $ 71,597 $ 75,711 $ 57,562 $ 62,092
    JSON 52 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "atra-10q_20200331.htm": { "axisCustom": 0, "axisStandard": 15, "contextCount": 110, "dts": { "calculationLink": { "local": [ "atra-20200331_cal.xml" ] }, "definitionLink": { "local": [ "atra-20200331_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "atra-10q_20200331.htm" ] }, "labelLink": { "local": [ "atra-20200331_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "atra-20200331_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml" ] }, "schema": { "local": [ "atra-20200331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 330, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2019-01-31": 3, "http://xbrl.sec.gov/dei/2019-01-31": 6, "total": 9 }, "keyCustom": 36, "keyStandard": 235, "memberCustom": 16, "memberStandard": 28, "nsprefix": "atra", "nsuri": "http://www.atarabio.com/20200331", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.atarabio.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Net Loss per Common Share", "role": "http://www.atarabio.com/20200331/taxonomy/role/DisclosureNetLossPerCommonShare", "shortName": "Net Loss per Common Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Financial Instruments", "role": "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstruments", "shortName": "Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Property and Equipment", "role": "http://www.atarabio.com/20200331/taxonomy/role/DisclosurePropertyAndEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - License and Collaboration Agreements", "role": "http://www.atarabio.com/20200331/taxonomy/role/DisclosureLicenseAndCollaborationAgreements", "shortName": "License and Collaboration Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Commitments and Contingencies", "role": "http://www.atarabio.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Stockholders' Equity", "role": "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.atarabio.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Net Loss per Common Share (Tables)", "role": "http://www.atarabio.com/20200331/taxonomy/role/DisclosureNetLossPerCommonShareTables", "shortName": "Net Loss per Common Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "atra:SummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Financial Instruments (Tables)", "role": "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsTables", "shortName": "Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "atra:SummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Property and Equipment (Tables)", "role": "http://www.atarabio.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "role": "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200331", "decimals": "-3", "lang": null, "name": "us-gaap:ShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Stockholders' Equity (Tables)", "role": "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityTables", "shortName": "Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityIncorporationStateCountryCode", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Description of Business (Detail)", "role": "http://www.atarabio.com/20200331/taxonomy/role/DisclosureDescriptionOfBusinessDetail", "shortName": "Description of Business (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R22": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)", "role": "http://www.atarabio.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R23": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200101_20200331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Net Loss per Common Share - Antidilutive Securities Excluded From Computation of Diluted Net Loss per Common Share (Detail)", "role": "http://www.atarabio.com/20200331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail", "shortName": "Net Loss per Common Share - Antidilutive Securities Excluded From Computation of Diluted Net Loss per Common Share (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200101_20200331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Financial Instruments - Summary of Estimated Fair Value and Related Valuation Input Hierarchy of Available-for-Sale Securities (Detail)", "role": "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail", "shortName": "Financial Instruments - Summary of Estimated Fair Value and Related Valuation Input Hierarchy of Available-for-Sale Securities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "atra:SummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200331", "decimals": "-3", "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Financial Instruments - Amortized Cost and Fair Value of Available-for-Sale Securities by Contractual Maturity (Detail)", "role": "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsAmortizedCostAndFairValueOfAvailableForSaleSecuritiesByContractualMaturityDetail", "shortName": "Financial Instruments - Amortized Cost and Fair Value of Available-for-Sale Securities by Contractual Maturity (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200331", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InterestReceivable", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Financial Instruments - Additional Information (Detail)", "role": "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail", "shortName": "Financial Instruments - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200331", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InterestReceivable", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Financial Instruments - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail)", "role": "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetail", "shortName": "Financial Instruments - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R28": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Detail)", "role": "http://www.atarabio.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail", "shortName": "Property and Equipment - Schedule of Property and Equipment (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200101_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Property and Equipment - Additional Information (Detail)", "role": "http://www.atarabio.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetail", "shortName": "Property and Equipment - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R3": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited)", "role": "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200331", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200331", "decimals": "0", "first": true, "lang": null, "name": "atra:DueToLicensorsCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - License and Collaboration Agreements - Additional Information (Detail)", "role": "http://www.atarabio.com/20200331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail", "shortName": "License and Collaboration Agreements - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200331", "decimals": "0", "first": true, "lang": null, "name": "atra:DueToLicensorsCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200331", "decimals": "INF", "first": true, "lang": null, "name": "atra:AccruedTerminationCharges", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "role": "http://www.atarabio.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200331", "decimals": "INF", "first": true, "lang": null, "name": "atra:AccruedTerminationCharges", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CapitalUnitsAuthorized", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Stockholders' Equity - Additional Information (Detail)", "role": "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "shortName": "Stockholders' Equity - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CapitalUnitsAuthorized", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Stockholders' Equity - Summary of RSU Activity (Detail)", "role": "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquitySummaryOfRSUActivityDetail", "shortName": "Stockholders' Equity - Summary of RSU Activity (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20191231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Detail)", "role": "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail", "shortName": "Stockholders' Equity - Summary of Stock Option Activity (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20191231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "atra:CommonStockReservedForFutureIssuanceTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Stockholders' Equity - Schedule of Common Stock Reserved for Future Issuance Under Equity Incentive Plans (Detail)", "role": "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceUnderEquityIncentivePlansDetail", "shortName": "Stockholders' Equity - Schedule of Common Stock Reserved for Future Issuance Under Equity Incentive Plans (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "atra:CommonStockReservedForFutureIssuanceTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_us-gaapPlanNameAxis_atraTwoThousandEighteenInducementPlanMember_20200331", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200101_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Stockholders' Equity - Schedule of Stock-based Compensation Related to All Employee And Non-employee Stock Awards (Detail)", "role": "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationRelatedToAllEmployeeAndNonEmployeeStockAwardsDetail", "shortName": "Stockholders' Equity - Schedule of Stock-based Compensation Related to All Employee And Non-employee Stock Awards (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200101_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200101_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "role": "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200101_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20181231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)", "role": "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited", "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20181231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20200101_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical) (Unaudited)", "role": "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParentheticalUnaudited", "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical) (Unaudited)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20200101_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200101_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100060 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200101_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "atra:BusinessDescriptionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100080 - Disclosure - Description of Business", "role": "http://www.atarabio.com/20200331/taxonomy/role/DisclosureDescriptionOfBusiness", "shortName": "Description of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "atra:BusinessDescriptionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.atarabio.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "atra-10q_20200331.htm", "contextRef": "C_0001604464_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 46, "tag": { "atra_AccruedCostsOfFinancingActivitiesChargedToStockholdersEquity": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued costs charged to stockholders' equity.", "label": "Accrued Costs Of Financing Activities Charged To Stockholders Equity", "terseLabel": "Accrued costs related to ATM facilities" } } }, "localname": "AccruedCostsOfFinancingActivitiesChargedToStockholdersEquity", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "atra_AccruedResearchAndDevelopmentExpensesCurrent": { "auth_ref": [], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10130.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued research and development expenses current.", "label": "Accrued Research And Development Expenses Current", "terseLabel": "Accrued research and development expenses" } } }, "localname": "AccruedResearchAndDevelopmentExpensesCurrent", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "atra_AccruedTerminationCharges": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued termination charges.", "label": "Accrued Termination Charges", "terseLabel": "Accrued termination charges" } } }, "localname": "AccruedTerminationCharges", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "atra_AggregateOfferingPriceOfCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Aggregate Offering Price of common stock.", "label": "Aggregate Offering Price Of Common Stock", "terseLabel": "Common stock aggregate offering price" } } }, "localname": "AggregateOfferingPriceOfCommonStock", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "atra_AtTheMarketOfferingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "At the market offering.", "label": "At The Market Offering [Member]", "terseLabel": "At The Market Offering" } } }, "localname": "AtTheMarketOfferingMember", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParentheticalUnaudited", "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "atra_BusinessDescriptionTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the business description concept. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.", "label": "Business Description [Text Block]", "terseLabel": "Description of Business" } } }, "localname": "BusinessDescriptionTextBlock", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureDescriptionOfBusiness" ], "xbrltype": "textBlockItemType" }, "atra_CashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail": { "order": 10010.0, "parentTag": "atra_CashEquivalentsAmortizedCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Cash equivalents, accumulated gross unrealized gain, before tax.", "label": "Cash Equivalents Accumulated Gross Unrealized Gain Before Tax", "negatedLabel": "Total Unrealized Gain" } } }, "localname": "CashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail" ], "xbrltype": "monetaryItemType" }, "atra_CashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail": { "order": 10020.0, "parentTag": "atra_CashEquivalentsAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash equivalents, accumulated gross unrealized loss, before tax.", "label": "Cash Equivalents Accumulated Gross Unrealized Loss Before Tax", "terseLabel": "Total Unrealized Loss" } } }, "localname": "CashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail" ], "xbrltype": "monetaryItemType" }, "atra_CashEquivalentsAmortizedCost": { "auth_ref": [], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash equivalents, amortized cost.", "label": "Cash Equivalents Amortized Cost", "negatedTotalLabel": "Total Amortized Cost" } } }, "localname": "CashEquivalentsAmortizedCost", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail" ], "xbrltype": "monetaryItemType" }, "atra_CashEquivalentsFairValue": { "auth_ref": [], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail": { "order": 10030.0, "parentTag": "atra_CashEquivalentsAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash equivalents, fair value.", "label": "Cash Equivalents Fair Value", "negatedLabel": "Total Fair Value" } } }, "localname": "CashEquivalentsFairValue", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail" ], "xbrltype": "monetaryItemType" }, "atra_ClassOfWarrantOrRightTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Class of warrant or right, term.", "label": "Class Of Warrant Or Right Term", "terseLabel": "Warrants, term" } } }, "localname": "ClassOfWarrantOrRightTerm", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "atra_CommonStockAveragePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Common stock average price.", "label": "Common Stock Average Price", "terseLabel": "Common stock average price" } } }, "localname": "CommonStockAveragePrice", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "atra_CommonStockReservedForFutureIssuanceTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Common stock reserved for future issuance.", "label": "Common Stock Reserved For Future Issuance Table [Text Block]", "terseLabel": "Schedule of Common Stock Reserved for Future Issuance Under Equity Incentive Plans" } } }, "localname": "CommonStockReservedForFutureIssuanceTableTextBlock", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "atra_CommonStockValueRemainedAvailableToBeSold": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Common stock value remained available to be sold.", "label": "Common Stock Value Remained Available To Be Sold", "terseLabel": "Common stock value remaining to be sold" } } }, "localname": "CommonStockValueRemainedAvailableToBeSold", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "atra_ComputerEquipmentAndSoftwareMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Computer equipment and software.", "label": "Computer Equipment And Software [Member]", "terseLabel": "Computer Equipment and Software" } } }, "localname": "ComputerEquipmentAndSoftwareMember", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "atra_CowenAndCompanyLimitedLiabilityCompanyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cowen and Company Limited Liability Company.", "label": "Cowen And Company Limited Liability Company [Member]", "terseLabel": "Cowen" } } }, "localname": "CowenAndCompanyLimitedLiabilityCompanyMember", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "atra_DueToLicensorsCurrentAndNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all licensors.", "label": "Due To Licensors Current And Noncurrent", "terseLabel": "Contractual obligations due to MSK and QIMR" } } }, "localname": "DueToLicensorsCurrentAndNoncurrent", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "atra_EmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Employee stock purchase plan.", "label": "Employee Stock Purchase Plan [Member]", "terseLabel": "ESPP Share Purchase Rights" } } }, "localname": "EmployeeStockPurchasePlanMember", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail" ], "xbrltype": "domainItemType" }, "atra_EmployeesAndNonEmployeesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Employees and non-employees.", "label": "Employees And Non Employees [Member]", "terseLabel": "Employees And Non Employees" } } }, "localname": "EmployeesAndNonEmployeesMember", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "atra_FinanceLeaseAssetsObtainedInExchangeForLeaseObligations": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Finance lease assets obtained in exchange for lease obligations.", "label": "Finance Lease Assets Obtained In Exchange For Lease Obligations", "terseLabel": "Finance lease assets obtained in exchange for lease obligations" } } }, "localname": "FinanceLeaseAssetsObtainedInExchangeForLeaseObligations", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "atra_FinancialInstrumentsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "financial instruments disclosure.", "label": "Financial Instruments Disclosure [Abstract]" } } }, "localname": "FinancialInstrumentsDisclosureAbstract", "nsuri": "http://www.atarabio.com/20200331", "xbrltype": "stringItemType" }, "atra_FromDateOfGrantMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Expire from date of grant.", "label": "From Date Of Grant [Member]", "terseLabel": "From Date Of Grant" } } }, "localname": "FromDateOfGrantMember", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "atra_IncreaseDecreaseInAccruedResearchAndDevelopment": { "auth_ref": [], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10220.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Increase (decrease) in accrued research and development.", "label": "Increase Decrease In Accrued Research And Development", "terseLabel": "Accrued research and development expenses" } } }, "localname": "IncreaseDecreaseInAccruedResearchAndDevelopment", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "atra_IncreaseDecreaseInOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10240.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Increase (decrease) in operating lease liabilities.", "label": "Increase Decrease In Operating Lease Liabilities", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "atra_InducementPlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Inducement plan.", "label": "Inducement Plan [Member]", "terseLabel": "Inducement Plan" } } }, "localname": "InducementPlanMember", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "atra_IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Issuance of Common Stock, Net of Commissions and Offering Costs, Shares.", "label": "Issuance Of Common Stock Net Of Commissions And Offering Costs Shares", "terseLabel": "Issuance of common stock, net of commissions and offering costs, shares" } } }, "localname": "IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsShares", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "atra_IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Issuance of common stock, net of commissions and offering costs, value.", "label": "Issuance Of Common Stock Net Of Commissions And Offering Costs Value", "terseLabel": "Issuance of common stock, net of commissions and offering costs, value" } } }, "localname": "IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "atra_IssuanceOfCommonStockPursuantToEmployeeStockAwardsShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Issuance of common stock pursuant to employee stock awards shares.", "label": "Issuance Of Common Stock Pursuant To Employee Stock Awards Shares", "terseLabel": "Issuance of common stock pursuant to employee stock awards, shares" } } }, "localname": "IssuanceOfCommonStockPursuantToEmployeeStockAwardsShares", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "atra_IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Issuance of common stock pursuant to employee stock awards value.", "label": "Issuance Of Common Stock Pursuant To Employee Stock Awards Value", "terseLabel": "Issuance of common stock pursuant to employee stock awards" } } }, "localname": "IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "atra_LiabilitiesRelatedToIndemnificationAgreements": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Liabilities related to indemnification agreements.", "label": "Liabilities Related To Indemnification Agreements", "terseLabel": "Liabilities related to indemnification agreements" } } }, "localname": "LiabilitiesRelatedToIndemnificationAgreements", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "atra_LicenseCollaborationAndManufacturingAgreementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "License, collaboration and manufacturing agreements.", "label": "License Collaboration And Manufacturing Agreements [Abstract]" } } }, "localname": "LicenseCollaborationAndManufacturingAgreementsAbstract", "nsuri": "http://www.atarabio.com/20200331", "xbrltype": "stringItemType" }, "atra_LicenseCollaborationAndManufacturingAgreementsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "License, collaboration and manufacturing agreements.", "label": "License Collaboration And Manufacturing Agreements [Line Items]", "terseLabel": "License Collaboration And Manufacturing Agreements [Line Items]" } } }, "localname": "LicenseCollaborationAndManufacturingAgreementsLineItems", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "atra_LiquidityAndGoingConcernPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Liquidity and Going Concern.", "label": "Liquidity And Going Concern Policy [Text Block]", "terseLabel": "Liquidity and Going Concern" } } }, "localname": "LiquidityAndGoingConcernPolicyTextBlock", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "atra_MaximumOwnershipPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Maximum ownership percentage.", "label": "Maximum Ownership Percentage", "terseLabel": "Maximum ownership Percentage" } } }, "localname": "MaximumOwnershipPercentage", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "atra_MemorialSloanKetteringCancerCenterAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "MSK agreement.", "label": "Memorial Sloan Kettering Cancer Center Agreement [Member]", "terseLabel": "MSK Agreements" } } }, "localname": "MemorialSloanKetteringCancerCenterAgreementMember", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "atra_NonCashOperatingLeaseExpense": { "auth_ref": [], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10160.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Non cash operating lease expense.", "label": "Non Cash Operating Lease Expense", "terseLabel": "Non-cash operating lease expense" } } }, "localname": "NonCashOperatingLeaseExpense", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "atra_PaymentsForResearchAndDevelopment": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payments for research and development.", "label": "Payments For Research And Development", "verboseLabel": "Payments for research and development" } } }, "localname": "PaymentsForResearchAndDevelopment", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "atra_PercentageOfCommissionToBePaidOnGrossSalesProceedsOfCommonStockSold": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of commission to be paid on gross sales proceeds of common stock sold.", "label": "Percentage Of Commission To Be Paid On Gross Sales Proceeds Of Common Stock Sold", "terseLabel": "Percentage of commission to be paid on gross sales proceeds of common stock sold" } } }, "localname": "PercentageOfCommissionToBePaidOnGrossSalesProceedsOfCommonStockSold", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "atra_PotentialMilestonePaymentsPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Potential milestone payments payable.", "label": "Potential Milestone Payments Payable", "terseLabel": "Potential milestone payments payable" } } }, "localname": "PotentialMilestonePaymentsPayable", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "atra_PriorNoticePeriodToIncreaseOrDecreaseMaximumOwnershipPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Prior notice period to increase or decrease maximum ownership percentage.", "label": "Prior Notice Period To Increase Or Decrease Maximum Ownership Percentage", "terseLabel": "Prior notice period" } } }, "localname": "PriorNoticePeriodToIncreaseOrDecreaseMaximumOwnershipPercentage", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "atra_ProceedsFromIssuanceOfCommonStockGross": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds from issuance of common stock gross.", "label": "Proceeds From Issuance Of Common Stock Gross", "verboseLabel": "Proceeds from sale of common stock, gross" } } }, "localname": "ProceedsFromIssuanceOfCommonStockGross", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "atra_ReceivableForOptionsExercised": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Receivable for options exercised.", "label": "Receivable For Options Exercised", "terseLabel": "Receivable for options exercised" } } }, "localname": "ReceivableForOptionsExercised", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "atra_ScheduleOfLicenseCollaborationAndManufacturingAgreementsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of license, collaboration and manufacturing agreements.", "label": "Schedule Of License Collaboration And Manufacturing Agreements [Table]", "terseLabel": "Schedule Of License Collaboration And Manufacturing Agreements [Table]" } } }, "localname": "ScheduleOfLicenseCollaborationAndManufacturingAgreementsTable", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAndRestrictedStockUnitsOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments options and restricted stock units outstanding.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options And Restricted Stock Units Outstanding", "terseLabel": "Outstanding options and RSUs" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAndRestrictedStockUnitsOutstanding", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "atra_ShareholderOwnershipPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Shareholders ownership percent.", "label": "Shareholder Ownership Percent", "terseLabel": "Ownership percent" } } }, "localname": "ShareholderOwnershipPercent", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "atra_StockIssuedDuringPeriodSharesStockOptionsExercisedOfPreFundedWarrants": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock issued during period shares stock options exercised of pre-funded warrants.", "label": "Stock Issued During Period Shares Stock Options Exercised Of Pre Funded Warrants", "terseLabel": "Exercise of pre-funded warrants, shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercisedOfPreFundedWarrants", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "atra_StockIssuedDuringPeriodValueStockOptionsExercisedOfPreFundedWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Stock issued during period value stock options exercised of pre funded warrants.", "label": "Stock Issued During Period Value Stock Options Exercised Of Pre Funded Warrants", "terseLabel": "Exercise of pre-funded warrants" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedOfPreFundedWarrants", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "atra_SummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Summary of estimated fair value and related valuation input hierarchy of available-for-sale securities.", "label": "Summary Of Estimated Fair Value And Related Valuation Input Hierarchy Of Available For Sale Securities Table [Text Block]", "terseLabel": "Summary of Estimated Fair Value and Related Valuation Input Hierarchy of Available-for-Sale Securities" } } }, "localname": "SummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesTableTextBlock", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "atra_TenPercentShareHolderMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Ten percent share holder.", "label": "Ten Percent Share Holder [Member]", "terseLabel": "10% Shareholder" } } }, "localname": "TenPercentShareHolderMember", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "atra_TwoThousandAndFourteenEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two thousand and fourteen equity incentive plan.", "label": "Two Thousand And Fourteen Equity Incentive Plan [Member]", "terseLabel": "2014 Equity Incentive Plan" } } }, "localname": "TwoThousandAndFourteenEquityIncentivePlanMember", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceUnderEquityIncentivePlansDetail" ], "xbrltype": "domainItemType" }, "atra_TwoThousandEighteenInducementPlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two thousand eighteen inducement plan.", "label": "Two Thousand Eighteen Inducement Plan [Member]", "terseLabel": "2018 Inducement Plan" } } }, "localname": "TwoThousandEighteenInducementPlanMember", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceUnderEquityIncentivePlansDetail" ], "xbrltype": "domainItemType" }, "atra_TwoThousandFourteenEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two thousand fourteen employee stock purchase plan.", "label": "Two Thousand Fourteen Employee Stock Purchase Plan [Member]", "terseLabel": "2014 Employee Stock Purchase Plan" } } }, "localname": "TwoThousandFourteenEmployeeStockPurchasePlanMember", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceUnderEquityIncentivePlansDetail" ], "xbrltype": "domainItemType" }, "atra_TwoThousandFourteenEquityIncentivePlanAndInducementPlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2014 EIP and Inducement Plan.", "label": "Two Thousand Fourteen Equity Incentive Plan And Inducement Plan [Member]", "terseLabel": "2014 EIP and Inducement Plan" } } }, "localname": "TwoThousandFourteenEquityIncentivePlanAndInducementPlanMember", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" ], "xbrltype": "domainItemType" }, "atra_TwoThousandNineteenAtTheMarketOfferingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two thousand nineteen at the market offering.", "label": "Two Thousand Nineteen At The Market Offering [Member]", "terseLabel": "2019 ATM Facility" } } }, "localname": "TwoThousandNineteenAtTheMarketOfferingMember", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "atra_TwoThousandTwentyAtTheMarketOfferingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two thousand twenty at the market offering.", "label": "Two Thousand Twenty At The Market Offering [Member]", "terseLabel": "2020 ATM Facility" } } }, "localname": "TwoThousandTwentyAtTheMarketOfferingMember", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "atra_UnderwrittenPublicOfferingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Underwritten public offering.", "label": "Underwritten Public Offering [Member]", "terseLabel": "Underwritten Public Offering" } } }, "localname": "UnderwrittenPublicOfferingMember", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "atra_WriteOffOfAccruedInterestReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Write off of accrued interest receivable.", "label": "Write Off Of Accrued Interest Receivable", "terseLabel": "Write off, of accrued interest receivable" } } }, "localname": "WriteOffOfAccruedInterestReceivable", "nsuri": "http://www.atarabio.com/20200331", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r231" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r232" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "verboseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r233" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r233" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r233" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationDateOfIncorporation": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Date when an entity was incorporated", "label": "Entity Incorporation Date Of Incorporation", "terseLabel": "Entity incorporation date" } } }, "localname": "EntityIncorporationDateOfIncorporation", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureDescriptionOfBusinessDetail" ], "xbrltype": "dateItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code", "verboseLabel": "Entity incorporation state" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureDescriptionOfBusinessDetail", "http://www.atarabio.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r234" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r233" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r233" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r233" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r233" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r229" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r230" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r35", "r73" ], "lang": { "en-US": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Member]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Repurchase Agreement Counterparty Name [Domain]", "terseLabel": "Counterparty Name" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r92", "r194" ], "lang": { "en-US": { "role": { "label": "Title Of Individual [Axis]", "terseLabel": "Title of Individual" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Title Of Individual With Relationship To Entity [Domain]", "terseLabel": "Title of Individual" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r24" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10110.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionExpense": { "auth_ref": [ "r123", "r124" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10170.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.", "label": "Accretion Expense", "terseLabel": "Asset retirement obligation accretion expense" } } }, "localname": "AccretionExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r22", "r119" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail": { "order": 10020.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment", "negatedLabel": "Less: accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r38", "r39", "r40" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10060.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income Loss Net Of Tax", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r37", "r40", "r41", "r180" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Income [Member]", "terseLabel": "Accumulated Other Comprehensive (Loss) Income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r13" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10050.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid In Capital Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid In Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r144", "r146", "r170", "r171" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "auth_ref": [ "r132", "r139" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.", "label": "Adjustments To Additional Paid In Capital Stock Issued Issuance Costs", "terseLabel": "Stock issuance, discounts, commissions and offering costs" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParentheticalUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r146", "r166", "r169" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share Based Compensation Expense", "verboseLabel": "Total stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationRelatedToAllEmployeeAndNonEmployeeStockAwardsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r80" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r80" ], "lang": { "en-US": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r80" ], "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Arrangements And Nonarrangement Transactions [Member]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AssetBackedSecuritiesMember": { "auth_ref": [ "r104", "r141" ], "lang": { "en-US": { "role": { "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.", "label": "Asset Backed Securities [Member]", "terseLabel": "Asset-Backed Securities" } } }, "localname": "AssetBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r90", "r199", "r214" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r1", "r2", "r34" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10150.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r97" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail": { "order": 10040.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax", "terseLabel": "Total Unrealized Gain" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r98" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail": { "order": 10050.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax", "negatedLabel": "Total Unrealized Loss" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r95", "r114" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Debt Securities Amortized Cost Basis", "totalLabel": "Total Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": { "auth_ref": [ "r102" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsAmortizedCostAndFairValueOfAvailableForSaleSecuritiesByContractualMaturityDetail": { "order": 10040.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost", "terseLabel": "Maturing in one to five years, Amortized cost" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsAmortizedCostAndFairValueOfAvailableForSaleSecuritiesByContractualMaturityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "auth_ref": [ "r99", "r102", "r210" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsAmortizedCostAndFairValueOfAvailableForSaleSecuritiesByContractualMaturityDetail": { "order": 10020.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Available For Sale Securities Debt Maturities After One Through Five Years Fair Value", "terseLabel": "Maturing in one to five years, Estimated fair value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsAmortizedCostAndFairValueOfAvailableForSaleSecuritiesByContractualMaturityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Available For Sale Securities Debt Maturities Fair Value [Abstract]", "terseLabel": "Estimated Fair value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsAmortizedCostAndFairValueOfAvailableForSaleSecuritiesByContractualMaturityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis": { "auth_ref": [ "r99", "r103", "r211" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsAmortizedCostAndFairValueOfAvailableForSaleSecuritiesByContractualMaturityDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.", "label": "Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis", "totalLabel": "Total available-for-sale securities, Amortized cost" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsAmortizedCostAndFairValueOfAvailableForSaleSecuritiesByContractualMaturityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis [Abstract]", "terseLabel": "Amortized cost" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsAmortizedCostAndFairValueOfAvailableForSaleSecuritiesByContractualMaturityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "auth_ref": [ "r101" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsAmortizedCostAndFairValueOfAvailableForSaleSecuritiesByContractualMaturityDetail": { "order": 10030.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Available For Sale Securities Debt Maturities Within One Year Amortized Cost", "terseLabel": "Maturing within one year, Amortized cost" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsAmortizedCostAndFairValueOfAvailableForSaleSecuritiesByContractualMaturityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r99", "r101", "r209" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsAmortizedCostAndFairValueOfAvailableForSaleSecuritiesByContractualMaturityDetail": { "order": 10010.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Available For Sale Securities Debt Maturities Within One Year Fair Value", "terseLabel": "Maturing within one year, Estimated fair value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsAmortizedCostAndFairValueOfAvailableForSaleSecuritiesByContractualMaturityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r94", "r96", "r114" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsAmortizedCostAndFairValueOfAvailableForSaleSecuritiesByContractualMaturityDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail": { "order": 10060.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Securities Debt Securities", "terseLabel": "Total Fair Value", "totalLabel": "Total available-for-sale securities, Estimated fair value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsAmortizedCostAndFairValueOfAvailableForSaleSecuritiesByContractualMaturityDetail", "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r147", "r168" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquitySummaryOfRSUActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis Of Accounting Policy Policy [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r69", "r70", "r71" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred But Not Yet Paid", "terseLabel": "Property and equipment purchases included in accounts payable and other accrued liabilities" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalUnitsAuthorized": { "auth_ref": [ "r222" ], "lang": { "en-US": { "role": { "documentation": "Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.", "label": "Capital Units Authorized", "terseLabel": "Authorized capital stock" } } }, "localname": "CapitalUnitsAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r0", "r20", "r67" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetail": { "order": 10010.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 }, "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10200.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash And Cash Equivalents At Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetail", "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r61", "r67", "r72" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period", "totalLabel": "Total cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetail", "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r61", "r189" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect", "totalLabel": "Decrease in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsMember": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Equivalents [Member]", "terseLabel": "Amounts Classified As Cash Equivalents" } } }, "localname": "CashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]", "terseLabel": "Non-cash investing and financing activities" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_CertificatesOfDepositMember": { "auth_ref": [ "r212" ], "lang": { "en-US": { "role": { "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.", "label": "Certificates Of Deposit [Member]", "terseLabel": "Certificates of Deposit" } } }, "localname": "CertificatesOfDepositMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class Of Stock [Line Items]", "terseLabel": "Class Of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceUnderEquityIncentivePlansDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r75" ], "lang": { "en-US": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1", "terseLabel": "Warrants, exercise price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right", "terseLabel": "Number of securities called by each warrant" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [ "r76" ], "lang": { "en-US": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class Of Warrant Or Right Outstanding", "terseLabel": "Warrants outstanding" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r173", "r174", "r176" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "License and Collaboration Agreements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureLicenseAndCollaborationAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r128" ], "lang": { "en-US": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r29", "r126", "r205", "r219" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10020.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments And Contingencies", "terseLabel": "Commitments and contingencies (Note 7)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments And Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r125", "r127" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments And Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r31" ], "lang": { "en-US": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock Capital Shares Reserved For Future Issuance", "terseLabel": "Total reserved shares of common stock", "verboseLabel": "Shares of common stock, reserved for issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceUnderEquityIncentivePlansDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Common Stock Including Additional Paid In Capital Net Of Discount [Abstract]" } } }, "localname": "CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParentheticalUnaudited", "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock Par Or Stated Value Per Share", "terseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock Shares Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r12", "r132" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock Shares Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r12" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10040.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock Value", "terseLabel": "Common stock\u2014$0.0001 par value, 500,000 shares authorized as of March 31, 2020 and December 31, 2019; 58,940 and 56,806 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r43", "r45", "r46" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income Net Of Tax", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction In Progress [Member]", "terseLabel": "Construction in Progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r141", "r143", "r221" ], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate Debt Obligations" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CreditLossAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Credit Loss [Abstract]" } } }, "localname": "CreditLossAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CreditLossFinancialInstrumentTextBlock": { "auth_ref": [ "r109", "r110", "r111", "r112", "r113", "r115", "r116" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security.", "label": "Credit Loss Financial Instrument [Text Block]", "terseLabel": "Credit Losses" } } }, "localname": "CreditLossFinancialInstrumentTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureCreditLosses" ], "xbrltype": "textBlockItemType" }, "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.", "label": "Cumulative Effect Of New Accounting Principle In Period Of Adoption", "periodStartLabel": "Effect of the adoption of ASC topic 842 (Leases)" } } }, "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis": { "auth_ref": [ "r168" ], "lang": { "en-US": { "role": { "documentation": "Information by type of deferred compensation related to equity-based payment arrangements. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes broad group equity-based compensation plans, defined benefit pension plans, defined benefit other postretirement benefit plans and other deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan.", "label": "Deferred Compensation Arrangement With Individual Share Based Payments By Type Of Deferred Compensation [Axis]", "terseLabel": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation" } } }, "localname": "DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r65", "r117" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10140.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation And Amortization", "terseLabel": "Depreciation and amortization expense" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetail", "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net loss per common share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r79" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share Basic And Diluted", "terseLabel": "Basic and diluted net loss per common share" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r82" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss per Common Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureNetLossPerCommonShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r26" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10120.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee Related Liabilities Current", "terseLabel": "Accrued compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]", "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationRelatedToAllEmployeeAndNonEmployeeStockAwardsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r167" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1", "terseLabel": "Unrecognized stock-based compensation weighted average recognition period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r167" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options", "terseLabel": "Unrecognized stock-based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r167" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options", "terseLabel": "Unrecognized stock-based compensation" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r164" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Vested and Unvested Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail", "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Lab Equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain": { "auth_ref": [ "r168" ], "lang": { "en-US": { "role": { "documentation": "Deferred compensation related to equity-based payment arrangements. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes broad group equity-based compensation plans, defined benefit pension plans, defined benefit other postretirement benefit plans and other deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan.", "label": "Equity Based Arrangements Individual Contracts Type Of Deferred Compensation [Domain]", "terseLabel": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation" } } }, "localname": "EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r132" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParentheticalUnaudited", "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r141", "r142", "r143", "r184", "r195" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value By Fair Value Hierarchy Level [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r183", "r184", "r185", "r186", "r188" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Fair Value By Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r141", "r142", "r143", "r184", "r196" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value Inputs Level1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r141", "r142", "r143", "r184", "r197" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value Inputs Level2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement frequency.", "label": "Fair Value Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Measurements Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r187", "r188" ], "lang": { "en-US": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value Measurements Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r192", "r193" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10070.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease Principal Payments", "negatedLabel": "Principal payments on finance lease obligations" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.", "label": "Financial Instruments Disclosure [Text Block]", "terseLabel": "Financial Instruments" } } }, "localname": "FinancialInstrumentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture And Fixtures [Member]", "terseLabel": "Furniture and Fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r49" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 10060.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General And Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r48" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General And Administrative Expense [Member]", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationRelatedToAllEmployeeAndNonEmployeeStockAwardsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r121" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationRelatedToAllEmployeeAndNonEmployeeStockAwardsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationRelatedToAllEmployeeAndNonEmployeeStockAwardsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r68" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid Net", "terseLabel": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r64" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10200.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase Decrease In Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r64" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10210.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase Decrease In Employee Related Liabilities", "terseLabel": "Accrued compensation" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "auth_ref": [ "r64" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10230.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in current liabilities classified as other.", "label": "Increase Decrease In Other Current Liabilities", "terseLabel": "Other current liabilities" } } }, "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r64" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10190.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase Decrease In Other Operating Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase Decrease In Other Operating Assets And Liabilities Net [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r64" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10180.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r59", "r62", "r68" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid Net", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestReceivable": { "auth_ref": [ "r33" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.", "label": "Interest Receivable", "terseLabel": "Accrued interest receivable" } } }, "localname": "InterestReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": { "auth_ref": [ "r50" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10150.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.", "label": "Investment Income Net Amortization Of Discount And Premium", "negatedLabel": "Amortization (accretion) of investment premiums (discounts)" } } }, "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r223", "r224", "r225", "r226" ], "lang": { "en-US": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r223", "r224", "r225", "r226" ], "lang": { "en-US": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investment Type Categorization [Member]", "terseLabel": "Investments" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.", "label": "Investments Classified By Contractual Maturity Date Table [Text Block]", "terseLabel": "Amortized Cost and Fair Value of Available for Sale Securities by Contractual Maturity" } } }, "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r118" ], "lang": { "en-US": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r25" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10010.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r17", "r200", "r217" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities And Stockholders Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities And Stockholders Equity [Abstract]", "terseLabel": "Liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r27" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10080.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery And Equipment [Member]", "terseLabel": "Machinery and Equipment" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r141" ], "lang": { "en-US": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r61" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10030.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided By Used In Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided By Used In Financing Activities [Abstract]", "terseLabel": "Financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r61" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10020.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided By Used In Investing Activities", "totalLabel": "Net cash provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided By Used In Investing Activities [Abstract]", "terseLabel": "Investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r61", "r63", "r66" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10010.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided By Used In Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r42", "r44", "r47", "r66", "r81", "r207", "r220" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 10010.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income Loss", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited", "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements Policy Policy [Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 10030.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income Loss", "terseLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r191" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10090.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease Liability Noncurrent", "terseLabel": "Operating lease liabilities - long-term" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r190" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10170.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease Right Of Use Asset", "terseLabel": "Operating lease assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r23" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10190.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]", "terseLabel": "Other comprehensive (loss) gain:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r36", "r38" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 10020.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.", "label": "Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax", "terseLabel": "Unrealized (loss) gain on available-for-sale securities", "verboseLabel": "Unrealized (loss) gain on available-for-sale securities" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited", "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r4", "r5", "r26" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10140.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r28" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10100.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r51" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 10040.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income Expense", "terseLabel": "Interest and other income, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r57" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10060.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payments Related To Tax Withholding For Share Based Compensation", "negatedLabel": "Taxes paid related to net share settlement of restricted stock units" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r53" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10110.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments To Acquire Property Plant And Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireShortTermInvestments": { "auth_ref": [ "r54" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10090.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Payments To Acquire Short Term Investments", "negatedLabel": "Purchases of short-term investments" } } }, "localname": "PaymentsToAcquireShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r147", "r168" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceUnderEquityIncentivePlansDetail", "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceUnderEquityIncentivePlansDetail", "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock Par Or Stated Value Per Share", "terseLabel": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock Shares Outstanding", "verboseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r1", "r18", "r19" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10230.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense And Other Assets Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r55" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10040.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds From Issuance Of Common Stock", "terseLabel": "Proceeds from issuance of common stock through ATM facilities, net", "verboseLabel": "Proceeds from sale of common stock, net" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r56", "r58", "r77" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10080.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds From Payments For Other Financing Activities", "terseLabel": "Other financing activities, net" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments": { "auth_ref": [ "r52" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10100.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Proceeds From Sale Maturity And Collection Of Shortterm Investments", "terseLabel": "Proceeds from maturities and sales of short-term investments" } } }, "localname": "ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockPlans": { "auth_ref": [ "r55" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10050.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the amount received from the stock plan during the period.", "label": "Proceeds From Stock Plans", "terseLabel": "Proceeds from employee stock awards" } } }, "localname": "ProceedsFromStockPlans", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r42", "r44", "r60", "r90", "r91", "r177", "r178", "r179", "r181", "r182" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10120.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Profit Loss", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Property Plant And Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r22", "r120" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property Plant And Equipment By Type [Axis]", "terseLabel": "Property, Plant and Equipment, Type" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r122" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.", "label": "Property Plant And Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosurePropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r21", "r118" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail": { "order": 10010.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Gross", "terseLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property Plant And Equipment [Line Items]", "terseLabel": "Property Plant And Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r7", "r8", "r120", "r218" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10160.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail", "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Property Plant And Equipment Net By Type [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentNetByTypeAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r7", "r120" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property Plant And Equipment [Text Block]", "terseLabel": "Schedule of Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r7", "r118" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property Plant And Equipment Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r172", "r228" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 10050.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research And Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research And Development Expense [Member]", "verboseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationRelatedToAllEmployeeAndNonEmployeeStockAwardsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r72", "r198", "r215" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted Cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r0", "r6", "r72" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetail": { "order": 10020.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 }, "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10220.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash Current", "terseLabel": "Restricted cash - short-term" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetail", "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r3", "r9", "r72", "r227" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetail": { "order": 10030.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 }, "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10180.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash Noncurrent", "terseLabel": "Restricted cash - long-term" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetail", "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.", "label": "Restricted Stock Shares Issued Net Of Shares For Tax Withholdings", "verboseLabel": "RSU settlements, net of shares withheld, shares" } } }, "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units R S U [Member]", "terseLabel": "Restricted Stock Units (RSUs)", "verboseLabel": "Unvested RSUs" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail", "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquitySummaryOfRSUActivityDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.", "label": "Restricted Stock Value Shares Issued Net Of Tax Withholdings", "negatedLabel": "RSU settlements, net of shares withheld" } } }, "localname": "RestrictedStockValueSharesIssuedNetOfTaxWithholdings", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r14", "r139", "r216" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10070.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings Accumulated Deficit", "negatedLabel": "Accumulated Deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale Of Stock Name Of Transaction [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParentheticalUnaudited", "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r80" ], "lang": { "en-US": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r80" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]", "terseLabel": "Antidilutive Securities Excluded From Computation of Diluted Net Loss per Common Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureNetLossPerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule Of Available For Sale Securities [Line Items]", "terseLabel": "Schedule of Available-for-sale Securities [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": { "auth_ref": [ "r100", "r103", "r105", "r106", "r107", "r108", "r208", "r211" ], "lang": { "en-US": { "role": { "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Schedule Of Available For Sale Securities [Table]", "terseLabel": "Schedule Of Available For Sale Securities [Table]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r146", "r165", "r169" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]", "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationRelatedToAllEmployeeAndNonEmployeeStockAwardsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r146", "r165", "r169" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]", "terseLabel": "Schedule of Stock-based Compensation, Related to Employee and Nonemployee Stock Awards" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r22", "r120" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule Of Property Plant And Equipment [Table]", "terseLabel": "Schedule Of Property Plant And Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "auth_ref": [ "r6", "r72", "r198", "r215" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.", "label": "Schedule Of Restricted Cash And Cash Equivalents [Text Block]", "terseLabel": "Reconciliation of Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r147", "r168" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquitySummaryOfRSUActivityDetail", "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r152", "r161", "r162" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]", "terseLabel": "Summary of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Schedule Of Sharebased Compensation Restricted Stock And Restricted Stock Units Activity Table [Text Block]", "terseLabel": "Summary of RSU Activity" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r30", "r74", "r129", "r130", "r131", "r133", "r134", "r135", "r136", "r137", "r138", "r139" ], "lang": { "en-US": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule Of Stock By Class [Table]", "terseLabel": "Schedule Of Stock By Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceUnderEquityIncentivePlansDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r64" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10130.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share Based Compensation", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r149" ], "lang": { "en-US": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1", "terseLabel": "Share based compensation, vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r156" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period", "negatedLabel": "Shares, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquitySummaryOfRSUActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r160" ], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquitySummaryOfRSUActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r158" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period", "terseLabel": "Shares, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquitySummaryOfRSUActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r158" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value", "verboseLabel": "Weighted Average Grant Date Fair Value, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquitySummaryOfRSUActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r157" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number", "periodEndLabel": "Shares, Outstanding as of March 31, 2020", "periodStartLabel": "Shares, Unvested as of December 31, 2019" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquitySummaryOfRSUActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r157" ], "lang": { "en-US": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted Average Grant Date Fair Value, Outstanding as of March 31, 2020", "periodStartLabel": "Weighted Average Grant Date Fair Value, Unvested as of December 31, 2019" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquitySummaryOfRSUActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r159" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period", "negatedLabel": "Shares, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquitySummaryOfRSUActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r159" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquitySummaryOfRSUActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquitySummaryOfRSUActivityDetail", "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r168" ], "lang": { "en-US": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant", "terseLabel": "Aggregate number of awards available for grant to be issued" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r156" ], "lang": { "en-US": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period", "negatedLabel": "Forfeited or expired, Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross", "terseLabel": "Granted, Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r168" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value", "terseLabel": "Aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r154", "r168" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number", "periodEndLabel": "Outstanding, Shares, ending balance", "periodStartLabel": "Outstanding, Shares, beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r153" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price", "periodEndLabel": "Outstanding, Weighted Average Exercise Price, ending balance", "periodStartLabel": "Outstanding, Weighted Average Exercise Price, beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": { "auth_ref": [ "r148" ], "lang": { "en-US": { "role": { "documentation": "Description of terms of award under share-based payment arrangement.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award", "terseLabel": "Stock option granted description terms" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r145", "r151" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquitySummaryOfRSUActivityDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price", "terseLabel": "Exercised, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price", "terseLabel": "Forfeited or expired, Weighted Average Exercise price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price", "terseLabel": "Granted, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r150" ], "lang": { "en-US": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period", "terseLabel": "Share based compensation award expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r163" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2", "terseLabel": "Outstanding, Weighted Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent", "terseLabel": "Percentage of employees purchase price of common stock" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r10", "r201", "r202", "r204", "r213" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10210.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short Term Investments", "terseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermInvestmentsMember": { "auth_ref": [ "r226" ], "lang": { "en-US": { "role": { "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.", "label": "Short Term Investments [Member]", "terseLabel": "Amounts Classified As Short-Term Investments" } } }, "localname": "ShortTermInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r78" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r32", "r132" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Statement Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParentheticalUnaudited", "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParentheticalUnaudited", "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement Of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement Of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement Of Stockholders Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParentheticalUnaudited", "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r11", "r12", "r132", "r139" ], "lang": { "en-US": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period Shares New Issues", "verboseLabel": "Common stock, shares issued" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock Issued During Period Shares Share Based Compensation Gross", "terseLabel": "Stock options, issued" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r11", "r12", "r132", "r139", "r155" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock Issued During Period Shares Stock Options Exercised", "negatedLabel": "Exercised, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r12", "r15", "r16", "r93" ], "calculation": { "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10030.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders Equity", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders Equity [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stockholders' equity including the portion attributable to noncontrolling interests, after the cumulative effect adjustment of a new accounting principle applied in the period of adoption.", "label": "Stockholders Equity Including Portion Attributable To Noncontrolling Interest Adjusted Balance1", "periodStartLabel": "Beginning balance, as adjusted" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r140" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Subsidiary Sale Of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParentheticalUnaudited", "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental cash flow disclosure" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r175" ], "lang": { "en-US": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Type Of Arrangement [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember": { "auth_ref": [ "r206" ], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae) which have maturities of one year or less. Excludes US Treasury securities and debt issued by Government-sponsored Enterprises (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae).", "label": "U S Government Agencies Shortterm Debt Securities [Member]", "terseLabel": "Government Agency Obligations" } } }, "localname": "USGovernmentAgenciesShorttermDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r141", "r143", "r203" ], "lang": { "en-US": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "U S Treasury Securities [Member]", "terseLabel": "U.S. Treasury Obligations" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r83", "r84", "r85", "r86", "r87", "r88", "r89" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use Of Estimates", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrant" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number Of Share Outstanding Basic And Diluted", "terseLabel": "Weighted-average shares outstanding used to calculate basic and diluted net loss per common share" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.atarabio.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27232-111563" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27337-111563" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27340-111563" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919269-210447" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919272-210447" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919236-210447" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r122": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "410", "URI": "http://asc.fasb.org/extlink&oid=6392676&loc=d3e7480-110848" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394232&loc=d3e17558-110866" }, "r125": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349" }, "r127": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r176": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6)(a)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.6(a)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62557-112803" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04.16(a))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=6488278&loc=d3e603758-122996" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(2)(i))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12C(1)(a))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=116631420&loc=SL116631458-115580" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r229": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r231": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r232": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r233": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r234": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6904-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(d),(e))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(i)(4))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r78": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r82": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4647-111522" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" } }, "version": "2.1" } XML 53 R23.htm IDEA: XBRL DOCUMENT v3.20.1
    Net Loss per Common Share - Antidilutive Securities Excluded From Computation of Diluted Net Loss per Common Share (Detail) - shares
    3 Months Ended
    Mar. 31, 2020
    Mar. 31, 2019
    Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
    Antidilutive securities excluded from computation of earnings per share 11,905,581 8,740,355
    Unvested RSUs    
    Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
    Antidilutive securities excluded from computation of earnings per share 3,630,713 1,860,374
    Vested and Unvested Options    
    Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
    Antidilutive securities excluded from computation of earnings per share 8,096,471 6,842,443
    ESPP Share Purchase Rights    
    Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
    Antidilutive securities excluded from computation of earnings per share 178,397 37,538
    XML 54 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}